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Facioscapulohumeral muscular dystrophy (FSHD) is a myopathy with an autosomal dominant 
pattern of inheritance. After Duchenne muscular dystrophy and myotonic dystrophy, this 
disease is the third most common hereditary muscular dystrophy with a prevalence of 
approximately 1 in 20000 worldwide. FSHD is characterised by progressive muscle weakness of 
the facial and shoulder girdle muscles, which may then progress to pelvic girdle weakness or 
foot-extensor weakness with highly variable expression. The muscle weakness is often 
asymmetrical. Also the rate and extent of disease progression may differ greatly per patient. In 
most cases FSHD is associated with a contraction of an EcoRI fragment that contains a repeat 
array, D4Z4, consisting of 3.3 kb repeat units, located within the subtelomeric region 4q35 on 
the long arm of chromosome 4. The majority of affected individuals has a parent with clinical 
characteristics and a contraction of this repeat array on 4q35 and are thus described as familial 
FSHD patients. Approximately 10-30% of individuals will develop FSHD as a result of a new 
mutation and are therefore called de novo or sporadic patients. A small percentage of patients 
(5%; so-called phenotypic FSHD patients) has a phenotype characteristic for FSHD, but lack the 
4q35 contraction. 
 
Since the linkage of FSHD to chromosome 4 in 1990, important observations have been made 
with respect to the molecular characteristics and pathogenesis of the disease. Unfortunately, no 
true candidate gene or genes responsible for the development and progression of FSHD have 
thus far been identified. Unravelling the molecular structure of the 4q35 region and gaining 
more knowledge of the behaviour of the D4Z4 repeat are therefore important to elucidate the 
disease mechanism, as both features can give more insight in complex genetic events and 
possible molecular mechanisms triggering or modifying FSHD pathology. The aim of this thesis 
was therefore to focus on the structure and behaviour of D4Z4, which would add to our 
understanding of the molecular mechanism underlying the disease. The research described here 
focuses on three topics: (1) interactions of the subtelomeric region 4q35, in which D4Z4 resides, 
with other regions in the genome; (2) the consequences of mosaicism for FSHD pathology; and 
(3) epigenetic modifications of the 4q35 region, including DNA methylation and histone 
acetylation. 
 
A literature overview on the FSHD phenotype and molecular characteristics of the chromosomal 
region 4q35 associated with FSHD is provided in Chapter 1. Furthermore, this chapter contains 
a broad overview on repeat characteristics, subtelomeric regions, the possible consequences of 
mosaicism, and the diverse functions of DNA methylation and histone modifications in the 
human genome in general. The observed interactions of the subtelomeric region 4q35 with 




Chapters 2 and 3. The studies on mosaicism for the FSHD-associated region presented in 
Chapters 3 and 4 mainly concentrate on the occurrence of mosaicism and the determination of 
frequency and possible consequences for FSHD. The epigenetic modifications of the 4q35 
region, D4Z4 and the proximal sequences, and their possible effects on chromatin 
conformation are addressed in Chapters 5, 6 and 7. Chapters 5 and 6 pertain to DNA 
methylation of D4Z4, with special attention to phenotypic FSHD patients and the effect of 
repeat array length on DNA methylation, whereas Chapter 7 outlines observations on histone 
acetylation. Chapter 8 summarises the results described in this thesis and discusses the 
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1.1 Clinical characteristics of FSHD 
 
1.1.1 Historical perspective 
Physicians presented many clinical descriptions of patients with a total of 18 different muscle 
diseases in the nineteenth century. Most of the progressive muscle diseases were thought to 
have neurogenic causes [339]. In 1868, Guillaume Duchenne de Boulogne described a form of 
muscular dystrophy, nowadays called Duchenne muscular dystrophy, a progressive proximal 
muscular dystrophy with characteristic pseudohypertrophy of the calves, which is linked to the 
X-chromosome. In that same period, Louis Landouzy published the characteristics of two boys 
with progressive muscular wasting [218]. Together with his colleague Joseph Dejerine he 
observed this family for more than ten years and they described the key features of 
facioscapulohumeral muscular dystrophy (FSHD) in the title of their article “De la myopathie 
atrophique progressive: myopathie héréditaire débutant, dans l’enfance, par la face, sans 
altération du système nerveux” (i.e. a progressive muscle atrophy, which is hereditary and 
starts in childhood with the face, without involvement of the nervous system). They 
emphasized the onset in facial and shoulder muscles to differentiate FSHD from Duchenne 
muscular dystrophy [219-221]. FSHD is therefore also known as Landouzy-Dejerine disease. 
 
1.1.2 Clinical characteristics 
1.1.2.1 Diagnostic criteria 
There are four key criteria, formulated by the international FSHD consortium, that specify 
FSHD at a clinical level [306]: 
1. Onset of the disease in facial or shoulder girdle muscles; sparing of the extraocular and 
pharyngeal muscles and the myocardium. 
2. Facial weakness is observed in more than 50% of the affected family members. 
3. Evidence of a myopathy seen in electromyography and muscle biopsy without biopsy 
features specific for alternative diagnoses in at least one affected member. 
4. An autosomal dominant inheritance pattern in familial cases. 
 
On a molecular level FSHD is in most patients (95%) associated with a contraction of the 
D4Z4 repeat located in the subtelomere of chromosome 4 (4q35) [419], which can be inherited 
from an affected parent or be the result of a new mutation. The molecular characteristics will 





1.1.2.2 Distribution of muscle weakness  
FSHD is characterised by weakness of specific muscles. Most patients note shoulder girdle 
weakness as a first symptom. Weakness of the facial muscles (with particular involvement of M. 
orbicularis oculi and M. orbicularis oris) is rarely an early complaint and is only in some cases 
(~5%) by patients recognised as onset of the disease [301]. Facial muscle involvement is often 
subtle and sometimes only noticeable by asymmetry of facial expression [306, 308]. On first 
clinical examination facial weakness is present in more than 90% of patients [206, 251, 298, 
308]. 
Most patients seek medical attention, because of weakness of the shoulder girdle [298, 
301, 339]. The scapula fixators are most prominently involved and also the pectoralis major 
muscles will in most cases become affected [306]. Most patients have at rest a sloped-shouldered 
posture with anterior rotation of the shoulders and elevation of the scapula from the rib cage 
[192]. The initially spared deltoid muscles become affected at a later stage [306]. Approximately 
30% of patients never worsen beyond shoulder weakness [251, 301], in the remaining patients 
the disease progresses with the involvement of abdominal muscles and foot-extensor muscles. 
Pelvic girdle weakness and weakness of the upper arms and upper legs may occur at a later stage 
after onset of shoulder girdle weakness [214, 306, 308]. The severe weakness of the abdominal, 
pelvic girdle and back extensor muscles can all contribute to a lumbar hyperlordosis [187, 308]. 
Two FSHD patients with prominent weakness of facial and shoulder girdle muscles are depicted 
in Figure 1.1. 
The muscle weakness is often asymmetrical and the degree of muscle weakness varies 
from person to person. Eventually, 10-20% of all patients will require a wheelchair due to 
Figure 1.1 
(A) Photograph of a male FSHD patient showing asymmetrical facial weakness, which is observed in more than 
50% of patients [301]. 
(B) Two photographs illustrating shoulder girdle weakness with elevation of the scapula on attempted anteflexion 
of the area in a female FSHD patient. 
 






proximal lower limb involvement [255, 308]. This is often by the fifth decade of life, but 
sporadic patients (i.e. patients with a new mutation) may even require a wheelchair before the 
age of 20 years [255, 298, 306]. 
 
1.1.2.3 Muscle biopsy features 
Muscle biopsies of FSHD patients do not show any disease-specific morphological characteristics 
and are to some extent variable, depending on disease progression and the site of biopsy [192, 
340]. These biopsies display general dystrophic features such as increased variation in fibre type 
and size [340], fibre necrosis and fibrosis and an increased number of internal nuclei. Also 
moth-eaten fibres are frequently seen as well as scattered small angular fibres, indicative for 
regeneration as they contain fetal myosin [9, 299, 306, 340]. Mononuclear inflammatory cells 
with an increase in necrotic fibres have been detected in up to 40% of FSHD patients. The 
mechanism that causes these infiltrates and their significance is still unknown [9, 105, 192, 
298]. 
 
1.1.2.4 Onset and progression of the disease 
The clinical presentation of FSHD exhibits a wide range of clinical severity and variable age at 
onset, even within one family where all patients carry an identical mutation in their DNA. 
Symptoms can vary from severe progressive proximal and distal involvement of upper and lower 
limbs together with an expressionless face in early life to minimal signs of asymptomatic 
scapular girdle or facial weakness and thus barely detectible even at old age [17, 112, 255]. 
Usually patients become symptomatic in their adolescence, when the individual notices 
symptoms that reveal shoulder girdle weakness or signs of muscle wasting in this region [173, 
251, 255, 292, 298, 444]. The disease manifests almost complete penetrance (95%) in all 
patients during the second decade of life and penetrance is probably close to 100% at 30 years 
[250, 298, 339]. 
Since facial weakness is almost never recognised as a first complaint, it is therefore very 
difficult to indicate the precise disease onset [298]. Because the development is usually 
determined in retrospect and depends on the recall of the patient, age at onset may be a 
doubtful marker for development [253]. Onset has now been defined as the moment a patient 
becomes aware of having FSHD or has difficulties caused by muscle weakness [308]. With this 
definition, one-third of all patients over 20 years old in large pedigrees do not have any 
complaints of muscle weakness. These individuals are also called non-penetrant gene carriers 
[298, 306-308, 380]. 
The disease is progressive in the majority of patients with a highly variable rate and 
usually spreads first to the abdominal and foot-extensor muscles and subsequently to pelvic 
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and upper arm muscles [214, 308]. Within families, approximately 50% of patients will 
develop lower limb involvement, and 20% of those become to some extent wheelchair-
dependent. As a result of this intrafamilial variation, a precise prediction about disease 
progression and severity is still not possible [255]. 
Disease onset before the age of 5 years is seen in more severe patients, who usually have 
a new mutation, where facial weakness is the earliest and most prominent sign [250, 255, 301, 
306]. In The Netherlands, less then 5% of patients have an onset before the age of 10 years [49], 
while in contrast Japanese researchers reported a frequency of 13-17% of early childhood cases 
[280, 437]. This early onset FSHD is part of the wide clinical spectrum of FSHD [51, 254] and 
has been somewhat arbitrarily defined by the following two criteria: signs or symptoms of facial 
weakness before the age of five and signs or symptoms of shoulder girdle weakness before the 
age of ten years [51, 300]. These patients often become wheelchair-dependent [301]. 
 
1.1.3 Fitness 
Most affected individuals (i.e. 70-90% of patients) have a parent with clinical characteristics 
and a contraction of the D4Z4 repeat on chromosome 4, and are thus described as familial 
FSHD patients. Approximately 10-30% of individuals will develop FSHD as a result of a new 
mutation and are therefore called de novo or sporadic patients [8, 14, 199, 253, 305, 377, 392, 
415, 419, 445]. Given this high mutation frequency, it is unlikely that the fitness, i.e. the ability 
to transmit one’s genes to the next generation and have them survive in that generation to be 
passed on to the next, is normal [298, 299]. Although the relative fitness has been calculated at 
1.0 in the Dutch kindreds studied, this does not correspond with the (probably conservative) 
estimation of 10% of living patients having de novo mutations [298]. The results collected from 
a Brazilian population suggest that new mutations may account for at least one-third of FSHD 
cases, and a reduced biological fitness of 0.6-0.82 by different estimates based on both familial 
and sporadic patients appears to be more correct [445]. 
 
1.1.4 Differences between males and females 
A consistent gender difference is observed when asymptomatic and symptomatic individuals of 
the same age are compared. There are significantly more asymptomatic females and when the 
symptomatic patients are considered, a later onset of the disease and a slower disease 
progression are noted in females [298], implicating that females show less severe features of 
FSHD then males of the same age [251, 307, 330]. These findings are confirmed by a study in 
which Zatz et al. [444] studied a large Brazilian patient population and suggested, based on 
molecular analyses, that the average penetrance is 83% at the age of 30 years, in which males 
from that population showed a significantly higher penetrance than females (95 versus 69%). 
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In patients mosaic for the D4Z4 contraction, the proportion of mutated cells also 
influences expression of the disease. A smaller percentage of cells carrying the disease allele is 
required for males to manifest signs of FSHD compared to the detected percentages in females 
and these males are more frequently symptomatic [257]. In addition, DNA analysis of parents 
of FSHD patients shows that there is a female predominance of mosaic asymptomatic carriers 
[199, 257, 444] (see also Paragraph 1.4 for more details on mosaicism). The underlying 
mechanism for the observed gender differences is not yet known. Maybe differences in 
hormone levels between males and females are of influence, but this needs further investigation. 
 
1.1.5 Extramuscular phenotypic features 
1.1.5.1 Pain 
Approximately 75% of all patients complain about multifocal muscle and tendon pains, mostly 
located to the shoulder, lower back and arm regions [196, 197, 299, 329, 395], but pain is also 
reported around the thighs [56]. This pain is often described as serious and disabling and 
presents a major problem in daily life. Some types of pain may be related to strenuous activities 
or postural problems [56, 329]. To find a possible cause, metabolic factors and components 
indicative for inflammation were examined in blood and muscle biopsies with histological, 
histochemical and immunocytochemical techniques, but no clues were found that indicate a 
cause for the pain or an association with the muscle dystrophy in FSHD patients [56]. 
 
1.1.5.2 Retinal abnormalities and sensorineural hearing loss 
The presence of retinal abnormalities, which include telangiectasis, microaneurysm formation, 
vessel occlusions, small exudates, haemorrhages, capillary closure and leakage in the macular 
area as well as in the peripheral retina, is observed in 50-75% of patients [113, 303, 305] with a 
high frequency in early onset cases [51]. These abnormalities can be visualised with fluorescein 
angiography, a method to diagnose and evaluate a variety of ocular diseases. Observed changes 
are often subtle and very focal and will usually not lead to any severe visual complications [112, 
113]. 
A significant difference in hearing levels with frequencies between 4000 and 6000 Hz is 
reported in patients when compared to healthy family members. The hearing deficiency often 
displays as high-tone hearing loss observed in 64% of familial autosomal dominant cases and 
20-30% of infantile cases [50, 173, 195, 198, 302] and may progress to involve all frequencies 
[306]. This hearing loss can be related to cochlear dysfunction in early onset FSHD [402], but 
hearing loss with a maximum of 8000 Hz in adult FSHD is also very difficult to distinguish 
from impairment in the normal population, which is age-related or caused by acoustic trauma 
[341]. Severe clinical deafness occurs rarely and has only been noted in severe childhood cases 
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[51, 112]. Comparing both sporadic and familial FSHD patients, no correlation between 
hearing impairment and disease severity was observed [302]. Häfner et al. [151] reported a 
locus linked to hearing loss at 4q35-qter (DFNA24) that could indicate a potential candidate 
gene for deafness in this region, but if this finding is of any significance for hearing deficits in 
FSHD remains to be investigated. 
 
1.1.5.3 Respiratory problems 
The respiratory capacity of FSHD patients diminishes with the progression of the disease, but 
usually does not lead to severe respiratory failure [187, 301]. Kilmer et al. [187, 188] reported a 
vital capacity evidence of restrictive lung disease measured in almost 50% of patients, but only 
13% showed severe involvement and only 22% had a history of pulmonary complications. In a 
Japanese study, 8% of FSHD patients had progressive respiratory failure [281], while in a 
Dutch survey about 1% of all FSHD patients suffer from respiratory insufficiency and require 
ventilation support [429]. These Dutch patients all have a disease onset before the age of 24 
years, a wheelchair-dependency and an abnormal curve of the vertebral column (scoliosis and 
lumbar lordosis) [429, 430]. A mild scoliosis is present in one third of all FSHD patients, 
mostly in early onset cases [301]. The presence of a pectus excavatum has been reported in 5% 
of all patients, which exceeds the incidence in the normal population [298, 308]. Both features, 
scoliosis and pectus excavatum, can impair respiratory function [429]. 
 
1.1.5.4 Unusual clinical observations 
Several phenotypic findings have been published that are observed in combination with a 
FSHD diagnosis: involvement of the lingual muscle [202, 437, 438], cardiac involvement [103, 
215, 283, 356, 366], schizophrenia [355], mental retardation and epilepsy [3, 49, 120, 271, 355, 
389, 437]. These findings may be disease-specific, but as most of them were only detected in a 
few patients it is likely that they are not part of the clinical core phenotype. 
 
1.1.6 Phenotype-genotype correlations 
FSHD is associated with a D4Z4 repeat contraction at 4q35 that in general causes disease when 
the EcoRI fragment in which the array is located becomes smaller than 38 kb (reviewed in 
[391]; see also Paragraph 1.2 for a detailed description on the molecular characteristics). Since 
the repeat array may vary in size between patients of different families, several research groups 
have studied the effect of residual repeat size on the severity of the phenotype. Comparing 
repeat size with clinical data revealed that age at onset and the severity in probands and de novo 
cases correlates roughly inversely with the size of the residual repeat array [8, 10, 167, 198, 253, 
330, 377, 445]. Very severely affected patients (usually children) with lower limb involvement 
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most often carry fragments of 10-17 kb, whereas patients with onset in their teens and large 
recognised families mostly carry fragments of 18-30 kb [112, 120, 251-253, 255, 380]. Thus 
individuals with a milder phenotype on average have larger fragments, whereas those more 
severely affected have the smaller ones [112, 255, 308, 380]. Early onset patients usually are 
severe sporadic cases with a de novo mutation resulting in a short residual fragment [49, 120, 
173, 253, 254, 301, 308]. Nevertheless, sporadic patients can also present a short fragment in 
combination with a mild phenotype [380, 435], short fragments are detected as well in 
asymptomatic gene carriers [380] and patients with repeat sizes above 30 kb can also show a 
severe presentation of the disease [57, 435], indicating that residual repeat length is not the 




1.2 Molecular characteristics of the FSHD-associated chromosomal region 
 
1.2.1 Identification of the FSHD-associated region 
1.2.1.1 Linkage analysis 
When polymorphic markers became available, it was possible to search for genes responsible 
for or associated with disease by association analysis and linkage analysis. In order to identify 
the genetic defect responsible for FSHD, linkage analysis was started in the early eighties with 
all available genetic markers, mainly consisting of blood group markers and enzyme and 
protein polymorphisms. Unfortunately, none of the 35 markers present at that time showed 
linkage to FSHD [304]. Next, the search for the FSHD locus was continued by use of restriction 
fragment length polymorphisms (RFLP) [250], but also these analyses did not yield any 
evidence for linkage. 
By the early nineties, almost 95% of the human genome was excluded [347], but the 
FSHD locus had not been found. Then marker technology shifted from RFLPs to (CA)n type 
microsatellite markers [133, 244, 411]. These markers were applied to DNA from two large 
Dutch FSHD families and gave promising results. One of these markers, Mfd22 [410], 
displayed positive linkage and located the putative FSHD locus to chromosome 4 [416]. A 
number of chromosome 4 markers were tested next to identify markers in closer linkage or 
flanking marker Mfd22. A variable number tandem repeat marker pH30 [269], showed high 
linkage corresponding to locus D4S139 and located the region associated with FSHD to 4q35 
[420]. 
 
1.2.1.2 Repeat array contractions 
After the linkage to chromosome 4q, clone 13E, which mapped distal to locus D4S139, was 
isolated from a chromosome 4 cosmid library. From this clone, which contained multiple 
copies of a 3.3 kb repeat sequence, an 800 bp probe termed p13E-11 (D4F104S1) flanking the 
repeats was isolated that could be used for hybridisation. On Southern blots human DNA 
digested with restriction enzyme EcoRI and probed with p13E-11 displayed a short fragment in 
FSHD families that co-segregated stably with the disease through generations [88, 415, 419] 
(Figure 1.2.A). This probe also displayed short fragments in sporadic FSHD patients, while this 
fragment was absent in either clinically unaffected parent, revealing a de novo DNA 
rearrangement [419] (Figure 1.2.B). Once this rearranged fragment had arisen, it could stably 
be transmitted to the next generation in association with the disease [415]. Additional genetic 
studies on FSHD families in other laboratories confirmed these findings [58, 137, 148, 261, 348, 




This EcoRI fragment observed with probe p13E-11 contained a polymorphic repeat array 
and accurate sizing indicated size differences in the number of repeat units between unrelated 
FSHD families. Healthy individuals carried an EcoRI fragment ranging between 40 to over 300 
kb, while the observed repeat array in FSHD patients was reduced to an EcoRI fragment of 10-
28 kb [419]. Nowadays, almost all patients (95%) have been linked to this locus on 
chromosome 4. The residual EcoRI fragment size observed in these patients is smaller than 38 
kb [231]. A minority of FSHD patients (5%), called phenotypic FSHD patients, who display all 
phenotypic characteristics of the disease, do not show a contracted 4q35 fragment after DNA 
analysis nor are linked to the identified chromosome 4 locus [49, 56, 138, 171, 205, 253, 255, 
379, 390, 394, 413, 420, 444]. Despite all efforts, a second locus for all these patients has not 
yet been identified [15, 136, 171, 364], although recently some evidence was presented for 
linkage to chromosome 15 in one family only [322]. 
 
1.2.2 Analysis of the FSHD-associated D4Z4 repeat 
The observed EcoRI fragment contains a repeat structure, termed D4Z4, consisting of KpnI 
units ordered in a head-to-tail fashion [88, 159, 419]. In healthy individuals this repeat array can 
contain from 11 up to more than 100 repeat units. In FSHD patients this repeat is contracted, 
which results in an array of 1-10 repeat units [88, 159, 419]. Therefore, the assumption was 
made that contraction of D4Z4 would lead to a partial or complete deletion of a gene. The 
most logical step then was to sequence the D4Z4 repeat units [123, 159, 226, 426]. A complete 
Figure 1.2 
(A) Molecular analysis of an FSHD family by linear gel electrophoresis of DNA digested with EcoRI followed by 
Southern blot analysis and hybridisation with probe p13E-11. In this FSHD family, transmission of an 18 kb 
EcoRI fragment is observed through three generations. This fragment, which is highlighted by an arrow, is 
transmitted from the affected grandmother (generation I) to four affected children (generation II) and three 
affected grandchildren (generation III). All affected individuals are indicated by black symbols (Adapted from 
[419]). 
(B) Molecular analysis of four families by linear gel electrophoresis of DNA digested with EcoRI followed by 
Southern blot analysis and hybridisation with probe p13E-11. In each patient (black symbol), a new short 
fragment is present that is absent in both unaffected parents. This de novo fragment is indicated with an arrow 





overview of the FSHD region with all currently available information, including surrounding 
sequences, candidate genes and probes, is schematically depicted in Figure 1.3. 
 
1.2.2.1 D4Z4 repeat unit 
D4Z4 is composed of tandem arranged repeat units that are 3.3 kb in size and consists of both 
highly conserved and variable regions [159, 226, 419]. Because the sequence is very GC-rich, it 
has characteristics of a CpG island [159, 433] (see also Paragraph 1.5.2.2). Several regions 
within the sequence show homology with other sequences in the human genome, like a 316 bp 
region with similarity to the GC-rich repeat LSau [2] and an extreme GC-rich DNA region of 
461 bp that shows homology with the human low copy repeat hhspm3 [446]. Throughout the 
repeat unit several microsatellites were identified as well [225, 226]. Distal to these GC-rich 
sequences, an open reading frame (ORF) of 405 bp was identified, now designated DUX4, that 
did not span the entire repeat unit and encodes a putative protein with two homeodomains 
[123, 159, 225, 226, 256, 426]. Homeodomains are DNA binding domains that regulate gene 
expression during embryonic development [292] and usually encode regulatory transcription 
factors [1, 68, 78]. The observed homeodomains in D4Z4 show similarity to other 
Figure 1.3 
Schematic representation of the FSHD-associated region at 4q35 and its homologous region on 10q26 (not drawn 
to scale). The relative position of three markers in the 4q35 region (i.e. D4S139, D4S2463 and D4F104S1) and the 
repeats on both chromosomes are visualised in (A). This part also shows the relative positions of the candidate 
genes on 4q35 and 10q26. (B) shows an enlarged section of (A) containing the sequence elements and regions of 
sequence similarity between the subtelomeres of 10q, 4qA and 4qB. Also indicated are the regions recognised by 
the various probes used for hybridisation after gel electrophoresis of DNA digested with proper restriction 








homeodomain sequences, like the human paired box gene family that includes PAX3, PAX6, 
the homeobox family gene OTX1 and the muscle-specific homeogene PMX1, Xenopus HmixX 
and Drosophila paired and Hmpr D. [225, 226]. 
EST databases and human genomic phage DNA and cDNA libraries were screened for 
DUX4 transcripts, but none of the transcripts detected mapped to 4q35 suggesting DUX4 is 
transcriptionally inactive [159, 225, 226, 426]. Sequences homologous to DUX4 were identified 
and some were named DUX1, DUX2, DUX3, DUX5 and DUX10. Gene expression has been 
detected, but all these sequences originate from regions other than chromosome 4 [25, 73, 90, 
123, 159, 256]. Recently, some evidence has been reported for protein expression of a DUX 
gene exclusively observed in FSHD myoblasts and needs further investigation [73]. 
 
1.2.2.2 D4Z4 proximal and distal sequences 
The 161 kb region proximal to the D4Z4 repeat was sequenced completely. Apart from a large 
number of repeat sequences, like L1 repeats, long terminal repeat transposons, Alu repeats and 
long interspersed nuclear elements (see also Paragraph 1.3.1), this region also contains 
sequences with (partial) homology to genes located on other chromosomes. Various computer 
software programs for sequence annotation were used to detect potential coding regions in the 
4q35 region and identified, in a region spanning 5 Mb proximal to D4Z4, five candidate genes, 
ANT1, ALP, FRG1, TUBB4Q and FRG2, which will be discussed in more detail in Paragraph 
1.2.4. 
The region distal to the repeat array is difficult to clone and therefore has only been 
partially sequenced. Sequence data derived from a clone that spans 11 kb distal to D4Z4 
uncovered only highly repetitive elements and pseudogenes [128] and no transcribed regions 
have been identified yet [129]. Recent analysis of the distal sequences revealed two variants of 
the 4qter sequence, designated 4qA and 4qB. Although both variants are almost equally present 
in the population, FSHD is uniquely associated with the 4qA variant [128, 228]. Variant 4qA 
contains a 6.2 kb region of ß-satellite DNA [128] that consists of 68 bp Sau3A monomers [88] 
and a 1 kb divergent (TTAGGG)n array, both features that are not present on the 4qB variant 
[128]. Furthermore, the terminal D4Z4 in the 4qB variant contains only 570 bp of a complete 
repeat, while variant 4qA carries a divergent repeat called pLAM that shows high homology with 
LSau and hhspm3 sequences, but does not contain homeobox sequences [128]. Consequently, 
even though this area was initially discarded for further analysis, these findings now emphasise 





1.2.2.3 Analysis of D4Z4 in the genome 
Fluorescence in situ hybridisation (FISH) analysis located the repeat array next to the telomere 
of 4q, less than 215 kb from the telomere sequence [426]. FISH-probes containing D4Z4 
sequences revealed (weak) hybridising signals throughout the entire human genome: 4q35, 
10q26, the Y-chromosome and all short arms of acrocentric chromosomes 13, 14, 15, 21 and 
22 as well as on chromosomes 3 and 8, chromosomal locations 1q12, 1p12, 2p11, 9q12, 16p11, 
centromeres of chromosomes 9, 10 and 20 and the centromere plus region q11 of chromosome 
10 [6, 16, 159, 163, 256, 268, 317, 419, 426]. Furthermore, probes containing the 
homeodomain sequences, such as 9B6A, hybridised to each copy of D4Z4 and also to a 2.5 kb 
truncated and inverted copy 40 kb proximal to the D4Z4 array that contains homeobox 
sequences similar to those of D4Z4 using Southern analysis [433]. 
Due to spreading of homologous D4Z4 sequences through the genome, it was 
suggested that D4Z4-related sequences are part of a 3.3 kb repeat family with two different 
structures: tandem arranged repeats, like D4Z4, or repeat clusters interspaced by ß-satellite 
repeats. Family members are organised into subfamilies and located at heterochromatic regions 
in the genome, mainly on the acrocentric chromosomes and partially interspersed with 
ribosomal RNA gene clusters [256, 427]. These regions seem to have a different organisation 
per locus as a consequence of inter- and intrachromosomal recombination events. Because no 
transcript of D4Z4 has yet been isolated from muscle or any other tissue, this sequence may 
have been amplified along with other repetitive sequences and scattered through the genome 
[256]. 
 
1.2.2.4 D4Z4 in other species 
The evolutionary conservation of D4Z4 was studied in a variety of species by the use of zoo-
blots. DUX4-derived probes cross-hybridised to a few sequences of DNA from baboon, chicken, 
cow, goat and pig, but no probes from D4Z4 hybridised with rodent DNA [159]. A Southern 
blot containing DNA from several Old World and New World monkeys did show signal with 
probe 9B6A recognising the homeoboxes of DUX4 [159], which suggests that D4Z4 is primate-
specific. 
 4q35-like sequences are localised at multiple loci in Old World simians (i.e. Catarrhini) 
[16, 70, 126, 159, 427], which include apes and humans (Hominoidea) and Old World 
monkeys (Ceropithecoidea) [259]. In macaques (Ceropithecoidea) and marmoset 
(Ceboidea/New World Monkeys) a reduced number of loci is detected [70]. This suggests that 
duplications of the 4q35 region have occurred frequently in these primates [16, 126, 427]. FISH 
analyses showed conservation of the subtelomeric 4q localisation in the analysed primates and 




4q region has been duplicated and transposed, followed by genome-specific deletion and 
expansion [16]. 
 Recently, it was possible to identify potential homologues of D4Z4 in mouse and rat by 
applying computational analysis of draft genome sequences [69]. Preliminary data revealed 
that the sequence and organisation of the mouse D4Z4 shows a 4.9 kb repeat and contains an 
ORF of 2 kb encoding two homeodomains with 55% homology on amino acid levels when 
compared to those encoded in the human D4Z4. Outside the coding region there is no 
sequence conservation observed between human and mouse. Furthermore, the mouse repeats 
are arranged in a large tandem array and are concentrated at one single locus in the mouse 
genome, the location of which still needs to be determined. The identified rat homologue of 
D4Z4 also encodes a potential homeodomain protein with 66% similarity on amino acid levels 
to the mouse protein [69]. These new findings weaken the D4Z4 primate-specific idea and may 
provide possibilities for the development of an animal model for FSHD. 
 
1.2.3 Complications due to D4Z4 sequence homology 
The disease-associated fragment can be visualised with probe p13E-11. Unfortunately, this is 
not a single-copy probe and detects other loci as well. In the human genome, it recognises a 9.4 
kb fragment only observed in males, which corresponds to a sequence on the Y-chromosome 
[392], and two additional highly polymorphic loci. One of these loci is the repeat array on 
chromosome 4q35 [419], while the other is a repeat array located on the subtelomere of 
chromosome 10q (10q26) with a similar organisation as the array on 4q35 [15, 82], which 
complicates DNA diagnosis. The organisation of the 10q26 region is also depicted in Figure 1.3. 
Thus, probe p13E-11 identifies a total of four polymorphic EcoRI fragments in females and five 
fragments in males, of which the Y fragment is not polymorphic. Usually linear gel 
electrophoresis is used to separate the FSHD allele from the larger alleles. Visualisation of all 
D4Z4 fragments of chromosomes 4 and 10 can only be achieved by pulsed-field gel 
electrophoresis (PFGE) or field inversion gel electrophoresis (FIGE) [232, 354]. 
 
1.2.3.1 Restriction sites discriminate between chromosomes 4 and 10 
Detailed sequence analysis demonstrated the high homology of the repeats on 4q35 and 10q26 
[82]. Comparing the 4q35 and 10q26 sequences also yielded a unique BlnI restriction site that 
was only present in repeat units originating from chromosome 10 [83]. This finding allowed 
discrimination of these two repeat arrays and subsequently resulted in more accurate diagnoses, 
because a contracted fragment on 10q26 could now easily be discriminated from a contracted 
fragment on chromosome 4 [15, 198]. Six years later, a second sequence difference was 
observed. A restriction site for XapI located in the chromosome 4 repeat sequence resulted in 
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complementary fragments to those detected with BlnI [227]. With these two enzymes it is now 
possible to obtain complete allele information and to deduce the chromosomal origin of the 
observed EcoRI fragment in most cases. The complete procedure to separate both sequences by 
the use of different restriction enzymes and probes was recently described in detail [231]. 
As a consequence of the high sequence homology and the subtelomeric location of the 
repeat arrays, translocations of repeat units between 4q35 and 10q26 are observed in 20% of 
individuals [86, 295]. This issue will be further addressed in Paragraph 1.3. 
 
1.2.3.2 A second FSHD locus? 
The identification of a chromosome 10 sequence hybridising with probe p13E-11 raised the 
question whether this sequence perhaps represented the second FSHD locus, since no linkage 
to chromosome 4 has been observed in 5% of FSHD patients [15, 136, 171, 322, 364]. Linkage 
analysis was applied to test the involvement of this locus in two large non-4q35 linked families, 
but this did not reveal evidence for linkage to chromosome 10qter [15, 364]. 
In some of the FSHD families without linkage to 4q35, markers on chromosome 12 
were also tested flanking the regions of two diseases with clinical features similar to FSHD, i.e. 
scapuloperoneal muscular dystrophy and scapuloperoneal muscular atrophy [379]. Both 
disease regions were excluded by extensive linkage analysis [379]. In addition, mutations in the 
gene myotilin, which has been identified for one of the autosomal dominant forms of limb 
girdle muscle dystrophy, were also eliminated as a cause of non-4q linked FSHD [156]. 
Further genomic screening has identified a region on chromosome 15 consistent with 
linkage (peak lod score 3.20) in one non-4q linked FSHD family [322]. Sequence analysis ruled 
out a possible candidate gene, POLG on 15q25 [22, 322], in which mutations are responsible 
for progressive external ophthalmoplegia [285]. Other possible candidates in this region were 
also evaluated [22], but no mutations were observed in desmuslin, an intermediate filament 
protein that may play an important role in maintaining muscle integrity [272, 285] nor in 
chromodomain helicase DNA binding protein 2 that may be involved in chromatin structure 
regulation and gene transcription [285, 432]. The sequences of three proteins recently 
identified to bind D4Z4 (YY1, nucleolin and HMGB2) [121], were also excluded as candidate 
genes [22]. Currently other potential candidate regions are under investigation [21, 22]. 
 
1.2.4 Identification of 4q35 genes 
Extensive analysis of the D4Z4 repeat together with the findings that DUX4 seems to be 
transcriptionally inactive and that haploinsufficiency of the 4q region including D4Z4 does not 
cause FSHD [386], made the assumption that one or more repeat units would comprise the 
FSHD gene unlikely. With the identification of several 4q35-derived genomic clones it was 
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possible to extend sequence analyses in the regions adjacent to D4Z4, but the detection of 4q35 
transcripts remained very difficult due to the presence of many repeat sequences and the 
spreading of (pseudogene-) sequences [84, 129, 158]. Despite sequencing difficulties, several 
genes were identified and characterised in the sequence proximal to D4Z4. Whether or not 
(some of) these genes on 4q35 indeed play a role in FSHD pathology is still not clear. In 
addition to DUX4, five genes have been studied extensively and will be discussed here in more 
detail. 
 
1.2.4.1 ANT1; adenine nucleotide translocator gene 1 
ANT is an integral protein of the inner mitochondrial membrane, organised in homodimers, 
with a single binding site for adenosine triphosphate (ATP) and adenosine diphosphate (ADP). 
ANT is responsible for the exchange of mitochondrial ATP for cytosolic ADP across the inner 
mitochondrial membrane. Since ANT is the only mitochondrial translocase for nucleotides, it 
is an important link between energy-producing and energy-consuming processes [93, 161]. 
ANT can also be converted into a pro-apoptotic pore and plays a significant role within the 
regulation of mitochondrial membrane permeability during apoptosis under the control of 
multiple apoptosis modulators [26]. In humans at least three different full length cDNAs for 
ANT have been detected so far: ANT1 of which the gene is located on chromosome 4, ANT2 
derived from the X-chromosome and ANT3 that is transcribed from both the Y-chromosome 
and the inactive and active X-chromosomes [351, 363]. 
ANT1 maps approximately 5 Mb proximal to D4Z4 [102, 155, 237, 421] and the highly 
abundant protein is expressed in post-mitotic cells, like differentiated tissues such as skeletal 
muscle, heart and brain [26, 93, 237]. Mutations in ANT1 are associated with autosomal 
dominant progressive external ophthalmoplegia in 11% of patients [161, 285]. This gene was 
an interesting candidate for FSHD, because of its function and expression in skeletal muscle. 
However, sequence analysis did not reveal any differences between patients and control 
individuals [155] and Wijmenga et al. [421] discarded this gene as a true candidate gene, 
because of its distance from the FSHD region. Recently, using radioactive PCR and 
immunoblotting ANT1 upregulation was demonstrated in FSHD muscle [121, 222], although 
this was not confirmed by quantitative real-time PCR [177] or expression profiling [428]. With 
these contradictory results, possibly due to applying different methods, ANT1 involvement in 
FSHD remains elusive. 
 
1.2.4.2 ALP; actinin-associated LIM protein gene 
By screening a human muscle cDNA array a novel muscle-specific transcript, ALP, was 




performed to evaluate ALP as being the FSHD gene [44]. ALP is expressed at high levels in 
differentiated skeletal muscle and an alternatively spliced form of the protein is also detected at 
low levels in heart. The PDZ domain of ALP interacts with the spectrin-like repeats of   α-
actinin-2 at the Z-lines of myofibres [436]. In two studies, no significant differences between 
FSHD patients and control biopsies were observed in protein sizes, expression levels and 
subcellular localisation [44, 436]. Also microarray data did not reveal an altered gene expression 
[428], which excludes ALP as a possible candidate gene for FSHD. 
 
1.2.4.3 FRG1; FSHD region gene 1 
FRG1 is located 120 kb proximal of the D4Z4 repeat array and has been identified through its 
association with a CpG island [87, 422, 433]. The gene has multiple related copies in the human 
genome with a minimum of seven locations that are in part expressed pseudogenes [147]. The 
protein is highly conserved in vertebrates and invertebrates, is ubiquitously expressed and 
localises to nucleoli, Cajal bodies and speckles after transient and stable transfection [87, 201]. 
Nucleoli are mainly involved in RNA ribogenesis, nuclear export of a subset of mRNAs and 
maturation of small nuclear ribonuclear proteins [42, 267, 314, 350, 361], while Cajal bodies 
are thought to be involved in the post-transcriptional modification of small nucleolar RNAs and 
small nuclear RNAs, and in shuttling small nuclear ribonuclear proteins from the nucleoplasm 
to the nucleus [40, 41, 59, 79, 286, 361, 362, 400]. Speckles may coordinate transcription and 
RNA processing, and may also be a storage site for protein splicing factors and small nuclear 
ribonuclear proteins [91]. The localisation of FRG1 could therefore imply a functional role in 
RNA processing [201]. Attempts to detect differences in allele-specific transcription of FRG1 
between patients and controls using reverse transcribed RNA isolated from muscle and 
lymphocytes failed [87], but recently upregulation of gene expression was observed in FSHD 
muscle biopsies ([121] and T Rijkers, unpublished results). In contrast, Jiang et al. [177] 
observed a modest, but significant decrease of transcription levels in FSHD muscle samples by 
using real-time PCR and recently generated microarray data does not show expression changes 
[428]. However, in the latter it is not possible to discriminate between expression from 
different copies of FRG1 in the genome [428]. Even though a reason for the discrepancy in all 
data is still unclear, this gene remains a candidate. 
 
1.2.4.4 TUBB4Q; tubulin beta polypeptide 4 member Q gene 
Exon-trapping experiments revealed an exon-trap clone 80 kb proximal to D4Z4 [127]. 
Sequence analysis identified a transcript that contains four exons encoding an ORF of 434 
amino acids. This putative gene sequence, designated TUBB4Q, is highly homologous to ß2-
tubulin, a member of a large tubulin family with copies on many chromosomes and maps to 
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various regions in the genome (see also Paragraph 1.3.4.1) [129]. The tubulin proteins form 
microtubuli in eukaryotic cells and are associated with chromosome division, cellular 
movement, cell polarity, cytoskeleton integrity and intracellular vesicle transport [150, 191]. 
The putative protein sequence indicates a truncated protein and displays amino acid 
substitutions in functional protein domains that are highly conserved in the ß-tubulin family. 
Furthermore, allelic sequence variation with the most relevant polymorphism at the initiation 
codon is detected, which is remarkable for a highly conserved ß-tubulin protein. These 
observations suggest that this gene might be inactive [126, 127]. Despite efforts to detect 
TUBB4Q expression no transcripts have been observed in fetal and adult tissues, suggesting 
that this copy of the ß-tubulin homologues is indeed an inactive pseudogene [85, 127]. 
 
1.2.4.5 FRG2; FSHD region gene 2 
Computer prediction algorithms identified a novel transcript 37 kb proximal to the D4Z4 
repeat array, called FRG2 [334, 335]. This gene has a putative muscle-specific promoter and 
generates a transcript of 2 kb, encoding a putative protein of 278 amino acids. Related copies of 
this gene are detected on multiple chromosomes, mostly in subtelomeric or pericentromeric 
regions. One of them is located on chromosome 10, which is highly homologous to the 
chromosome 4 copy. Furthermore, luciferase reporter assays indicated that increasing numbers 
of D4Z4 repeats inhibit FRG2 promoter activity. Transient transfection experiments revealed a 
nuclear localisation of the encoded protein, in which overexpression of FRG2 apparently causes 
morphological changes in all cell lines tested. Apart from constitutive active expression in the 
rodent monochromosomal chromosome 4 cell line GM11687, FRG2 expression from 
chromosomes 4 and 10 is only observed in primary myoblasts of FSHD patients upon 
differentiation and in fibroblasts of FSHD patients and control individuals that are forced into 
myogenesis with an adenovirus expressing MyoD. FRG2 transcripts detected in these cell lines 
were mainly derived from chromosome 10 and to a lesser extent from chromosome 4. The 
expression detected in myoblasts upon differentiation from non-FSHD myopathies is derived 
from FRG2-related copies on chromosome 3 or 22 [334, 335]. Recently, expression was 
detected in FSHD muscle biopsies [121], but Rijkers et al. [334, 335] could not confirm FRG2 
expression in muscle biopsies, neither in proliferating myoblasts, fibroblasts, peripheral blood 
lymphocytes or brain tissue. 
The FRG2 genes on chromosomes 4 and 10 are attractive candidate genes for FSHD, 
because of their location, the D4Z4-sensitive FRG2 promoter and the observed expression in 
differentiating FSHD myoblasts and fibroblasts that are forced into myogenesis [334, 335]. 
Recently, it was suggested that as a consequence of D4Z4 repeat contraction a disturbed 




Furthermore, this contraction can result in a local chromatin change [296]. Both features could 
lead to FRG2 expression in cis on chromosome 4 [334, 335]. Activation of FRG2 may also 
occur in trans for the chromosome 10 copy [334, 335], possibly via transvection, i.e. the ability 
of a locus to influence the activity of another allele in trans (reviewed in [318]). This process is 
possible during chromosomal pairing in interphase, which is also observed for chromosomes 4 
and 10 [367]. 
Lemmers and colleagues [229] described a healthy father with a normal D4Z4 repeat 
array, but lacking one of the FRG2 copies due to a deletion in the 4q35 region. His affected son 
inherited this chromosome lacking FRG2 in combination with a contraction of D4Z4 to three 
repeat units. Recently, also two other families with p13E-11-associated deletions were observed 
[230]. Although these results challenge a possible role for FRG2 in FSHD pathology, expression 
studies in these individuals may provide support for the proposed transvection mechanism for 
FRG2 [334]. 
 
1.2.4.6 Detection of gene expression 
Since the disease-causing mechanism of FSHD has still not been elucidated, several research 
groups decided to shift their focus to the detection of possible molecular changes as a 
consequence of D4Z4 contraction. A PCR-based subtractive hybridisation was used to study 
global differences in mRNA expression patterns in muscle from FSHD patients and healthy 
control individuals to identify genes involved in FSHD muscle [387]. With this method a global 
alteration of gene expression specific for FSHD muscle was observed in a significant number of 
muscle-specific genes and genes encoding transcription regulators. The hypothesis that the 
contraction of the D4Z4 repeat array initiates transcriptional deregulation by a positional effect 
(see Paragraph 1.6.2) was then further investigated using human muscle samples and revealed 
an FSHD muscle-specific overexpression of ANT1, FRG1 and FRG2 [121]. Furthermore, this 
study discovered an element in D4Z4 that binds a multiprotein complex, termed D4Z4 
recognition complex, which includes the transcription activator and/or repressor protein YY1, 
DNA helicase-containing nucleolin and HMGB2, a protein involved in chromatin architecture. 
This complex can bind to D4Z4 sequences in vitro and in vivo in HeLa cells and in a rodent-
human monochromosomal cell hybrid containing a single human chromosome 4 [121]. 
However, this has not yet been confirmed in myoblasts or muscle extracts. Furthermore, 
reducing the levels of the proteins in this D4Z4 recognition complex in cell culture resulted in 
FRG2 transcriptional upregulation. Gabellini et al. [121] therefore suggested that genes located 
at 4q35 would be inappropriately expressed in FSHD patients as a consequence of a reduced 





A global gene expression profile of mature FSHD muscle tissue was generated using microarrays 
to gain more insight in disease-specific muscle changes [428]. The profile contained altered 
genes that are involved in cell cycle control and cellular differentiation and proliferation. Also 
many observed deregulated genes are associated with myogenesis and direct targets of the 
transcription factor MyoD. This may suggest a defect in FSHD muscle cell differentiation, such 
as an inefficient completion of the myogenic program. Genes that confer a reduced capacity to 
buffer oxidative stress are deregulated as well. However, none of the 4q35 genes show an altered 
expression [428], which was also observed by other groups [44, 87, 97], but contrasts with the 
findings of Gabellini et al. [121]. The reason for this discrepancy remains to be elucidated. 
 
1.2.5 In vitro cell culture systems 
Because culturing of muscle cells in vitro may provide useful information, several groups 
explored cell culture techniques to clarify aberrant growth patterns and possible altered 
pathways [109, 346, 397, 428, 440]. 
 
FSHD myoblasts studied in culture present a necrotic phenotype displaying large vacuoles and 
swelling of the nucleus and cytoplasm, which could be due to a degradative process [108, 428]. 
This morphology is likely mediated by altered expression of extracellular matrix components. 
These myoblasts display a decreased replicative capacity, possibly because the normal cell cycle is 
disrupted or cells approach senescence [108]. Furthermore, FSHD myoblasts show an increased 
susceptibility to oxidative stress (induced with paraquat) before they differentiate and fuse into 
myotubes [428]. In addition, FSHD myoblasts fuse much faster than control myoblasts when 
exposed to differentiation media due to an upregulation of MyoD [108, 109]. These growth 
processes may contribute to the observed cellular morphology and eventually to a muscle disease. 
Unfortunately, none of the features observed in culture are detected in FSHD muscle biopsies 
(see Paragraph 1.1.2.3 for a description on muscle biopsy characteristics), but do suggest that a 
deviant gene expression may occur in the first phases of skeletal muscle development, i.e. in 
undifferentiated myocytes [108, 428]. This altered myogenic differentiation process was 
supported by the results obtained from GeneChip expression profiling of mature FSHD muscle 




1.3 Organisation of repeats and subtelomeric regions in the genome 
 
As FSHD is associated with the D4Z4 repeat located in the subtelomeric region of chromosome 
4q, a description on several repeat characteristics and the consequences when repeats are 
involved in human disease is given below, followed by a characterisation of subtelomeric 
regions. The observed D4Z4 behaviour in relation to FSHD will then be discussed in more 
detail. 
 
1.3.1 Repetitive elements in the genome 
A substantial fraction of the eukaryotic genome, at least 50% [217], consists of repetitive 
sequences of various sizes and composition that can occur in tandem, inverted and dispersed 
organisations [166], organised as clusters in specific chromosomal regions or randomly spread 
throughout the genome [240, 373]. Repetitive DNA components consist of families of 
sequences that are related to each other, but not identical [234]. There are various classes of 
repetitive DNA in the human genome [53, 94, 217, 233, 235, 368, 373]: (1) telomere repeats 
(TTAGGG)n located at the ends of chromosomes that have a size of 5-12 kb; (2) subtelomeric 
repeats, classes of repetitive sequences that are interspersed in the last 500 kb of non-repetitive 
DNA located adjacent to the telomere. Some of these repeat sequences are chromosome-
specific, while others can be observed near the ends of all chromosomes; (3) microsatellite 
repeats (also called simple tandem repeats or short tandem repeats), which are common in the 
human genome in a variety of simple mono-, di-, tri-, tetra-, and penta-nucleotide tandem 
repeats that are dispersed in the euchromatic arms of most chromosomes. Their whole 
repetitive region spans less than 150 bp. The dinucleotide repeat is the most common with a 
size of 20-60 bp and a total copy number of 100000, occurring approximately every 30 kb in 
the genome. Many of these sequences are polymorphic in copy number; (4) minisatellite 
repeats, a class of dispersed tandem repeats in which the repeating unit is on average 25-35 bp 
that has a variable sequence, but does contain a 10-15 bp core sequence. These satellites range 
in size from 200 bp up to several kb and have a lower copy number than the mircosatellites. 
These repeats tend to occur in greater numbers towards the ends of chromosomes. One type of 
minisatellite repeat is the variable number of tandem repeats (VNTR); (5) Alpha satellite DNA 
(or alphoid DNA), a family of related repeats that occur as long tandem arrays consisting of 
two dimers of each approximately 170 bp long at both sides of the centromeres of all human 
chromosomes and extend over a 1-5 kb region; (6) Satellite I, II and III repeats, of which type I 
is AT-rich and composed of alternating arrays of 17-25 bp repeat units, while satellite II and III 
repeats are both derived from the repeat unit ATTCC. The size may vary from 100 kb to over 1 
Mb. All types occur as long tandem arrays in heterochromatic regions of chromosomes 1, 9, 16, 
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17 and Y and in satellite regions on chromosomes 13p, 14p, 15p, 21p and 22p; (7) mega- or 
macrosatellite DNA, which is characterised by array sizes that can be modest compared to 
some satellite DNA arrays. The prefix “mega-“ or “macro-“ has been used to emphasize the 
large size of the repeating unit that can be several kb; (8) Cot1 DNA is a fraction of repetitive 
DNA that contains sequences that have copy numbers of 10000 or more; (9) A large category 
of transposon-derived interspersed repeats that can be divided in four different sub-groups: (a) 
Alu repeats, which are the most common interspersed repeats in the human genome, are part 
of the non-viral superfamily consisting short interspersed nuclear elements (SINEs). This 100-
400 bp sequence occurs on average once every 3300 bp with a total copy number of one million 
copies. Another major human SINE family is the mammalian-wide interspersed repeat family 
that is present in approximately 2% of the genome; (b) L1 repeats are long interspersed nuclear 
elements (LINEs) originating from a viral super family that are 1-7 kb in length. These repeats 
occur on average every 28 kb in the genome with a total copy number of about 500000; (c) 
Long terminal repeat retroposons (LTRs), which are autonomous interspersed elements. 
Although a variety of LTRs exist, only the vertebrate-specific endogeneous retroviruses appear 
to have been active in the mammalian genome; and (d) DNA transposons, which are also 
interspersed repeats. This group resembles bacterial transposons, of which the human genome 
contains at least seven different classes. 
About 45% of the human repeat sequence belongs to the last category (category 9), with 
SINEs and LINEs for 34%, LTRs for 8% and DNA transposons for 3% of the sequence [53, 94, 
217, 235, 368, 373]. Two percent of the total repetitive sequences encode multigene families, 
usually arranged in tandem arrays [241, 242, 311]. This extensive repetition of a gene may 
occur when large amounts of the gene product are required [233], like those for ribosomal 
RNAs and U1 and U2 small nuclear RNAs [241, 242, 311]. However, the majority of these 
repetitive sequences seems to be non-coding [217]. 
 
1.3.2 Mechanisms of repeat evolution 
Repetitive sequences in all organisms can evolve in a concerted fashion to maintain sequence 
homogeneity within a repeat array sequence. This is a universal biological phenomenon, 
described as a complex process that leads to homogenisation of DNA sequences that belong to 
a given repetitive family containing both homologous and non-homologous sequences [240]. 
Homogenisation occurs by unequal crossover, gene conversion or sister chromatid exchange of 
the repeat array and implies that individual repeats of a tandem array are very similar or even 
identical within a species, but deviate significantly from the orthologous repeats of closely 
related species ([241] and all references therein). To account for the sequence homogeneity, 
two distinct complex processes operating at different rates are involved: intrachromosomal and 
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interchromosomal exchanges [240, 241]. Intrachromosomal events homogenise individual 
repeat arrays within a single lineage completely, while interchromosomal exchanges will 
homogenise all repeat arrays within the population. Homogenisation within an array occurs at 
a much higher rate than between arrays [241]. A good example of a repeat array that evolves in 
this way is the RNU2 locus encoding human U2 small nuclear RNA [241, 242]. Though not all 
repetitive multigene families undergo concerted evolution, as is demonstrated for the major 
histocompatibility complex and immunoglobin multigene families [240, 289]. There is also 
evidence that concerted evolution of repetitive non-coding DNA sequences is possible and may 
work via similar mechanisms [99, 240]. However, repetitive non-coding DNA can also evolve 
via recent amplification and transposition of the repetitive sequence [240]. 
 
1.3.3 Repeat sequences associated with disease 
Recombination is a key event in the genome that occurs during meiosis. This mechanism, 
which is most likely to occur between homologous DNA sequences, takes place approximately 
1 or 2 times per chromosome during a meiotic division and is essential for both survival and 
evolution of a species as it generates genetic diversity [132]. However, when chromosomes are 
misaligned to homologous sequences, these recombination processes can, for example, result 
in rearranged gene clusters, but also in damaging mutations and disease [132, 320]. The 
existence of repeated sequences make such unequal crossover events possible. 
 
1.3.3.1 Low Copy Repeats 
Low copy repeats, which are present in approximately 5% of the human genome, influence the 
stability of the genome. By non-allelic homologous recombination between these repeats 
structural rearrangements may occur, resulting in deletions, duplications, inversions and 
translocations and may eventually result in genomic disorders (reviewed in [365]). For 
example, Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to 
pressure palsies are both caused by non-allelic homologous recombination between flanking 
low copy repeats in which a 1.4 Mb duplication on 17p12 causes Charcot-Marie-Tooth disease 
type 1A, while deletion of this fragment results in hereditary neuropathy with liability to 
pressure palsies. Some other examples are Williams syndrome in which most patients have a de 
novo deletion of 1.6 Mb of chromosome 7q11.23, hemophilia A in which 45% of males carry a 
500 kb inversion of Xq, and two syndromes linked to imprinting genes, Prader-Willie 
syndrome and Angelman syndrome, that are both (in most cases) due to a 4 Mb deletion of 
15q11-13 on the inherited paternal chromosome in the case of the Prader-Willie syndrome or 




1.3.3.2 Trinucleotide repeat expansions 
Trinucleotide repeats are simple stretches of DNA (like for example CCG or CAG) that, when 
expanded, sometimes cause disease [77, 125, 174, 233, 331, 409]. These repeat sequences vary 
in copy number and become unstable when they increase in size beyond a certain threshold. 
Several shared characteristics have been identified for diseases associated with these unstable 
repeat expansions: (1) the mutation manifests as a change in repeat copy number and the 
mutation rate is related to the initial copy number of the repeat; (2) rare “founder” events will 
result in alleles that have an increased likelihood of undergoing changes in the number of 
repeats; (3) a disease that results from a repeat expansion displays a relationship between 
repeat copies and the severity and/or age at onset of the disease, which means that an earlier 
age at onset and increasing severity of the disease are correlated with larger repeat size; (4) the 
origin of the disease allele (i.e. maternal or paternal) will often influence repeat expansion in 
subsequent generations as paternal transmission carries a greater risk of expansion; and (5) 
mutated repeats are usually instable both in the germline as in somatic cells. For each disease, 
the repeat sequence involved, the specific location of the mutation with respect to a gene (or 
genes) (i.e. 3’ or 5’ untranslated region, coding region or within intron sequence), the 
threshold for the amount of repeats allowed and the consequences of the loss and/or gain of 
function of the proteins involved will vary. As a result, this will cause differences in gene 
expression, cellular specificity and function(s) that may lead to various disease phenotypes [77, 
125, 174, 233, 331, 409]. Surprisingly, all published disease phenotypes are primarily related to 
neurological and neuromuscular dysfunction [125]. 
 
The first trinucleotide repeat expansion disease identified is the fragile X syndrome with a 
repeat expansion located in non-coding sequence [77, 130, 208]. Friedriech ataxia, myotonic 
dystrophy 1 and 2, two forms of spinocerebellar ataxia (type 8 and type 12) and fragile XE 
syndrome are also examples of diseases associated with non-coding repeats characterised by 
large variable expansions, which will cause mental retardation, behavioural abnormalities and 
eventually multiple tissue dysfunction or degeneration [77, 125, 323]. 
The CAG repeat expansions, which are located within exons and coding for 
polyglutamine tracts, are observed in neurodegenerative disorders, like Huntington’s disease, 
dentatorubral pallidoluysian atrophy, spinobulbar muscular atrophy, and several types of 
spinocerebellar ataxia that are characterised by progressive neuronal dysfunction in particular 
brain regions that will begin in mid-life and eventually will result in severe neurodegeneration 
[77, 239, 331, 409]. These expansions observed are much smaller and show less variation than 
those observed for non-coding repeat expansions. The role of these expansions appears to be a 
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complex process with many different components involved, but due to similar phenotypic 
characteristics common mechanisms will most likely be the cause of these diseases. 
The expansions of alanine tracts (GCG, GCA, GCC) (reviewed in [52]) usually do not 
exceed more than 20 repeats and are all approximately of the same size. They often occur in a 
gene encoding for a transcription factor. The effect can be a loss-of-function or a gain of an 
abnormal function and will result in a disturbance of body plan development, probably 
through an altered expression of downstream genes. Synpolydactyly type II and Cleidocranial 
dysplasia are examples of these alanine expansions. In contrast, oculopharyngeal muscular 
dystrophy is the result of an expansion in a gene that does not code for a transcription factor, 
but for a polyadenine-binding protein. This disease is similar to the polyglutamine expansion 
diseases on the clinical and molecular level. 
 
The exact cause of these repeat expansions is not known, although it is thought that the DNA 
secondary structure plays an important role [125]. One proposed mechanism is the DNA 
slippage model, which predicts that repeat size variability arises during DNA replication in a 
cell division-dependent manner [332]. The repetitive character of trinucleotide sequences 
allows them to fold into hairpins, slipped-stranded DNA or more complex configurations [125, 
174, 310], which can cause delay and slippage of DNA polymerase [310]. The DNA mismatch 
repair pathway should repair these structures, when they are formed during DNA replication, 
to avoid expansions and deletions. However, with large expansions these structures may occur 
too frequent, and may, consequently, not all be repaired and thus eventually result in repeat 
size changes [141, 312]. However, since most cell types have recombination and repair 
mechanisms, the instability of trinucleotide repeats can also arise from gene conversion as a 
consequence of an unequal recombination or by error-prone DNA repair [216]. 
Recently, Gomes-Pereira et al. [141] proposed a new hypothetical model in which 
repeats usually replicate in the form of standard duplex DNA, but at some point in the cell 
cycle this duplex is melted. The repeat sequences then have the opportunity to misalign and 
form loop-outs, like hairpins or slipped-stranded DNA, on both strands. These structures are 
targets for repair by mismatch repair components, but in the absence of a strand-specific signal 
for the correct sequence the mismatch repair machinery incorporates these looped structures 
and introduces a single stranded nick on the other strand, which could act as a initiation point 
for nuclease-mediated gap extension. DNA polymerase then fills the gaps and the free ends are 
joined by DNA ligase to generate a product expanded by the length of the loop-outs. When 
mismatch repair components are absent, small loop-outs may accumulate and form large loop-
outs. These large loops may be detected by another DNA repair mechanism and result in the 




The examples mentioned above show how repeat arrays may behave and can cause disease 
when mutated. These repetitive DNA sequences can also be beneficial for an organism, like the 
repeated sequences that allow the rapid production of ribosomal RNA when needed [166, 233]. 
An excess of repetitive DNA will eventually cost an organism energy when replicating, 
interferes in chromosomal crossovers, and recombinates and duplicates resulting in a disturbed 
chromosomal integrity. These sequences are usually located in constitutive heterochromatin 
[166] and have been mapped to specific chromosomal regions, like centromeres and 
(sub)telomeres [343]. 
 
1.3.4 Subtelomeric regions 
Chromosomes of organisms as diverse as yeast, Drosophila and human, contain subtelomeric 
regions, located immediately adjacent to the simple telomeric repeat sequence (TTAGGG)n 
[344, 443]. These regions, which are often GC-rich as a consequence of a diversity of GC-rich 
minisatellites [344], are defined by multichromosomal blocks of sequence that contain a wide 
variety of repetitive DNA, ranging from low copy interspersed repeats found on a few 
chromosome ends, to highly repetitive repeat sequences present in many subtelomeric regions 
[114, 266, 344]. These subtelomeres show comparable features in structure, function and 
composition of various repeated elements, but the sequences of different elements and sizes of 
these regions can vary between organisms [54, 266]. Subtelomeric regions are more often 
involved in recombination processes at chromosome ends than at other parts of the genome 
[34, 64, 115]. Due to exchanges between subtelomeres of different chromosomes as a 
consequence of sequence homology, copies can be dispersed throughout the genome [344]. As 
a result of this dynamic behaviour, the composition of a chromosome may vary distinctly 
among individuals of the same species [243, 266] and the size of a subtelomere sequence can 
vary from a few hundred bp, like the human XpYpter [13], to more than 100 kb, like the 
regions on 4qter [87] and 16pter [423], before unique DNA sequences specific for each 
chromosome are detected. 
 
1.3.4.1 Function of subtelomeres 
Several hypotheses have been proposed for a function of subtelomeric regions. It has been 
suggested that they could act as a buffer between functional telomeric repeats and genes 
proximal to subtelomeric regions to protect these genes from heterochromatinisation and 
silencing [16, 266, 317]. Subtelomeres may also act as a storage area, where genomic sequences 
that are no longer used can be discarded. Many repetitive sequences, pseudogenes and partial 
regions of homology to genes that function elsewhere in the genome are located in the 
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subtelomeres and support this hypothesis [243]. In contrast, subtelomeres can also be seen as 
functionally active regions and, because they are more prone to recombination, could then 
serve as a region where new genes are generated and modified [243, 265]. In favour of this 
hypothesis are genes that are actually transcribed from the subtelomeric sequences. A good 
example is the olfactory receptor (OR) gene family observed at various chromosomal locations 
at more than 40 sites in the human genome and preferably located subtelomerically, 
comprising at least 30 sequences [243, 265]. Their behaviour may contribute to the 
amplification and generation of variation in these OR genes, which encode various receptors 
that allow the recognition of ~10000 odorants [243]. Individuals can carry up to 56 copies of 
subtelomeric OR genes [383], but so far only one gene copy (OR-A) shows expression [243]. 
This gene copy varies per individual in number, sequence and location due to recent 
duplications of subtelomeric sequences and is actively transcribed from several chromosomal 
regions. Individuals may express different combinations of the multiple OR-A gene copies and 
therefore display a prominent aspect of gene diversity and phenotypic variation that will 
eventually allow humans to recognize numerous new odorants and result in differences 
between individuals [243]. 
The ß-tubulins are also a good example to underline this hypothesis. In humans, ß-
tubulins are part of a multigene family that consists of several isotypes with many associated 
pseudogenes. Seven functionally expressing genes have been reported [247]. Van Geel et al. 
[127] described the identification and characterisation a novel ß-tubulin gene family. Besides a 
copy in the subtelomeric location on 4q35, called TUBB4Q (see Paragraph 1.2.4.4 for a 
detailed description), related sequences were also identified on chromosomes 1, 9, 10, 12, 16, 
18 and Y. All these sequences show high homology to functional ß-tubulin genes. Analysis of 
the TUBB4Q sequence compared to the seven known functional genes suggests that this 
sequence is a novel isotype of the ß-tubulin family and might even be a new member [127]. A 
model suggested for tubulin evolution proposes that structural constraints are lifted after gene 
duplication, which causes a relatively fast protein change [245]. TUBB4Q might thus have 
changed into a pseudogene very recently or is still evolving towards a functional ß-tubulin. At 
this moment, this gene is most likely in dormant or inactive state. Because sequences related to 
TUBB4Q have been identified on other chromosomes as well, these novel ß-tubulin family 
members were presumably distributed through the genome by duplications and 
rearrangements [127]. 
 
1.3.4.2 Organisation of subtelomeres 
Flint and colleagues [114] proposed a model for subtelomeric organisation based on the 




proximal subdomain separated by degenerated (TTAGGG)n repeats and putative origin-of-
replication consensus sequences. The subdomains of 4p, 16p and 22q show homology to the 
subtelomeric region on 4q, but further to no other chromosome end. The distal subtelomeric 
region is composed of small repetitive sequences that show interrupted homology of less than 2 
kb with many other chromosome ends, while the proximal subdomain only interacts with a 
subset of chromosome ends and the blocks of uninterrupted homology tend to be longer (10-40 
kb). The function of the repeats that separate the two subdomains is not clear yet, but it can be 
involved in limiting interactions with non-homologous chromosomal regions. 
 
A chromosomal region, like a subtelomere, can increase gene expression and variation in 
phenotype by its dynamic behaviour. However, subtelomeric deletions and translocations 
(reciprocal and/or cryptic) can also cause human diseases. Examples are idiopathic mental 
retardation [116], developmental decay and learning difficulties [408], Wolf-Hirschhorn 
syndrome [5], Miller-Dieker syndrome [213],   α-thalassaemia [115] and FSHD. For the FSHD 
locus subtelomeric rearrangements of the D4Z4 repeat can even occur with or without 
pathological consequences [86, 262, 295, 370, 407, 435]. 
 
1.3.5 Subtelomeric region 4q35 and its association with FSHD 
Due to the spreading of homologous D4Z4 sequences over the entire genome, and especially the 
presence of a highly homologous and equally recombinogenic repeat array on 10q26 [15, 82], 
one can expect the opportunity for mispairing between non-homologous chromosomes and 
suspect exchanges between 4q35 and 10q26 subtelomeres. 
When the restriction enzyme BlnI is used in combination with EcoRI, one expects that 
two fragments corresponding to chromosome 4 remain visible after hybridisation with probe 
p13E-11, whereas chromosome 10-derived repeat units are cleaved by BlnI [83] (see Paragraph 
1.2.3.1; reviewed in [231]). Unexpectedly, in a study applying these double digests to 102 Dutch 
FSHD patients evidence was acquired for exchanges between the repeat arrays of 4q35 and 
10q26 [86]. Besides the expected pattern also individuals displaying none, one, three or four 
BlnI-resistant EcoRI fragments were encountered. This suggested that chromosome 4-derived 
repeat units can be present on chromosome 10, and vice versa, as schematically depicted in 
Figure 1.4.A. The exchange of the highly homologous repeat units between chromosomes 4 and 
10 could have implications for the molecular diagnosis of FSHD, since, as a consequence of 
these translocations, a contracted chromosome 10-derived repeat array on 4q35 also results in 
FSHD. To establish the frequency of these translocations in a healthy population a randomly 
selected panel of 50 Dutch control males was tested and interchromosomal exchanges were 





1.3.5.1 Identification of complex exchange patterns 
To study the structure of the exchanged repeat arrays in these above described 10 control 
individuals in more detail, the same membranes were rehybridised with probe 9B6A that 
recognises the D4Z4 repeat instead of the unique region proximal to the repeat array [229]. 
Thereafter, seven individuals showed a hybridisation pattern consistent with a homogeneous 
repeat array, which indicates homogeneous chromosome 10-derived repeats on one of the 
Figure 1.4 
(A) Schematic overview of possible exchanges between the subtelomeric regions on chromosomes 4q35 and 
10q26. Chromosome 4 sequences are depicted in white, while chromosome 10 sequences are depicted in black. 
The rounded tip of each chromosome indicates the repeat. Most individuals display a standard repeat array 
configuration of a chromosome 4 repeat array on chromosome 4 and a chromosome 10 repeat array on 
chromosome 10 (disomic for D4Z4 repeat, indicated as “disomy”). Exchanges may result in the presence of a 
chromosome 4-derived repeat array on chromosome 10 (trisomic for D4Z4 repeat; “trisomy”) or a chromosome 
10-derived repeat array on chromosome 4 (monosomic for D4Z4 repeat; “monosomy”). The presence of two 
chromosome 4-derived repeat arrays on chromosome 10 (quatrosomic for D4Z4 repeat; “quatrosomy”) or two 
chromosome 10-derived repeat arrays on chromosome 4 (nullisomic for D4Z4 repeat; “nullisomy”) may also be 
observed. The situation in which a chromosome 4-derived repeat array resides on chromosome 10 and a 
chromosome 10-derived repeat array resides on chromosome 4, termed “apparent disomy”, cannot be 
discriminated from the standard “disomy” configuration by PFGE of DNA digested with the appropriate 
restriction enzymes. Furthermore, the repeat arrays on chromosomes 4 or 10 may consist of repeat units derived 
from both chromosomes, indicating hybrid structures (hybrid and complex hybrid). 
(B) Examples of exchanges observed between the repeats on chromosomes 4q35 and 10q26. Molecular analysis of 
DNA from six individuals by PFGE of DNA digested with EcoRI (“E”) or EcoRI/BlnI (“B”) followed by Southern 
blot analysis and hybridisation with probe p13E-11. After EcoRI digestion four alleles will be identified: two from 
chromosome 4 and two from chromosome 10. Treatment with both EcoRI/BlnI will fragment chromosome 10 
repeat units, while the fragment containing chromosome 4 repeat units remains undigested, apart from digestion 
at the only BlnI restriction site present 3 kb distal to the proximal EcoRI site on 4q35. Individuals 1, 2, 4 and 5 
display the standard pattern (“disomy”), the most common allele configuration or “apparent disomy”, which is 
observed in 1% of cases [295]. Individual 3 is an example of “monosomy”, where three repeat arrays are sensitive 
to BlnI. Individual 6 is an example of “trisomy”, where three arrays are resistant to BlnI. Marker sizes (“M”; in kb) 






chromosome 4 alleles or homogeneous chromosome 4-derived repeats on one of the 
chromosome 10 alleles. In the other three, a more complex hybridisation pattern was obtained, 
indicating a hybrid structure of the repeat array on one of the chromosomes that consisted of 
repeat units derived from chromosomes 4 and 10. All possible rearrangements are depicted in 
Figure 1.4.A. Examples of some observed hybridisation patterns probed with probe p13E-11 are 
depicted in Figure 1.4.B. 
 
1.3.5.2 Somatic pairing of 4qter and 10qter 
Detailed sequence analysis revealed that the two subtelomeres of 4q and 10q are more than 95% 
homologous [82], which makes the exchange of genomic material resulting in repeat arrays 
composed of chromosome 4-derived or chromosome 10-derived repeat units (or a mixture of 
both) on the other homologous chromosome during meiosis possible. This is supported by the 
observation that homologous chromosome pairing is initiated in subtelomeric regions during 
meiosis in humans [19, 61, 404]. The hypothesis that chromosome ends may pair preferentially 
was further explored by studying spatial orientation in interphase nuclei. Stout and colleagues 
[367] applied FISH on interphase nuclei to test the hypothesis that chromosome regions located 
in close proximity will be more often involved in somatic recombinations leading to 
rearrangements than chromosomes positioned at a greater distance. 
The frequency of somatic pairing between subtelomeres was significantly higher than 
between non-telomeric regions (average of 3.5% versus average of 2.1%) and the pairing 
frequencies depended to a great extent on specific regions involved. Furthermore, subtelomeric 
regions tended to replicate asynchronously. The authors then focussed on the 4q subtelomeric 
region to study alterations in nuclear positioning and interactions with other parts of the 
genome. This revealed a minor but significant increase in the pairing frequency of 10q and 4q 
subtelomeres in FSHD patients when compared to control individuals, indicating that this 
pairing may promote exchanges between the 4q35 and 10q26 subtelomeric repeat arrays. In this 
way interchromosomal rearrangements might participate in FSHD pathology. 
 
Considering these two phenomena, translocations between 4q35 and 10q26 and somatic 
pairing of 4qter and 10qter, our laboratory decided to investigate the percentage of exchanges in 
a large healthy population to gain more insight in the normal occurrence and overall repeat size 
distributions. These results are described in Chapters 2 and 3. 
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1.4 Mosaicism and its consequences for human disease 
 
The term mosaic was used in ancient times to refer to floors or windows with numerous little 
colourful pieces of stone or glass representing mostly religious or historical events. In a biological 
context, mosaicism may refer to two distinct phenomena. Mosaicism can refer to a viral disease 
of plants, resulting in light and dark areas in the leaves, which then often become shrivelled. An 
alternative definition, and one more appropriate for molecular biology, is a condition in which 
an individual has two or more genetically distinct cell lines derived from a single zygote, but 
differing by virtue of the presence of a mutation or non-disjunction [131]. Mosaicism arises 
when an error disrupts the correct number of chromosomes segregating to each cell during cell 
division or creates a mutation in a single gene or locus [313]. The first paper on the existence of 
chromosomal mosaicism was published in 1959. Here, the phenotype of a case of Klinefelter 
syndrome was described, in a man with two distinct cell populations in his cultured bone 
marrow. One cell population contained the normal karyotype (46,XX), whereas the other cell 
population contained the karyotype (47,XXY) [117]. Mosaicism is a very common 
phenomenon in multicellular organisms. In humans, for example, female cells display random 
inactivation of the maternally or paternally derived X-chromosome, and so they exhibit 
mosaicism for the expression of specific genes on the X-chromosome. Moreover, as the number 
of cells in the adult human body (1014) exceeds the mutation frequency of most genes, one 
must conclude that every individual must exhibit some degree of genetic mosaicism. Thus, 
everyone probably carries mutations in any given gene in some proportion of his or her cells 
[153]. 
The range of diseases that have been associated with mosaicism is very broad and 
includes almost all processes in the human body. Observations of mosaicism in all its forms 
could thus have important clinical implications. All events that induce mosaicism can influence 
the phenotype in a negative or positive manner. The effect of a mosaic population is usually 
masked, but can also result in major phenotypic expression and disease. Mosaicism has already 
been described for more than 30 different diseases, including both Mendelian and non-
Mendelian disorders, like hemophilia, Duchenne muscular dystrophy, Friedreich ataxia and 
FSHD [144]. The next paragraphs will give a general overview on mosaicism, followed by a 
description on the occurrence of mosaicism for the 4q35 region and its consequences for FSHD. 
 
1.4.1 Inheritance of mosaicism 
Mosaic cell populations can be the result of mutations in nuclear or mitochondrial DNA in 
post-zygotic cells, epigenetic alterations of DNA, numerical or structural chromosomal 
abnormalities (such as missing or extra chromosomes) or of spontaneous reversion of inherited 
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mutations. This may occur in any given cell and can be passed on to all daughter cells at any 
particular point in development or lifetime of an individual. From here on, any mutation 
described will be referred to as a mosaicism-inducing event. 
 
One of the most important issues in genetic counselling is whether a mutation is likely to be 
transmitted to the next generation. This depends on the nature of the mutation and more 
importantly, when and where it occurs. When the mutation occurs in one of the first few cell 
divisions after fertilisation, it yields a larger proportion of mutant cells in the total cell 
population than when the mutation occurs in a later developmental stage [153, 313, 442, 442].  
A post-zygotic mutation can be passed on to the offspring only if it is present in cells 
that give rise to germ cells. Therefore, a distinction is made between germline mosaicism (also 
termed gonadal mosaicism) and somatic mosaicism. In the latter form, the absence of the 
mutation in germ cells will prevent transmission to progeny. When mosaicism arises during an 
early stage in embryogenesis, the same mutation can coexist in both somatic and germ cells 
within the same individual. This is dependent on the specific cell (type) affected and the 
developmental timing of the mosaicism-inducing event. A mutation will be passed on through 
the germline, but will be absent from somatic cells only if the mutation occurred in cells already 
committed to germline formation [153, 442]. The next paragraph will discuss these two types of 
mosaicism in more detail. 
 
1.4.2 Germline and somatic mosaicism 
When two or more children manifest a phenotype of an autosomal dominant or X-linked 
disorder in a family with no history of disease, germline mosaicism in a substantial number of 
germ cells in one of the parents could be the underlying cause and has been demonstrated in 
disorders like osteogenesis imperfecta, hemophilia A and Duchenne muscular dystrophy [24, 72, 
100, 153, 442]. In this type of mosaicism, which is depicted in Figure 1.5.A, the mutation can 
occur (1) only in the germ cell precursor which will undergo meiosis to yield a germ cell that will 
continue to divide, or (2) very early in embryonic development, before the cell fate 
determination to germinal or somatic cells, and will thus be present in both cell types. The 
latter is also called gonosomal mosaicism. Factors such as the gene or locus involved, tissue 
specificity and the degree of mosaicism will eventually determine if a carrier may be 
asymptomatic or present various characteristics of a disease [448]. The exact risk of passing on a 
disease-associated mutation is variable in this case, but can be as high as 50% [448]. 
A classification in two different groups of germline mosaicism-associated disorders has 
been proposed by Zlotogora [448]. The first group contains parents in whom mosaicism is 
suspected, because there is transmission of the mutation to two or more children, while they 
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themselves have very mild symptoms or no disease characteristics at all. In the second group, 
parents present clinical symptoms of a disease caused by the expression of somatic mosaicism 
and have at least one child who has received the mutation and is clinically affected, indicative of 
gonosomal mosaicism. The mutation present in both somatic and germ cells confirms that the 
mutation most likely occurred very early on in embryonic development. 
Whether a mutation will affect only somatic or germ cells or both cell lineages will thus 
depend on cell fate. During human embryogenesis, at least four cells are allocated to the 
germline before the emergence of somatic cell lineages [442, 448]. All evidence points out that 
this must happen at an early developmental stage, but the exact timing is not yet known [448]. 
Mutations that appear at later time points in the development of somatic cell lineages will only 
give rise to somatic mosaicism [442, 448] (Figure 1.5.B). 
 
The phenotypic consequences of a somatic mutation depend on various factors such as the cell 







(A) Schematic representation of development and inheritance risk for germline mosaicism only, or both somatic 
and germline mosaicism. The black bar in the chromosome represents the disease-inducing mutation that, 
depending on the developmental stage in which this mutation occurs, spreads throughout germ cells alone or 
both somatic and germ cells, which is indicated by a dotted arrow. Depending on the timing, the mutation can 
already be identified in clinically unaffected parents of non-mosaic patients. The inheritance risk for future 
offspring depends on the proportion of germ cells that contains the mutation. The maximum risk will be 50% 
[448]. 
(B) Schematic representation of development and inheritance risk for somatic mosaicism. The black bar in the 
chromosome represents the disease-causing mutation that will be visible in somatic cells due to clonal expansion 





in some cells, whilst being lethal in others or instead having a selective advantage as observed in 
malignancies. When a gene is necessary for normal cell function in a certain tissue, non-
mutated cells may then select against cells with a mutated gene and hence induce mosaicism, 
whilst the same mutation is tolerated in other tissues [153]. Therefore, phenotypic variability in 
expression levels can, besides alterations in DNA sequences in specific genes or mutations in 
modifying genes, also be influenced by mosaicism. The timing of somatic mutations will then 
be important, as an early mutation is likely to have a greater effect on the expressed phenotype 
[144]. As an example, the X-linked dominant disease Rett syndrome is usually lethal in 
hemizygous males, but some survive due to somatic mosaicism [382]. In these men, normal 
cells may arise that outgrow the mutant cell population. The healthy cells will spread throughout 
the developing individual and compensate for the mutant cells, allowing survival of the 
individual who would otherwise have died during development. Although it is not yet 
understood why these mutations occur before fertilisation or as a post-zygotic event, the 
presence of an X-linked disease in a male is rare and is therefore an important diagnostic 
indicator of the occurrence of somatic mosaicism in that individual [297]. Also numerical or 
structural abnormalities of chromosomes are resulting from somatic mosaicism, like observed in 
the Pallister-Kilian syndrome caused by a tetrasomy of the short arm of chromosome 12 [442]. 
 
1.4.3 Mosaicism is a common feature in cancer 
Cancer pathology is probably the best-known example of mosaicism [29, 101, 442]. Nearly all 
cancers are monoclonal in origin, and a critical mutation event has (or multiple mutations 
have) transformed this single cell into a cancer cell with uncontrolled proliferation leading to 
the formation of a neoplasm. When a mosaic cell population arises due to a mutation in a 
tumour suppressor gene, this mutation represents the ‘first hit’ towards the development of 
cancer in these cells. Cells carrying such a mutation are predisposed to malignant formation 
once a second somatic mutation has inactivated the remaining normal copy of the gene [29, 
101, 442]. In the hereditary cancer retinoblastoma, for example, somatic and germline 
mosaicism for the initial mutation in the retinoblastoma gene is well documented. Not all 
mosaic individuals have or will develop retinoblastoma [360]. Also material of patients 
diagnosed with neurofibromatosis type 2, a severe autosomal dominant disorder that predisposes 
to multiple benign tumours of the nervous system, displays mosaicism. Since the detection rate 
of mutations in blood samples of neurofibromatosis type 2 founders (i.e. patients with clinically 
unaffected parents) was lower compared to that in non-founders, the failure to find mutations 
in blood leucocytes here turned out not to be because of a limitation in the applied screening 
technique, but was best explained by the high percentage of mosaicism that was observed in 
tumour specimens in as much as 25% of founders [194]. Germline and somatic mosaicism 
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associated with human cancer is also observed in, for example, neurofibromatosis type 1, 
testicular tumour development and von Hippel-Lindau disease [33, 224, 279] and is now 
regarded as a major contributor to the development of the pathogenesis of cancer. 
 
1.4.4 Detection of mosaicism in FSHD 
In 1993, Weiffenbach et al. [413] mentioned two families with germline mosaicism. 
Examination of the parents and offspring in these two families revealed clinically confirmed 
FSHD in the children, but no signs of muscle weakness in the face or shoulder girdle of both 
couples of parents. In both families, DNA analysis on peripheral blood lymphocytes confirmed 
a contracted fragment in all patients, but no contracted bands present in either parent. This 
suggested that only some or all germ cells of the father or mother contained the mutation and 
no somatic cells (at least no lymphocytes) were affected. This mutation probably occurred in a 
germ cell that continued to divide. In the same year, another publication by Griggs et al. [148], 
describing new mutations in sporadic cases, mentioned the same observation in one of their 
seven families studied. 
The first complete survey dedicated to studying germline mosaicism in FSHD was 
published in 1995 [393]. This article reported three sporadic FSHD families in whom the 
affected proband had inherited a potential rearranged D4Z4 fragment from one of the parents 
and was severely affected in all three cases. Analysis of DNA isolated from peripheral blood 
lymphocytes showed that in all three families the contracted D4Z4 fragment in the child was 
also visible in the mother, but the fragment was less intense after hybridisation with probe 
p13E-11. This indicated that these three mothers transmitted the disease allele to their children. 
Since only a faint EcoRI fragment was seen in the lymphocytes of these mothers, also a small 
percentage of their somatic cells must be mosaic for the contracted D4Z4 repeat. As the 
mutation is present in both gametes and somatic cells (here only lymphocytes were analysed), 
the mutation must have occurred before the differentiation of cells into endodermal, 
ectodermal and mesodermal cell lineages.  
Parents of apparently isolated FSHD cases may have insufficient expression of the 
mutation in different tissues due to mosaicism and therefore show no or only a very mild FSHD 
phenotype. This may explain the early observation made by Brooke [48] of the unusual 
manifestations of severe infantile FSHD with a minimally affected parent. With these new 
insights, germline mosaicism could explain the occurrence of several affected FSHD offspring of 
unaffected parents and close the debate regarding a possible autosomal recessive inheritance of 
FSHD [393]. In addition, the occurrence of mosaicism for the FSHD-associated region may, at 




Subsequent to the first studies, other groups started to report mosaicism as well (Table 1.1) [14, 
124, 143, 148, 167, 198, 199, 232, 249, 257, 305, 342, 380, 393, 413, 444, 445]. A total of 20 
patients have been reported to be mosaic for a chromosome 4 allele associated with FSHD in a 
total of 983 families tested. However, one must take into account, that most research 
laboratories tested lymphocyte DNA from the individuals with conventional gel electrophoresis, 
while mosaic alleles are more easily visualised with PFGE [232]. Seven patients transmitted the 
mosaic allele to their offspring and are therefore also mosaic in their germ cells. From the other 
patients gonadal tissue was not analysed and transmission of the mosaic allele has not yet been 
observed, because these individuals did not have children at the moment of lymphocyte testing. 
Mosaicism in one of the unaffected parents (or parents that are not aware of having FSHD) was 
reported in 89 parents of a non-mosaic patient in the 983 families tested. Nine individuals were 
only mosaic in their germ cells, because no contracted fragment was observed in their 
lymphocytes. In 80 individuals mosaicism was observed in both somatic and germ cells. Somatic 
mosaicism was always analysed in lymphocyte DNA. Germline mosaicism in unaffected parents, 
however, was always suggested by multiple affected offspring. However, in none of the cases 
gonadal tissue was actually tested to confirm the presence of the mosaic allele. 
 
In general, all studies on mosaicism for the contracted D4Z4 repeat in FSHD indicated a wide 
range of phenotypic expression of two genetically distinct cell populations for a single 
chromosome 4 with one of the cell populations carrying a contracted D4Z4 repeat array. 
Clinical effects of mosaicism can be absent or very mild in adults, and parents could therefore 
be at risk to pass on the condition to their children if their germ cells contain the mutated allele. 
Interestingly, in all studies the majority of mosaic parents are female putting asymptomatic 
mothers at a higher risk of being a carrier of a mosaic FSHD allele. 
We decided to analyse multiple Dutch de novo FSHD families to determine the 
occurrence of mosaicism in patients and parents and the effect of “being a mosaic” on 
development of the disease (Chapter 4). Whereas we would expect to observe a mosaic mixture 
of one contracted allele and an unchanged ancestral allele, in three families we detected two 
rearranged D4Z4 repeat arrays instead of one. Therefore, we analysed these families in more 
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1.5 Epigenetic modifications 
 
Chromatin is a dynamic structure that determines gene activity of transcriptional DNA 
sequences. Transcription usually occurs when the chromatin structure is open, while tightly 
packaged chromatin is associated with transcriptional repression. The different epigenetic 
processes that are each by themselves able to change chromatin conformation, e.g. DNA 
methylation, histone modifications and ATP-dependent remodelling complexes [11, 169], can 
also interact with each other to achieve gene expression or stable molecular silencing. Numerous 
examples in literature have made clear that compaction of genomic DNA into chromatin is 
fundamental for the regulation of gene expression. Each protein involved in modification of 
chromatin might, when mutated, play a role in human disease and some proteins have already 
been associated with diseases. For FSHD, epigenetic modifications of the subtelomere 4q35 have 
not been studied extensively, although there are several models that propose an alteration of 
chromatin structure in FSHD patients (see Paragraph 1.6). We have investigated chromatin 
structure present in the 4q35 region by focussing on DNA methylation and histone acetylation. 
After a description on chromosome architecture, the following paragraphs will therefore 
primarily focus on the role of DNA methylation and the function of histone modifications in 
the human genome. 
 
1.5.1 Chromatin architecture 
1.5.1.1 Heterochromatin and euchromatin 
In the nucleus DNA is assembled with proteins into in a nucleoprotein complex, designated 
chromatin [67, 321]. Most eukaryotic genomes can roughly be divided into two types of 
chromatin: heterochromatin and euchromatin. Heterochromatin mainly consists of 
transcriptionally inactive regions in a tightly packed chromatin structure replicating late in S-
phase and is usually highly DNA methylated and poorly histone acetylated [89, 282, 338]. 
Heterochromatin occurs in two varieties: constitutive and facultative heterochromatin. The first 
is rich in non-coding repetitive sequences and contains few transcribed genes. This type of 
heterochromatin is often observed at centromeric and (sub)telomeric regions of chromosomes. 
It tends to be permanent transcriptionally inactive and can induce repression of nearby genes 
by a position effect [80, 248, 315, 321]. Facultative heterochromatin has a compact 
conformation and can be specific for one or two homologous chromosomes or for certain cell 
types or developmental stages. This chromatin form describes the inert state of sequences that 
contain many genes that also exist in active copies [315, 321] and is only silenced in specific 
contexts, for example when it contains tissue-specific genes that are silenced in all but the 
proper tissue [324]. 
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Euchromatin has an open chromatin structure characterised by DNA hypomethylation 
and histone acetylation and is, due to its accessibility, generally associated with actively 
transcribed regions [80, 282, 321, 338]. It has a high density of functional genes, mainly 
comprises single copy sequences and usually replicates early in the cell cycle [89, 405]. 
 
1.5.1.2 Nucleosome conformation 
The basic unit of chromatin is the nucleosome, which consists out of 146-180 bp of DNA 
wrapped around a protein core in approximately two left-handed superhelical turns [184]. This 
protein core of eight histone proteins (also termed octamer) is made up of two copies each of 
histone 2A (H2A), histone 2B (H2B), histone 3 (H3) and histone 4 (H4) [67]. Nucleosomes are 
connected by short segments of linker DNA and compacted by linker histones 1 (H1) and 
other non-histone proteins into chromatin fibres [111, 204]. The position and density of the 
histone octamers are mediated by ATP-dependent chromatin remodelling complexes that 
mobilise nucleosomes via alterations of the contact between DNA and histones [388]. Several 
processes mediate the affinity of the histone octamers for DNA and ATP-dependent chromatin 
remodelling complexes: acetylation, methylation, phosphorylation, ubiquitination, sumoylation 
and ADP-ribosylation of histone residues [28, 46, 92]. The position of the histones and these 
modifications will organise chromatin together with the other epigenetic changes in an open or 
condensed state and in this manner regulate the accessibility of DNA for the transcription 
machinery [282]. 
 
Four groups of proteins have the ability to modify and remodel chromatin and regulate gene 
expression: DNA cytosine methyltransferases, methyl-CpG binding proteins, histone 
modification enzymes and ATP-dependent remodelling complexes. Often these proteins 
interact with each other to form a higher-order chromatin structure and to regulate the 
accessibility of DNA [238]. One of the proposed models for this interaction is schematically 
depicted in Figure 1.6. 
 
1.5.1.3 Epigenetics 
Eukaryotic cells have the capacity to epigenetically modify their genomes. A current definition 
of epigenetics is “mitotically and/or meiotically heritable changes in gene function that cannot 
be explained by changes in DNA sequence” [345]. Epigenetics can be seen as a system that 
selectively uses genome information by activating or inactivating functional genes [282] and 
alters the phenotype without changing the genotype [67]. Three major biochemical epigenetic 





1.5.2 DNA modification by methylation 
DNA methylation is the most prevalent endogenous DNA modification in eukaryotes [75, 359] 
and involves the addition of a methyl group to the carbon 5 position of the cytosine ring within 
the context of the sequence 5’-CG-3’, also called a CpG dinucleotide [35, 359]. Although non-
CpG sequences may also be methylated, nearly all methylation of cytosines in eukaryotes is 
observed in CpG dinucleotides [11, 75, 333]. 
 
1.5.2.1 DNA methyltransferases 
Cytosine residues in newly synthesized DNA are methylated via a DNA-specific enzymatic 
reaction by a DNA methyltransferase (DNMT) that catalyses the addition of a methyl group 
from the methyl donor S-adenosyl-L-methionine to the carbon 5 position of cytosine [336, 
359]. Eukaryotic DNMT establishes and maintains the methylation status of transcriptionally 
Figure 1.6 
Schematic model proposed by Robertson [336] depicting how HDACs, ATP-dependent chromatin remodelling 
enzymes and DNMTs may cooperate to generate region-specific methylation patterns on DNA wrapped around 
nucleosomes. The acetylated histones (acetyl groups indicated with black dots) located within a (potential) 
transcriptionally active region become deacetylated by HDACs. It is not yet known how HDACs are targeted 
towards the histones and this may require other chromatin remodelling activities. Deacetylation likely starts the 
transcriptional shutdown of the region (I). ATP-dependent chromatin remodelling enzymes will then recognise 
the chromatin and alter the chromatin structure or nucleosome positioning (II) so that a DNMT can access its 
DNA target sites directly or via creating a chromatin signature recognised by a DNMT or a DNMT-associated 
complex (III). DNMT will then methylate the cytosines in the DNA region (III; depicted with open dots). 
Evidence exists that DNMT and HDAC are components of a single complex, but it still needs to be determined if 
the ATP-dependent chromatin remodelling enzyme is also associated with this complex or acts independently. 
The methylated region then locks the chromatin in a silent state (IV) and the methylated cytosines of the DNA 
will recruit methyl-CpG binding proteins (MBP) and associated co-repressors to further strengthen the 
established transcriptional repression and chromatin compaction (V). 
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inactive sequences such as repetitive elements and imprinted alleles [291]. Until now five 
human DNMTs have been identified: DNMT1, DNMT2, DNMT3A, DNMT3B and DNMT3L 
(reviewed in [336]). DNMT1 has a preference for hemimethylated DNA and is believed to be 
responsible for the propagation of methylation patterns after each round of replication in 
somatic cells. The role of DNMT2 is not yet clear, but it is thought to play a role in centromere 
functioning. DNMT3A and DNMT3B are involved in de novo methylation of specific 
sequences such as pericentromeric satellite sequences, probably during specific stages of 
gametogenesis and early development. DNMT3B is also required for maintaining the 
methylation patterns of pericentromeric regions through cell division, which indicates that a 
separate function in maintenance and de novo methylation for each DNMT cannot (always) be 
defined. Finally, DNMT3L is expressed during gametogenesis and is essential for the 
establishment of maternal genomic imprinting [31, 258, 374]. 
 
1.5.2.2 CpG islands 
Approximately 70-80% of all CpG residues in the mammalian genome are methylated [11, 37, 
333], except for dense CpG clusters, which are observed in genomic regions of 200 bp to several 
kb [35, 75]. These regions, termed CpG islands, have a very high CpG frequency (60-70%) [76] 
and are often located in or near promoter regions or coding regions of nearly all housekeeping 
genes and of 40% of genes with an expression pattern restricted to specific tissue types or 
developmental stage [7, 11, 38, 76, 223, 338, 359, 398]. All CpG islands together make up 
approximately 2% of the genome [76]. The chromatin conformation of these CpG islands is 
open, which makes the DNA sequence accessible for transcription factors [39, 359]. CpG 
islands not associated with promoters or coding sequences are often methylated, just like CpGs 
located outside CpG islands, which are frequently detected in satellite sequences and 
transposable elements [11, 396]. 
 
1.5.2.3 DNA methylation and development 
DNA methylation patterns are established during the development of an organism and serve to 
suppress genes dispensable for the function of the mature cell [333]. After fertilisation, but 
before implantation, genomic methylation is almost completely converted into unmethylated 
cytosines [182, 274]. However, imprinted genes do not lose their methylation pattern [236]. 
This wave of demethylation is then followed by de novo methylation upon embryo implantation 
to re-establish the methylation pattern inherited from the gametes [182, 274, 327]. This de novo 
methylation does not apply to the active copy of imprinted genes, most of the tissue-specific 
genes that are unmethylated in the tissue of expression, and CpG islands associated with active 




441]. In this manner, a bimodal pattern of methylation is created [358], which is inherited and 
remains stable through multiple cell divisions [38, 326]. These patterns can only alter during 
developmental or pathological changes of the cell or as a response to environmental 
modifications [149]. 
 
1.5.2.4 Influence of DNA methylation on silencing 
DNA methylation is an effective suppressor of gene expression in many processes and can 
interfere with transcription in various ways [38, 180, 359]. The repressive effect of DNA 
methylation depends on the nature of control elements present (like an enhancer or promoter), 
the density of methylated CpGs, the protein environment in a specific type of cell and the 
chromosomal context [45, 165, 277, 352]. DNA methylation has a stabilising effect and can 
cause transcriptional repression in several ways. The first involves direct interference of the 
methylated cytosines in binding of a protein to its corresponding CpG-containing DNA 
recognition sequence. In this case methylation alone hinders or eliminates binding of the basal 
transcription machinery or ubiquitous transcription factors (like E2F, NF-κB, AP2 and CREB), 
which require contact with an unmethylated cytosine [38, 185, 282]. Methylation within gene 
regulatory elements, like promoters, enhancers and insulators, will consequently repress the 
function of these elements [75]. Secondly, repression may involve methyl-CpG binding 
proteins that bind specifically to methylated CpGs. By limiting access to regulatory elements 
they can indirectly inhibit the binding of transcription factors, such as CTCF, Sp1 and YY1, 
that can even bind to CpG-containing sequences when these are methylated [38, 45, 75, 277, 
282]. A third mechanism by which methylation may mediate repression of transcription is by 
altering the chromatin structure through an interaction between DNA, histones and proteins 
that together form chromatin [277, 359]. Finally, methylation induces and stabilises the 
inactive state of chromatin by affecting the positioning of nucleosomes, influencing the DNA 
sensitivity to DNaseI and targeting sequences for assembly into the condensed state [96, 186, 
264]. This mechanism probably also is affected by the action of (or interactions with) methyl-
CpG binding proteins [277]. 
 
1.5.2.5 Suppression and defence 
DNA methylation may also be a mechanism to suppress “parasitic” DNA sequences. In 
mammalian cells transposable sequences, which are mobile genetic elements that are scattered 
within and around most genes, represent at least 35% of the genome [441]. These transposons, 
of which the Alu repeat family is the most abundant, are very often methylated and 
transcriptionally silenced in the genome [38]. Two ideas have been put forward that set this 
repression in an evolutionary context. The first hypothesised that methylation acts as a stabiliser 
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for a genome that contains large amounts of repetitive DNA by masking or inhibiting 
homologous recombination between these repetitive sequences. This prevents repetitive DNA 
from spreading throughout the genome and thus avoids DNA damage [406, 441]. The other 
proposed that the irrelevant transcription of all these promoter sequences would generate a high 
level of transcriptional noise that would interfere with all necessary gene expression. Therefore, 
repression would be necessary to reduce this transcriptional noise, thereby allowing vertebrates 
to gather and selectively use genes that are essential for development [36]. 
Besides the suppression of transposons, cytosine methylation may also be part of a 
genome defence system in mammals that evolved primarily to oppose to the threats posed by 
parasitic sequence elements [32, 263]. De novo methylation especially affects promoters of viral 
genes which would thus become inactivated, like those of the herpes viruses [18, 210, 337]. 
 
1.5.3 DNA modifications via histones 
The highly conserved core histone proteins H2A, H2B, H3 and H4 located in the nucleosome 
and the linker histone H1 are the major protein components of chromatin in the eukaryotic 
nucleus and function as blocks to package eukaryotic DNA into higher-order chromatin fibres 
[65, 184, 203]. Chromatin structure can be disrupted by nucleosome remodelling, the 
replacement of histones that form the nucleosome by histone variants or by covalent histone 
modification (reviewed in [106]). 
These posttranslational chemical modifications are located on histone residues, such as 
lysine or arginine, in the flexible amino-terminal domains, which protrude out of the 
nucleosome surface [106], or on globular carboxy-terminal domains comprising the 
nucleosome scaffold [4]. These domains are commonly reffered to as “tails” [184]. The 
acetylation, methylation, phosphorylation, ubiquitination, sumoylation and ADP-ribosylation 
of histones correlates with specific transcriptional states [28, 152]. However, histone residues 
will only be modified if histone-modifying enzymes are targeted to the histones by DNA-bound 
activators or repressors, since they are unable to access to the histone residues themselves [204]. 
Nowadays, multiple residues per histone have been identified as possible modification sites and, 
taking the variety of modifications into account, this will allow many combinatory possibilities 
that can play a role in gene expression (e.g. modulation of transcription during development 
and X-chromosome inactivation in females), DNA replication, DNA repair, genome stability, 
chromosome dynamics and apoptosis [140, 211, 369, 384]. 
 
1.5.3.1 Histone acetylation 
Histone acetylation is the most intensively studied modification, which is reversible and plays a 
prominent role in higher-order chromatin packing [27, 28, 80, 145, 190]. Furthermore, histone 
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acetylation is involved in replication, nucleosome assembly and interactions of nucleosomes 
with non-histone proteins [145]. Histone acetyltransferases (HATs) and histone deacetylases 
(HDACs) modify histones by the addition or removal of an acetyl group [28, 146, 189]. Sites of 
acetylation include conserved lysines in the amino-termini of H4 and H3 and less conserved 
lysine residues in H2A and H2B [212]. Histone acetylation may influence transcription by 
altering the folding properties of chromatin by changing the accessibility of DNA [66, 162] or 
provide specific binding places for repressors and activators of gene expression through this 
specific modification [139, 212]. Because this modification is involved in many cellular 
processes, different functions may require the acetylation of specific histones [178]. 
Like DNA methylation, the distribution of acetylated histones is not randomly 
distributed over the genome. Very low levels of histone acetylation are observed in 
heterochromatic regions, which are associated with high levels of DNA methylation, while high 
levels of histone acetylation are seen along coding regions in euchromatin [178]. This concurs 
with the view that transcriptional repression by DNA methylation is linked to histone 
acetylation through the recruitment of HDACs by methyl-CpG binding proteins [75, 178, 284, 
290, 333]. 
 
1.5.3.2 Histone methylation 
Primarily the amino-terminal histone tails of H3 and H4 are modified by histone methylation 
[369]. The modification occurs both at lysine and arginine residues [28], is established by 
specific histone methyltransferases [140, 204] and is biochemically stable [401]. The effects of 
lysine and arginine methylation depend on the specific residue and the number of methyl 
groups in a modification (mono-, di- or trimethylated for lysine and mono- or dimethylated for 
arginine) [170, 190, 204, 369]. Methylation of lysines (K) in H3 and H4 is involved in gene 
regulation [27]: H3-K9 dimethylation and H3-K27 trimethylation are associated with gene 
silencing, while methylation of H3-K4, H3-K36 and H3-K79 are associated with gene activation 
[204]. Arginine methylation is correlated with the active state of transcription, is involved in 
signal transduction pathways and recruits methylases as co-activators to promoters [27, 204]. 
 
1.5.3.3 Histone phosphorylation 
Histone phosphorylation involves serines and threonines, particularly of H3 and H2B [28] and 
the linker H1 [81]. H1 is phosphorylated at serines and threonines in both amino-terminal 
domains as carboxy-terminal domains, while phosphorylation of the nucleosome histones is 
only located in the amino-terminal tails [81]. This modification, which is established by a 
balance between kinases and phosphatases, is highly reversible [4, 81]. It is an important 




genes, like c-fos and c-jun [81]. Furthermore, phosphorylation is often associated with 
chromosomal condensation that includes mitosis and meiosis, apoptosis and DNA damage [4, 
27, 152]. This indicates that one modification is involved both in opening and closing of 
chromatin, but it is not yet clear how phosphorylation generates the condensed chromatin 
structure [28]. 
 
1.5.3.4 Histone ubiquitination 
Ubiquitination (by some authors also called ubiquitylation) is a dynamic process involving the 
coupling of ubiquitin to lysines in the carboxy-terminal domains of histones, which will 
generally become mono-ubiquitinated [43, 80, 106, 293]. This coupling has been observed in 
H2A and H2B. Also ubiquitination of H3 was reported in vivo in elongated spermatids of rat 
testis and H1 ubiquitination is observed in Drosophila, but the sites for this modification at H1 
and H3 are not yet elucidated [62, 316]. Ubiquitination is associated with many cellular 
processes, like protein degradation, DNA repair, cell cycle control, stress and heat shock 
response, endocytosis signalling, ribosome biosynthesis, neural and muscular degradation, and 
transcription [43, 275]. Levels of ubiquitination are dependent on the activity of a family of 
ubiquitin-conjugating enzymes, of which Rad6 is a member [175, 183]. Ubiquitination of 
histones can affect spermatogenesis, chromosomal segregation and condensation, and 
transcription [43, 175, 434]. This modification could label certain genomic regions to interact 
with specific proteins or to be packaged in a special manner in metaphase chromosomes [175, 
275]. Ubiquitination on H2B is critical for cell cycle progression in mitosis and meiosis [27] 
and plays a role in transcriptional activation by defining regions of active chromatin [183, 293]. 
Ubiquitination of H1 also plays a role in transcriptional activation [27]. 
 
1.5.3.5 Histone sumoylation 
Small ubiquitin-related modifier (SUMO) family proteins, which show resemblance to 
ubiquitin, are involved in dynamic histone modification by the addition of a SUMO to lysines 
in the carboxy-terminal domain [278, 287]. These proteins are activated in an ATP-dependent 
manner and transferred to UBC9, until now the only SUMO-conjugating enzyme known to 
function in vivo [287], after which they are attached to a specific lysine in the target protein 
[399]. The best-characterised member is the SUMO protein (also termed smt3, sentrin, GMP1 
or PIC1; reviewed in [278]) that has been shown to stimulate activity of for example p53 and 
heat shock factors HSF1 and HSF2, but most frequently correlates with repression of target 
genes, such as c-jun and Sp3 [278, 399]. Recently, it was suggested that histone sumoylation 
mediates transcriptional repression and gene silencing through the recruitment of HDACs and 




1.5.3.6 Histone ADP-ribosylation 
Two non-enzymatic protein modifications, glycation and glycoxidation, result in the formation 
of protein glycoxidation products, termed AGE [60, 375]. These two processes are potentially 
toxic, which suggests that there should be mechanisms to repair or minimize these 
modifications [60]. In vitro ADP-ribose is an efficient source for glycation and glycoxidation 
[60], ADP-ribose formed conjugates of histone H1 in cell cultures after DNA damage [207] and 
Wong and colleagues reported a stable complex that contained a dimer of histone H1 and 
ADP-ribose polymers [431]. These observations suggest that the covalent linkage of histone 
molecules is the result of histone glycoxidation initiated by ADP-ribose [60]. Histones organised 
in a chromatin structure studied in sugar-incubated nuclei were, in contrast to purified histones 
in solution, less reactive in the glycation reaction, as a consequence of the accessibility of the 
histones in the chromatin structure. However, H1, H2B and H2A were more reactive than H3 
and H4, which are most protected from this reaction. When tested in vivo, high concentrations 
of ADP-ribose were able to induce apoptotic cell death indicating the toxic character of these 
modifications [375]. By contrast, in sea urchins ADP-ribosylation plays a vital role after 
fertilisation by protecting the integrity of maternal histone proteins against nuclear proteinases, 
while sperm-specific histones are degraded and replaced by maternal histone variants. This 
suggests that ADP-ribosylation can also act as a mechanism to protect nuclear proteins from 
proteolysis in a specific manner [276]. However, this has not yet been demonstrated in other 
organisms. 
 
1.5.3.7 Histone interactions 
All histone modifications can affect one another and many correlated in a positive or negative 
manner [106]. In the process of transcriptional activation histone phosphorylation is applied 
together with histone acetylation, in which phosphorylation occurs before acetylation and even 
promotes acetylation, resulting in the recruitment of the transcription machinery. Also histone 
acetylation and histone methylation are thought to influence each other both in a positive and 
negative manner (reviewed in [27]). Furthermore, histone modifications on H3 and H4 are 
interrelated to and interdependent on each other, suggesting specific patterns for activation and 
repression [28]. Besides the interaction of histone modifications, also the interplay of different 
histone modification enzymes with DNMTs and chromatin remodelling factors can lead to 





1.5.3.8 Histone variants 
Remodelling of chromatin can also be established by the exchange of the histones within the 
nucleosome by variants [152, 349]. These histone variants (also termed replacement histones; 
[246]) can substitute “normal” histones and this may cause transcriptional changes [106, 162]. 
The replacement of H2A by H2AZ is associated with increased nucleosome stability, while 
variant H2AX seems to be involved in recombination events. Furthermore, inactive X- 
chromosomes in mammals are enriched for variant macroH2A at the onset of differentiation 
[349]. H3.3 is a variant of H3 and is linked to transcriptionally active genes [164, 371]. Another 
homologue of H3 is CENP-A observed at centromeric regions of vertebrate chromosomes, 
which is essential for kinetochore formation and plays an early role in organising centromeric 
chromatin at interphase [164, 371]. Every variant is involved in local chromatin structures as 
they can be chemically modified as well. This is illustrated by the carboxy-terminal domain of 
H2AX that is rapidly phosphorylated in response to double strand breaks and plays an 
important role by associating with factors essential for DNA-damage repair [170]. 
 
1.5.3.9 Function of histone modifications 
Currently, there are two models for the function of histone modifications. The first model 
suggests that these modifications directly affect chromatin or nucleosome structure by 
preventing the binding of specific transcription factors, changing the mutual interaction of 
nucleosomes in array or by altering the interaction of histones and DNA in a nucleosome [27, 
447]. The second model, the histone code hypothesis, proposes a role for these modifications as 
a site for recruiting other chromatin-associating proteins in which different histone 
modifications can act consecutively or in combination to form a histone code. This code will be 
recognised and read by other proteins to trigger downstream events that will generate various 
chromatin remodelling effects and translate the code into a particular chromatin state, either 
active or repressed. Multiple marks on histone domains may amplify these downstream events, 
subsequently leading to a larger change in chromatin structure of target sequences [27, 204, 
369]. The list of histone modifications is increasing and all modifications appear to represent a 
mechanism for the regulation of chromatin. The exact way in which this histone code is 
established and maintained and the specific function of each modification has not yet been 
determined [74, 106, 369]. 
 
1.5.4 Imprinting and X-inactivation 
The structure of chromatin is the result of DNA methylation, variation in histone composition, 
histone modifications, presence of non-histone proteins, the balance of all ATP-dependent 
chromatin remodelling complexes and the interaction of all these processes [11, 169, 189]. 
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These modifications provide a mechanism to permanently turn off transcription of genes whose 
activity is not necessary in a particular stage of development or differentiated cell type [179]. 
Two good examples of these modifications are genomic imprinting and X-chromosome 
inactivation. In both processes the transcriptional repression is strongly associated with 
epigenetic changes of CpG islands within the promoters of silenced genes [38, 75, 76, 333]. 
In the case of genomic imprinting, i.e. a chromosomal modification that leads to the 
preferential expression of a paternal or maternal allele [403], differences in DNA methylation, 
histone modifications and conformation changes of the maternal or paternal allele will 
determine which allele will be expressed [104, 107, 119]. The mechanisms for the regulation of 
this type of gene expression are likely to be specific for each locus or region [119] and also 
include the involvement of insulator elements, boundary elements, repressor proteins and 
antisense transcripts [328]. Approximately 1% of all mammalian genes are imprinted [20]. 
Another group of genes associated with epigenetic modifications are genes located on 
the inactive X-chromosome of female mammals [309]. This process occurs early in 
embryogenesis and involves the random transcriptional silencing of one of the two X-
chromosomes in females, necessary to ensure comparable levels of gene expression as observed 
in males (reviewed in [12]). This silencing is mainly characterised by hsitone hypoacetylation 
and DNA hypermethylation of the gene promoters [12]. The inactive X-chromosome is then 
stably inherited through subsequent cell divisions, so that only one X-chromosome is functional 
per cell [12, 321]. 
 
1.5.5 Chromatin remodelling and human disease 
Mutations or inactivation of genes that are involved in the process of regulating or remodelling 
chromatin structure often lead to disease in humans. In cancers, for example, a change in DNA 
methylation status is one of the most common epigenetic alterations [75, 95, 179]. The 
regulation of methylation is disturbed that results in a genome-wide decrease in DNA 
methylation, which often includes repeated DNA sequences, but also shows an increase of DNA 
methylation in promoter regions of tumour suppressor genes important in the early 
development of cancer [96, 319]. This leads to a loss in gene function, oncogenic 
transformation and tumour progression [96, 104, 179], like observed for pRb in retinoblastoma 
[160], APC in colorectal carcinoma [160] and BRCA1 in breast cancer [160]. DNA 
hypomethylation of proto-oncogenes may contribute to an increase in gene expression and 
promote translocations and mutations [333]. Furthermore, because DNA methylation prevents 
homologous recombination between repetitive elements, this overall DNA hypomethylation 
may also lead to an increase of inappropriate recombinations and eventually cause 




To date only one human disease is associated with mutations in a DNMT. Mutations in the 
DNMT3B gene located at locus 20q11.2 [418] are observed in patients with the ICF syndrome 
(i.e. immunodeficiency, centromeric region instability and facial anomalies syndrome), a very 
rare autosomal recessive disease that has been reported in fewer than 50 patients worldwide 
(reviewed in [97, 157]). This disease is characterised by facial abnormalities, psychomotor 
retardation and immunoglobulin deficiencies and, less frequently, mental retardation and 
digestive disorders [200]. Since mutations detected are either nonsense mutations leading to a 
premature termination of the translation process, or missense and splice-site mutations in the 
catalytic domain of the gene, researchers suggest that it is probably a reduced or even absent 
DNA methyltransferase activity that is responsible for the disease phenotype and the abnormal 
hypomethylation of specific satellite sequences, repeat sequences NBL2 and D4Z4 [176, 200, 
270, 417], the H19 gene [353] and several genes on the inactive X-chromosome [154]. 
Another inherited condition is Rett syndrome, a X-linked autosomal dominant 
neurodevelopmental disorder. The molecular defect in a large fraction of Rett syndrome 
patients are mutations in gene coding for the methyl-CpG binding protein MeCP2 that cause a 
deceleration in head growth, the loss of language and motor skills during early childhood and 
sporadic mental retardation in females [11, 122, 157, 209]. This disease is also very rarely 
observed in males that usually have an extra X-chromosome [157]. In addition, MeCP2 
mutations also cause neonatal-onset encephalopathy and autism [168]. 
 
Aberrant ATP-dependent remodelling complexes and histone-modifying enzymes have as well 
been associated with several human diseases [95, 157, 168]. Mutations of the ATRX gene at 
Xq13, which encodes an ATP-dependent helicase, cause not only mental retardation, but can 
also cause microcephaly and α-thalassemia together with facial, skeletal and urogenital 
abnormalities [168]. These characteristics are (in part) observed in the ATR-X syndrome, 
Juberg-Marsidi syndrome, Sutherland-Haan syndrome and Smith-Fineman-Myers syndrome 
[135, 157, 168]. The ATRX protein may act as a transcriptional regulator [30] and mutations 
result in unusual gain or loss of methylation of some highly repetitive DNA sequences [134]. 
Other diseases linked to mutations in ATP-dependent remodelling complexes are for example 
Cockayne syndrome type B, cerebro-oculo-facio-skeletal syndrome and Schimke immuno-
osseous dysplasia, while the Rubistein Taybi syndrome and mutations of EP300 in several 





1.5.6 Epigenetic modifications and FSHD 
The 4q45 region associated with FSHD is located on a subtelomere [419], which appears upon 
Giemsa staining as a dark band, indicative for a high level of chromatin condensation [378]. 
The region harbours D4Z4 that contains several sequence motifs associated with 
heterochromatic regions of the genome [2, 446] and has a high CpG content [159, 433]. 
Furthermore, D4Z4 is part of a family of repetitive elements that are mainly located at 
heterochromatic regions in the human genome [256]. These observations suggest that D4Z4 has 
a heterochromatic character. 
 
Yang and colleagues [439] examined whether there was a heterochromatin-like or other atypical 
higher-order chromatin structure that could distinguish normal-sized D4Z4 arrays from 
contracted D4Z4 arrays using immuno-FISH in which the regions studied were in close 
proximity to D4Z4. The results indicated that no characteristics of constitutive heterochromatin 
were observed in myoblasts of control individuals nor of FSHD patients, since they observed no 
co-localisation with heterochromatic foci in interphase nuclei, no co-localisation with 
chromatin regions staining intensively for antibodies binding to heterochromatin protein 1α or 
to H3 trimethylated at lysine 9, which are both enriched in constitutive heterochromatin, and 
there was no co-localisation of antibodies binding to H4 acetylation of lysine 8 and H3 
methylation of lysine 4 that both bind preferentially to regions enriched in transcriptionally 
active genes. Moreover, no differences were observed between FSHD patients and control 
individuals in this limited set of samples, demonstrating no altered behaviour due to chromatin 
structure of FSHD-sized D4Z4 repeat arrays at the resolution of interphase FISH. 
 
Since it is known that epigenetic influences on gene expression can also result from differential 
nuclear localisation of genomic loci [23, 118, 172, 273], the localisation of 4q35 within the 
interphase nucleus was examined as well. FISH analysis with a D4Z4-sequence probe revealed 
cross-hybridisation with nucleolar organising regions, which are heterochromatic sequences 
located on all acrocentric chromosomes that contain ribosomal DNA copies [2, 426]. The 
hybridisation signal was located interspersed both within the ribosomal DNA gene cluster and 
ß-satellite sequences [419, 426], which led to the idea that the D4Z4 array might require a 
positioning of the 4q telomere near the nucleolus for proper gene expression. However, no 
differences in positioning of chromosome 4qter loci to the nucleolus were observed when 
FSHD interphase lymphoblasts were compared to those of control individuals [427, 427]. 
Recently, these findings were confirmed using immuno-FISH and, in addition, revealed that 
most of the 4q35 FISH signals were located at the nuclear periphery [260, 376, 439]. 
Furthermore, Masny et al. [260] observed that lamin A/C, a major component of the nuclear 
Chapter 1 
 70 
lamina underlying the nuclear envelope, was necessary for the localisation of the 4q subtelomere 
to the nuclear periphery, while the D4Z4 repeat itself was not responsible. As chromatin is 
anchored to the nuclear periphery via lamin A/C, Lamin B, LAP2 and BAF [55, 294, 424], these 
observations may indicate that the chromatin structure of the FSHD-associated region may be 
directly associated with the nuclear envelope. 
 
Given that epigenetic remodelling of chromatin is an ongoing area of research and the disease-
causing mechanism for FSHD has not yet been found, we and other laboratories investigated if 
epigenetic modifications of the subtelomere on 4q might be important for FSHD pathology. In 
parallel with the localisation studies mentioned above we investigated the chromatin structure 
in which the D4Z4 repeat array is located and if this local structure would change as a 
consequence of the rearrangement observed in FSHD patients. Tsien et al. [385] observed high 
levels of DNA methylation of normal-sized D4Z4 arrays in a small control group, so we first 
concentrated on levels of DNA methylation in healthy controls and FSHD patients using 
digests of DNA with CpG methylation-sensitive enzymes (Chapters 5 and 6). In collaboration 
with colleagues in New Orleans we also measured histone acetylation patterns of the 4q35 
region by performing chromatin immunoprecipitation with an antibody that discriminates 





1.6 Postulated disease models for FSHD pathology 
 
The forthcoming chapters (Chapters 2-7) will present new insights on structure and behaviour 
of the FSHD-associated D4Z4 repeat addressing (1) interactions of the subtelomeric region 
4q35, in which D4Z4 resides, with other regions in the genome; (2) the consequences of 
mosaicism for FSHD; and (3) epigenetic modifications of the 4q35 region, including DNA 
methylation and histone acetylation. This section will provide an overview of the proposed 
models that are currently applied in FSHD research, implicating a direct or indirect role of 
D4Z4 in the development of FSHD. Chapter 8 will discuss the validility of these models in 
relation to the data presented in this thesis. 
 
Several observations made in the 4q35 region point to a possible role of chromatin structure or 
nuclear positioning of 4qter. First, D4Z4 is located in a subtelomere, which is a type of region 
that is more often involved in recombination than other parts of the genome [34, 64, 115]. 
This recombination-sensitivity is also emphasized by the high frequency of exchanges in this 
region [86, 295]. Second, several sequences within D4Z4 are associated with heterochromatin 
and, even though D4Z4-related sequences are scattered throughout the genome, they are 
mainly observed in heterochromatic regions. Finally, contracted repeats have been suggested to 
influence gene expression of (nearby) genes [121, 177, 428]. Different models have been 
proposed in which the D4Z4 contraction in this region located near the telomere plays a direct 
or indirect role in FSHD pathology. All models can be divided in three main groups: (1) direct 
effect of D4Z4; (2) changes in the chromatin structure of the 4q35 region; and (3) the nuclear 
localisation of the 4q35 region. These groups will be discussed in more detail below. One must 
take into account that all models assume that the consequences of the proposed model will 
eventually cause or influence FSHD pathology. However, supporting data is still not available 
to conclusively pinpoint all the phenotypic characteristics of FSHD to one defined molecular 
event. 
 
1.6.1 Direct effect of D4Z4 
Several models have suggested a role for the D4Z4 sequence itself in the development of FSHD. 
The most obvious one is that the gene responsible for the FSHD phenotype is located within 
the D4Z4 repeat array encoded by one or more repeat units or that the total array is part of a 
much larger gene. When a segment of the repeat array is contracted, this might result in loss of 
all or part of the FSHD gene if a minimum number of repeat units is required for proper gene 
function [85, 110]. Supporting this idea, each repeat unit contains a putative gene DUX4, the 
sequence of which suggests a role in regulation of gene expression possibly in a temporal, 
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regional or tissue-specific manner [123, 159]. However, haploinsufficiency of the 4q35 region 
does not cause disease, as individuals with a terminal deletion of 4qter including the whole 
repeat array and 200 kb proximal of the array do not have any features of FSHD [386]. 
Gabellini and colleagues [121] suggested, that binding of D4Z4 recognition complexes 
to a specific sequence in D4Z4 influences the phenotype. In healthy individuals these 
complexes containing the proteins YY1, HMGB2 and nucleolin would actively suppress gene 
expression, while in patients the number of bound repressor complexes is reduced and 
consequently results in a partial or complete decrease of transcriptional repression of the genes 
on 4q35 leading to the FSHD phenotype. 
Lastly, Jiang et al. [98, 177] proposed a looping model in which communication 
between a contracted D4Z4 repeat array and a target gene (or genes) occurs in cis by 
intrachromosomal looping. This looping may extend over long distances and can therefore 
involve a target gene far away. Repeat arrays longer than 33 kb in size will in this model 
normally display intra-array looping, while arrays with 5-10 repeat units will form less stable 
intra-array loops and repeats with 1-4 repeat units will almost never form these interactions. 
This would explain the increased severity of symptoms and decreased age at diagnosis 
associated with very short D4Z4 repeat arrays. The abnormal intrachromosomal looping 
interactions may increase gene expression of the target gene by direct delivery of a 
transcription factor through this interaction, by changing chromatin structure of the promoter 
region of the target gene or by influencing the association that a target gene may have with a 
nuclear membrane or nuclear scaffold. A contracted D4Z4 repeat array may also activate 
inappropriate gene expression itself by the binding of the transcription factor Sp1 and (some 
of) the proteins that are located in the D4Z4 recognition complex proposed by Gabellini et al. 
[121], which can all contribute to gene expression through this intrachromosomal looping 
interaction. 
 
1.6.2 Changes in chromatin structure of the 4q35 region 
Expression of a gene can be strongly influenced by its position in the genome. When located in 
heterochromatin, a gene will not be easily accessible to the transcription machinery and 
therefore usually be silenced [372]. Most expressed genes are located in euchromatic areas with 
a more open chromatin structure. A positional effect (i.e. position effect variegation (PEV)) 
was first defined in Drosophila as a deleterious change in the level of gene expression brought 
about by a change in the position of the gene relative to its normal chromosomal environment, 
but not associated with intragenic mutations or deletions [193]. PEV can occur when a 
chromosomal rearrangement causes the juxtaposition of a euchromatic gene with a region of 
heterochromatin. The heterochromatic organisation spreads as a cis-acting silencing activity 
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into the juxtaposed euchromatic region and silences the nearby gene(s) [193, 372]. Position 
effects can occur over several hundred kb up to several Mb away from the rearrangement [414]. 
In humans, several diseases have been linked to a possible involvement of PEV (reviewed in 
[193]). For FSHD two different models postulate the role of a PEV-like mechanism. Both 
models result in a change of DNA conformation and subsequently in an aberrant expression of 
genes in the 4q35 region, which will eventually lead to the development of the FSHD 
phenotype. 
The first model involves heterochromatinisation of the 4q35 region. The telomeric 
region of all chromosomes is composed of heterochromatin. D4Z4 contraction may disable the 
function of the array as a buffer zone between telomeric heterochromatin and proximal 
euchromatin region 4q35. This buffer zone will become smaller when the array is contracted 
and through spreading of telomeric heterochromatin in a proximal direction a position effect 
on gene(s) located proximal to the 4q telomere will be induced, thus inactivating genes located 
in the FSHD region [6, 85, 426]. 
The second model assumes a loss of heterochromatin and is also called “the loss-of-
PEV-model” [177]. Three regions with homology to D4Z4, LSau, hhspm3 and Sau3A, are 
located in heterochromatic regions in the human genome [268] and D4Z4 repeats have been 
associated with heterochromatic regions as well [256]. If D4Z4 repeat units are important for 
normal folding of the chromosome in a heterochromatic state, a contraction may result in a 
change in (local) chromatin conformation, consequently a loss of heterochromatin and 
thereby having an impact on gene expression by extinguishing or altering gene activity on 4q35 
[159, 225, 226, 426]. For example, the contractions in the array may destabilise the 
heterochromatic character of D4Z4 itself, thereby permitting gene expression of DUX4. In 
muscle cells, the translated DUX4 protein is then thought to be toxic due to a strong 
dimerisation potential shown in in vitro experiments, which may explain that severity roughly 
correlates with the residual repeat array size and that haploinsufficiency on 4q does not result 
in a disease phenotype [123]. This model thus suggests that a heterochromatic chromatin 
conformation of D4Z4 is a requirement for proper functioning of genes in the 4q35 region. 
 
1.6.3 Nuclear localisation of the 4q35 region 
The nuclear localisation model implies a pivotal role in the interactions and position for 4qter 
in the nucleus. FISH has been used to study the spatial orientation of, among others, the 4qter 
and 10qter subtelomeric regions in the interphase nucleus and revealed an increased somatic 
pairing frequency of subtelomeres when compared to interstitial chromosomal sites, 
depending on the specific regions involved [367]. In addition, a slightly more frequent pairing 
of the 4q with the 10q subtelomere in FSHD patients was detected that may facilitate possible 
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trans-interactions [367]. An inappropriate nuclear positioning of the FSHD region was 
proposed as a model by Winokur et al. [428] to explain the genome-wide disruption of genes 
observed in an expression profiling study. The transcriptional deregulation of genes involved 
in FSHD myogenesis and oxidative stress may arise from a global effect on gene regulation due 
to improper nuclear positioning of 4qter. The D4Z4 contractions may affect the localisation of 
the 4q telomere to a nuclear domain, in which aberrant gene expression can occur [428]. The 
same group recently examined the nuclear organisation of the FSHD region in patient 
myoblasts to gain more evidence for this improper nuclear positioning [260]. Masny and 
colleagues [260] observed that during the cell cycle 4q telomeres of both normal and FSHD 
alleles in these cells were specifically localised to the nuclear rim, an area in the nuclear 
periphery rich in nuclear envelope proteins, in contrast to the other telomeres measured (1q, 
5q, 10q and 18q) that were dispersed throughout the nucleus. The presence of lamin A/C is 
necessary for this positioning, as absence of this protein leads to a drastic reduction in 
localisation of 4q35 to the nuclear rim. In addition, FISH experiments revealed that not the 
D4Z4 sequence on normal and FSHD alleles directs the location to the nuclear rim, but a 
sequence closer to the chromosome 4-specific locus D4S139. Based on these findings, the 
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Chromosomal rearrangements occur more frequently in subtelomeric domains than in other 
regions of the genome and are often associated with human pathology. To further elucidate the 
plasticity of subtelomeric domains, we examined the 3.3 kb D4Z4 repeat array on chromosome 
4 and its homologue on chromosome 10 in 208 Dutch blood donors by pulsed-field gel 
electrophoresis. These subtelomeric repeats are known to rearrange and partial deletions of this 
polymorphic array on chromosome 4 are associated with facioscapulohumeral muscular 
dystrophy (FSHD), an autosomal dominant myopathy. Our results show that mitotic 
rearrangements occur frequently as 3% of individuals display somatic mosaicism for a repeat 
expansion or contraction explaining the high variability of subtelomeric repeat array sizes. 
Translocated 4-type repeat arrays on chromosome 10 and the reverse configuration of 10-type 
repeat arrays on chromosome 4 are observed in 24% of individuals. The translocated repeat 
arrays on chromosome 4 tend to be more heterogeneous than 4-type repeats on chromosome 
10. The repeat length on chromosome 4 is on average larger than on chromosome 10. But on 
both chromosomes we observe a multi-modal repeat length distribution with equidistant peaks 
at intervals of 65 kb, possibly reflecting a higher-order chromatin structure. Interestingly, in as 
many as six random blood donors (3%) we identified FSHD-sized 4-type repeat arrays. 
Assuming that these individuals are clinically unaffected, these results imply an incomplete 
penetrance in the upper range of FSHD alleles. Overall, the observed dynamic characteristics of 





The chromosomes of many organisms contain subtelomeric regions, which include single copy 
sequences, highly repetitive sequences and non-homologous chromosome ends [23, 28]. These 
regions lie immediately adjacent to the dynamic (TTAGGG)n telomere repeat arrays and display 
a variable size distribution ranging from a few hundred base pairs (e.g. human XpYpter) [2] to 
>100 kb (4qter [11] and 16pter [43]). In yeast, chromosome ends are composed of different 
subtelomeric repeated sequences, such as X and Y’ [7, 36, 39], and rearrangements of Y’ 
elements can easily be detected in mitosis and meiosis [20, 22]. Data from other systems also 
indicate that subtelomeric regions of chromosomes are dynamic structures and may in fact 
support high levels of meiotic recombination in the initial homology searches, which precede 




In 1997, a model was proposed in which subtelomeric regions can be divided in a distal 
and a proximal subdomain separated by degenerated (TTAGGG)n repeats [15]. The distal 
subdomain contains repetitive sequences that interact with all chromosome ends, whereas the 
proximal domain only interacts with a subset of (non-) homologous chromosome ends. It was 
suggested that subtelomeric regions act as a buffer between functional telomeric repeats and 
genes proximal of the subtelomeric regions, thereby protecting these genes from 
heterochromatinisation and silencing, as demonstrated in yeast [4, 6, 18, 21, 40]. 
Chromosomal rearrangements occur more frequently in (sub)telomeric domains than in 
other regions of the genome and often result in disease. Translocations of chromosome ends 
have been reported to cause for example α-thalassaemia mental retardation syndrome, Wolf-
Hirschhorn syndrome and Miller-Dieker syndrome [1, 24, 25]. Subtelomeric rearrangements 
may also account for 7% of the idiopathic mental retardation cases and congenital anomalies 
[16]. Probably the most intriguing example of disease-associated subtelomeric rearrangements is 
seen in facioscapulohumeral muscular dystrophy (FSHD), an autosomal dominant myopathy 
mapped to 4qter. This proximal subtelomeric domain harbours the polymorphic D4Z4 repeat 
array, which is composed of 11 up to 150 3.3 kb repeated elements in normal individuals. 
FSHD patients carry a repeat array of <11 units, due to a partial deletion of the D4Z4 repeat 
array [12, 42]. 
The subtelomere of chromosome 10 is highly similar to 4q35 and also contains a 
polymorphic repeat array highly homologous to D4Z4 [3, 8]. A specific BlnI site within each 
repeat unit of chromosome 10 allows discrimination between both chromosomes [9]. In a 
survey of 50 healthy Dutch male controls we could demonstrate the presence of chromosome 
10-type repeats on chromosome 4 in 10% of the Dutch population. The reverse configuration 
of chromosome 4-type repeats on chromosome 10 is equally frequent [10]. Hybrid repeats, 
consisting of both 4-type and 10-type repeat units, have also been identified. Several studies 
demonstrated that only short repeat arrays on chromosome 4 are causally related to FSHD [5, 
26]. 
Recently, we demonstrated that the partial D4Z4 repeat array deletion in FSHD arises 
mitotically in at least 40% of cases and that the presence of 4-type repeat arrays on 
chromosome 10 in these mosaic individuals is increased almost five times [30]. We hypothesised 
that the FSHD deletion occurs mainly by somatic interchromosomal gene-conversion in which 
the presence of a fully homologous repeat array on a non-homologous chromosome is a 
predisposing factor. 
In this study, we examined the subtelomeric repeat configurations on chromosomes 4 
and 10 of 208 unrelated healthy individuals of a Dutch control population. We confirmed the 




difference in repeat array length between these two chromosomes. Preferred repeat array lengths 
were observed possibly reflecting a higher order chromatin structure. Our results indicate a high 
incidence of mitotic rearrangements as part of the dynamic subtelomere characteristics. This 




2.3 Subjects and methods 
 
2.3.1 Control samples 
Genomic DNA was isolated from peripheral blood lymphocytes from 208 unrelated individuals, 
which were obtained in a coded form via the Dutch Bloodbank in Leiden after informed 
consent. DNA was extracted essentially as described by Miller et al. [31]. 
 
2.3.2 Digestion, PFGE and Southern blotting 
Five micrograms of DNA was double digested with restriction enzymes EcoRI-HindIII (MBI 
Fermentas, St Leon-Rot, Germany) or EcoRI-BlnI (Amersham, Litle Chalfont, UK) according to 
the manufacturer's instructions. After digestion, DNA was separated by PFGE on a 0.8% 
agarose gel (MP agarose; Boehringer, Mannheim, Germany). The electrophoresis was performed 
in 0.5× TBE and was run for 20 h at 8 V/cm2. In four identical cycles, switch times increased 
linearly from 1 to 16 s at the end of each cycle. A pause interval of 2% of the switch time was 
included. After electrophoresis, the gel was stained with ethidium bromide and blotted to a 
Nytran+ membrane (Schleicher & Schuell, Dassel, Germany). The probes used for hybridisation, 
p13E-11 (D4F104S1) [42] and 9B6A (D4Z4) [42], were labelled by random priming with 
[32P]dCTP, using the megaprime DNA labelling system (Amersham). Hybridisations were 
performed overnight at 65oC in a buffer containing 7% SDS, 10% PEG 6000 and 50 mM 
Na2HPO4, and the blots were washed at 65
oC with 2× SSC/0.1% SDS (p13E-11) or 1× 
SSC/0.1% SDS (9B6A). The blots were then exposed to phosphorimager screens. After exposure, 
the alleles were assigned to their respective chromosomes based on their BlnI sensitivity. Sizes 
were estimated independently by two individuals according to a 48 kb marker and λ 
concatamers. 
 
2.3.3 Classification of individuals 
All individuals were analysed for their allele sizes and origin of repeats and classified according 
to Table 2.1. Class A represents a standard repeat array distribution with 4-type arrays on 




type arrays on chromosomes 4, either homogeneous (B and E) or heterogeneous (C and D). The 
same holds true for translocated homogeneous (F and I) and heterogeneous (G and H) 4-type 
arrays on chromosome 10. Class X displays complex repeat array configurations, which could 
not be assigned to classes A-I. Class M is a separate class in which all mosaic cases are 
represented. 
 
2.3.4 Statistical analyses 
Standard allele sizes of males (n = 100; class A) and females (n = 58; class A) were compared 
using the Mann-Whitney U-test. Allele-size distributions on chromosomes 4 and 10 in these 
158 individuals were analysed according to the Kolmogorov-Smirnov test. Sensoring on 
chromosome 4 was performed for alleles of <38 kb (FSHD range). Differences in the 
composition of the translocated repeats (categories B, C and D versus F, G and H; i.e. only 4-
type repeats, only 10-type repeats or a combination of both) were tested against a χ2 
distribution. 
In order to determine whether the peaks in the multi-modal distribution of the allele 
sizes were equidistant, the following procedure was applied: allele sizes on a given chromosome 
Table 2.1 Subtelomeric repeat array constitutions on chromosomes 4q and 10q of 208 unrelated healthy Dutch 
individuals. 
The region hybridising to p13E-11 is represented by a square, whereas 4-type and 10-type repeat arrays are 
indicated by four white and black triangles, respectively. Dots indicate a similar repeat structure as on the top of 
the column. Individuals are classified in 11 different groups. Class A, the most common allele configuration, is a 
standard repeat array distribution with 4-type arrays on chromosome 4 and 10-type arrays on chromosome 10. 
Classes B-E are individuals that carry a 10-type repeat array on chromosome 4, either homogeneous (B and E) or 
heterogeneous (C and D). The same holds true for the individuals carrying either homogeneous (F and I), or 
heterogeneous (G and H) 4-type repeats on chromosome 10. Mosaic individuals are scored as M, whereas one 
individual had such complex repeat array structure (X) that we could not assign this individual to one of the 




were assumed to follow a mixture of two or three normal distributions with identical standard 
deviations but different means. Three hypotheses (H) were compared. 
 
H2. The distribution of the allele sizes was explained as a mixture of two normal 
distributions (four estimated parameters: mean of first distribution, difference between 
the means of the two distributions, standard deviation and proportion of alleles in the 
first distribution). 
 
H3e. A mixture of three normal distributions with equidistant means (with one additional 
estimated parameter: the proportion of alleles in the second distribution). 
 
H3u. As H3e but with non-equidistant means (one more estimated parameter: the distance 
between the means of the second and the third distribution). 
 
A comparison between likelihoods obtained for H3e and H3u yields a likelihood ratio test with 1 






2.4.1 Repeat array configurations 
We examined the subtelomeric repeat array configurations on chromosome 4q35 and 10q26 in 
208 unrelated healthy individuals: 128 males and 80 females. Alleles were sized by pulsed-field 
gel electrophoresis (PFGE) and assigned to their chromosomal origin based on their BlnI 
sensitivity. The various allele configurations were classified as indicated in Table 2.1. According 
to the Mann-Withney U-test, no significant differences between repeat array distribution of 
males and females were observed, neither for chromosome 4 (P = 0.84) nor chromosome 10 (P 
= 0.67). Accordingly, data of all individuals were pooled for further analyses. 
Most of the individuals (76%) displayed a standard pattern of 4-type arrays on 
chromosome 4 and 10-type arrays on chromosome 10, designated as class A. The remaining 
individuals (24%) displayed non-standard configurations with translocated repeat arrays. 
 
2.4.2 Repeat size distribution 
Only alleles of class A individuals were included in the analysis of allele size distribution (Figure 




classes the allele sizes may be influenced by the translocated repeat arrays. All alleles of class A 
individuals were grouped into intervals of 20 kb each. 
Excluding allele sizes of <38 kb (associated with FSHD when residing on chromosome 
4), the median of 4-type repeat arrays is 96 kb, while the median of 10-type repeat arrays is 75 
kb. After correction for the difference in median repeat size, no significant difference was 
detected between both repeat size distributions according to the Kolmogorov-Smirnov test. As 
plotted in Figure 2.1, the repeat sizes on both chromosomes do not display a uniform 
distribution. The observed distributions for chromosomes 4 and 10 both agreed significantly 
better with a mixture of three normal distributions with equidistant means than with a mixture 
of two normal distributions (χ2 = 27.25, P < 10-6 and χ2 = 19.76, P < 10-5, for chromosomes 4 
and 10, respectively). No significant further improvement of the likelihoods was obtained when 
a mixture of three normal distributions with non-equidistant means was fitted (χ2 = 0.54, P ≈ 
0.46 and χ2 = 0.84, P ≈ 0.36 for chromosomes 4 and 10). The most parsimonious model 
therefore indicates that the allele sizes follow distributions with periodicity. 
 
2.4.3 FSHD-sized repeat arrays 
Repeat arrays <38 kb and residing on chromosome 4 are associated with FSHD. In this survey, 
we identified 4-type repeat arrays <38 kb in six individuals (25, 25, 30, 32, 35 and 35 kb). One 
Figure 2.1 
Repeat array size distribution of 4-type and 10-type repeat arrays from individuals in class A. On the x-axis the 
repeat array length is plotted in intervals of 20 kb. The y-axis displays the number of alleles of class A in each size 
interval. Chromosome 4-type repeat arrays are represented in dark gray bars, whereas 10-type repeats are 






of the individuals carrying the 30 kb 4-type repeat array was classified as F, carrying only 4-type 
repeat units on chromosome 10. The other individuals carried a standard repeat array 
configuration (class A). 
 
2.4.4 Homogeneity of translocated repeat arrays  
Twenty-one percent of individuals displayed a non-standard repeat array configuration on 
chromosomes 4 and 10. Ten-type repeat arrays on chromosome 4, termed B-E, were identified 
in 18 individuals (9%), whereas the reverse configuration i.e. 4-type repeat arrays on 
chromosome 10, termed F-I, was present in 25 individuals (12%) (Table 2.1). One individual 
(class X) had such complex repeat array configuration that it could not be assigned to one of the 
previously defined classes. 
Studying all alleles in individuals carrying translocated repeat arrays (36 in classes B-E 
and 50 in classes F-I), 10-type arrays on chromosome 4 tended to be more heterogeneous than 
4-type arrays on chromosome 10. Of the translocated 10-type arrays on chromosome 4 (classes 
B-E), 17% (6/36) were composed of a homogeneous array of 10-type repeat units whereas 33% 
(12/36) were hybrid arrays, consisting of clusters of 4-type and 10-type repeat units. Conversely, 
44% (22/50) of chromosomes 10 carried a homogeneous translocated array of 4-type units only, 
whereas 10% (5/50) were hybrid arrays. 
There was a significant difference in homogeneity of translocated repeat arrays between 
classes D and H (P = 0.006). These classes carry a comparable repeat array structure: a 
chromosome 4 backbone with 10-type repeats followed by a cluster of 4-type repeats (class D) 
and a chromosome 10 backbone with 4-type repeats followed by a cluster of 10-type repeats 
(class H). The other types of comparable configurations (classes C and G) do not differ 
significantly. 
 
2.4.5 Somatic mosaicism 
In this survey, somatic mosaicism (defined as a fifth repeat array fragment on PFGE) was 
observed in 3% of individuals (6/208), 4 males and 2 females. Five individuals displayed somatic 
mosaicism with a standard allele configuration whereas the sixth individual carried an extra 4-
type repeat array on chromosome 10. Two of these individuals were mosaic for chromosome 4 
and three for chromosome 10-type arrays. The presence of an extra 4-type repeat in the sixth 









In this survey, we analysed the subtelomeric D4Z4 repeat array configuration of the human 
chromosomes 4qter and 10qter in 208 individuals of the Dutch population. This study 
corroborates on an earlier study [10] and provides new insights in the behaviour of these 
subtelomeric domains. 
The end of human chromosome 4q displays a similar structural organisation as reported 
for 4pter, 16pter and 22qter [15]. The distal subdomain on 4qter contains repetitive sequences 
as found on many chromosome ends (JE Hewitt, personal communication), whereas the 
proximal domain is largely comprised of the D4Z4 repeat array studied here. 
The proximal and distal subtelomeric domains on chromosomes 4qter and 10qter are 
>95% homologous. The distal subdomain comprises 25 kb, whereas the proximal domain may 
vary from 50 to >500 kb due to the polymorphic 3.3 kb repeat array. Despite their high 
homology, 10-type repeat units can be discriminated from 4-type repeat units by an internal 
BlnI site [9]. This BlnI-based array discrimination makes these subtelomeres ideal models to 
study subtelomere plasticity. Employing PFGE, we as well as others have already demonstrated 
the dynamic behaviour of these subtelomeres indicative for frequent exchanges between both 
chromosome ends [5, 10, 26, 30]. 
By studying a population of >200 individuals, we obtained detailed information on the 
size, distribution and behaviour of these subtelomeric repeat arrays. From this study, it becomes 
evident that both chromosome ends present similar characteristics with regard to their size 
distributions and compositions, but also display discrete differences. 
We found that the median of the repeat array on chromosome 4 is 21 kb larger than 
that on chromosome 10. A telomere position effect, in which telomeric heterochromatin has 
the capacity to silence genes in a distance-dependent manner, is well documented in yeast 
(reviewed in [19]). Similar to this telomeric gene silencing, it has been postulated that the D4Z4 
repeat on chromosome 4 and its homologue on chromosome 10 prevents spreading of 
heterochromatin into (euchromatic) regions proximal to the repeat and that partial deletion of 
the chromosome 4 repeat array in FSHD undermines this spacer function [44]. In this light, the 
length difference between both subtelomeric repeats may reflect a requirement for larger 
subtelomeric domains on chromosome 4 to prevent gene silencing of critical gene(s) in the 
region proximal to the subtelomere. 
An unexpected high frequency of 4-type repeat arrays <38 kb was observed in this survey 
(6 individuals = 3%). Five of them belong to class A. Whilst residing on chromosome 4, these 
arrays are associated with FSHD. Several possibilities may explain this finding. First, it is possible 




type repeat on chromosome 10 and an equal frequency of 10-type repeats on chromosome 4 is 
observed, we would expect the presence of ‘double exchanged’ alleles (i.e. a 4-type array on 
chromosome 10 and a 10-type allele on chromosome 4) in 1% of individuals. Second, one of 
the individuals carrying a 4-type array of 30 kb was assigned to class F and therefore carries three 
4-type repeat arrays. It may well be that in this individual the potential pathogenic repeat array 
resides on chromosome 10. Definite chromosomal assignments of these repeat arrays can only 
be obtained by additional PFGE analyses on agarose-embedded DNA plugs using chromosome 
4- and 10-specific probes [26]. Since DNA plugs of these random individuals are not available 
we are unable to pursue this procedure. Thirdly, ~30% of the gene carriers is asymptomatic or 
have subclinical FSHD signs [33, 34]. Moreover, a correlation has been established between the 
residual repeat size and the age at onset and severity of FSHD [29, 37]. Individuals carrying 
small sized FSHD alleles are generally more severely affected than individuals with larger FSHD 
alleles and it may well be that there is an incomplete penetrance for larger FSHD alleles. Since 
this unselected group was not clinically evaluated, it is very possible that individuals with a repeat 
array <38 kb have subclinical characteristics or are non-penetrant. In this light, it is noteworthy 
that the 4-type arrays in three of the five class A individuals are >30 kb. 
We confirmed that 4-type repeat arrays on chromosome 10 occur equally frequently as 
the reverse configuration of 10-type arrays on chromosome 4 (12% and 9%, respectively). 
However, the composition of these translocated arrays on both chromosomes differs 
significantly. Although 4-type repeats on chromosome 10 tend to be homogeneous (44% of all 
chromosome 10 alleles), 10-type repeats on chromosome 4 are mostly not homogeneous (only 
17%) but a combination of 4- and 10-type repeats (33% of all chromosome 4 alleles). This 
suggests a biological difference between both repeat arrays resulting in a preference of 4-type 
units on chromosome 4. However, that would also predict a significant difference between 
classes C and G, which is not observed. Therefore, we favour a mechanistic explanation. 
Most repetitive sequences, whether coding or non-coding, undergo concerted evolution. 
This process homogenises repetitive sequences and is thought to be important for the 
maintenance of the integrity of each repeat unit. Concerted evolution is achieved by a much 
faster intrachromosomal homogenisation than interchromosomal recombination (reviewed in 
[27]). The heterogeneity observed for the D4Z4 subtelomeric repeats suggests that these loci 
escape concerted evolution and evolve by rather unconstrained inter- and intrachromosomal 
recombination. This may imply that the putative open reading frame, DUX4, present in each 
repeat unit and for which no expression has been observed in vivo [17], may have lost its 
function during the rapid expansion of this repeat array. 
Our results are indicative for a multi-modal allele size distribution on both 




bimodal and trimodal distributions have been observed [35]. This is mostly attributed to a 
founder effect of two ancestral alleles that have a similar dynamic behaviour and show little 
inter-chromosomal interactions. Since we observe the same unequal size distribution on both 
chromosomes and have already demonstrated a frequent interchromosomal cross-talk, a 
founder effect for these loci is highly unlikely. An alternative explanation that the chromatin 
structure of repeat sequences may impose restrictions on repeat lengths seems more likely. 
Degradation of high molecular weight DNA by nuclease digestion has suggested that chromatin 
loops contain ~50 kb of DNA [14]. We have already demonstrated in mosaic individuals of de 
novo FSHD families that usually the shortest allele rearranges to an FSHD-sized allele [30]. This 
suggests that the unequal distribution on chromosome 4 separates the repeat arrays in a 
premutation domain (first peak) and a normal domain (larger than the first peak). 
Previously, we demonstrated that the FSHD deletion occurs mitotically in at least 40% 
of cases. Moreover, we showed that the presence of supernumerary fully homologous repeat 
arrays is a predisposing factor (in this case, the presence of 4-type repeats on chromosome 10) 
[30]. In this study, we have identified somatic mosaicism for one of the alleles in as many as 3% 
of the individuals. Mosaicism was observed for both 4-type and 10-type alleles. This high 
mutation frequency emphasises the importance of mitotic recombination in subtelomeric 
homogenisation. 
In conclusion, this study provides a detailed insight into the complex dynamic 
characteristics of the proximal subtelomeric domains on chromosomes 4 and 10. Although 
these domains share many properties and may frequently interact, they also display distinct 
differences in size and homogeneity. Their plasticity is emphasised by a very high somatic 
mutation frequency. It will be interesting to examine whether this dynamic behaviour is just a 
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Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD1A) is associated with 
contractions of the polymorphic D4Z4 repeat on chromosome 4qter. Almost half of new FSHD 
mutations occur post-fertilisation, resulting in somatic mosaicism for D4Z4. Detailed D4Z4 
analysis of 11 mosaic individuals with FSHD revealed a mosaic mixture of a contracted FSHD-
sized allele and the unchanged ancestral allele in 8 cases, which is suggestive of a mitotic gene 
conversion without crossover. However, in 3 cases, the D4Z4 rearrangement resulted in two 
different-sized D4Z4 repeats, indicative of a gene conversion with crossover. In all cases, DNA 
markers proximal and distal to D4Z4 showed no allelic exchanges, suggesting that all 
rearrangements were intrachromosomal. We propose that D4Z4 rearrangements occur via a 
synthesis-dependent strand annealing model that relatively frequently allows for crossovers. 
Furthermore, the distribution of different cell populations in mosaic patients with FSHD 
suggests that mosaicism here results from D4Z4 rearrangements occurring during the first few 





A large proportion of eukaryotic genomes consists of repetitive DNA. The head-to-tail tandem 
repetitive sequences, categorized according to repeat unit length, are highly polymorphic. Micro-, 
mini-, macro- and megasatellite repeats are distinguished, each with their own mutation 
characteristics. Several hypothetical rearrangement models have been proposed, mainly on the 
basis of micro- and minisatellite instability. These often include gene conversions with or 
without crossover [12, 35]. However, little is known about macro- and megasatellite instability 
in human cells. 
Facioscapulohumeral muscular dystrophy (FSHD1A [MIM 158900], hereafter referred 
to as “FSHD”) is an early onset, autosomal dominant myopathy mainly characterised by a 
progressive and variable atrophy and weakness of the facial, shoulder and upper arm muscles 
[32]. The FSHD phenotype also presents with extramuscular symptoms such as 
retinovasculopathy, hearing loss, and, in severe cases, mental retardation [1, 5, 27, 33]. FSHD is 
associated with a macrosatellite repeat instability: the contraction of the subtelomeric D4Z4 
repeat on 4q35. This polymorphic D4Z4 repeat is highly recombinogenic, since somatic 
mosaicism for a rearrangement of D4Z4 is found in as much as 3% of the general population 




tail fashion and varying between 11 and 100 units on healthy chromosomes [4]. Patients with 
FSHD carry a repeat of 1-10 units on one of their chromosomes 4 [40]. A rough and inverse 
correlation has been observed between the severity and age at onset of the disease and the 
residual repeat unit number [20, 38]. 
The subtelomere of chromosome 10q is nearly identical to chromosome 4qter and also 
contains a highly homologous and equally recombinogenic repeat. D4Z4 repeats on 
chromosomes 4 and 10 are visualised in EcoRI-digested DNA with probe p13E-11, which 
recognizes the region proximal to the D4Z4 repeat within the EcoRI fragment [40]. To 
discriminate between 4qter- and 10qter-derived repeats, in addition to EcoRI, the restriction 
enzyme BlnI is used, which digests only chromosome 10-derived repeat units [2]. Conversely, 
the restriction enzyme XapI is specific to 4qter-derived repeat units and can be used to 
complement BlnI [15]. DNA separated by pulsed-field gel electrophoresis (PFGE), combined 
with differential digestion with BlnI and XapI, allows sizing and chromosomal assignment of all 
D4Z4 alleles ranging from 10 to >350 kb. 
In 10% of the population, translocated 4-type repeats reside on chromosome 10q and, 
vice versa, translocated 10-type repeats on chromosome 4q are equally frequent. This was first 
found in a Dutch survey [3, 31], but comparable translocation frequencies have now also been 
reported in the Japanese, Korean and Chinese populations [23]. These translocated repeats can 
be homogeneous or heterogeneous (consisting of both 4-type and 10-type units). Although this 
observation may suggest frequent interactions between the regions of homology of both non-
homologous chromosomes, de novo exchanges between repeat arrays originating from 
chromosomes 4 and 10 have never been described. In contrast to chromosome 4, repeat 
contractions on chromosome 10 are non-pathogenic. 
Further complicating our understanding of FSHD pathogenesis, a 4qter polymorphism 
distal to D4Z4 was recently described, giving rise to two distinct 4q chromosome ends: 4qA and 
4qB [8]. Both alleles are almost equally common and equally recombinogenic in controls. 
Nevertheless, FSHD alleles are always of the 4qA type [16]. 
As many as 10-30% of patients with FSHD carry a new mutation [19, 34, 44], with 
D4Z4 repeat contractions varying from 1 to >50 units [22]. Several studies have shown that 
almost half of these D4Z4 rearrangements are of mitotic origin, resulting in somatic mosaicism 
for the FSHD allele in either patients or asymptomatic parents [7, 14, 22, 39, 43]. A 
relationship has been established between the severity of the disease and the percentage of 
peripheral blood lymphocytes (PBLs) carrying the disease allele in combination with the residual 
repeat size [22]. This suggests that the proportion of mosaicism detected in blood is 
representative of the mosaicism in muscle tissue. Furthermore, patients with FSHD have been 




in fibroblasts (RJLF Lemmers, unpublished data). Thus, mitotic D4Z4 rearrangements very 
likely occur early during embryogenesis. 
In all mosaic cases reported, two PBL cell populations were identified: one carrying the 
parental, non-rearranged allele, and one in which the D4Z4 repeat had been rearranged to 
FSHD size. Such an allele distribution generally is suggestive of a rearrangement by gene 
conversion without crossover, since the hallmark of this mechanism is an unchanged donor 
allele and a changed acceptor allele [35]. 
Although many macrosatellite repeats have been identified in the human genome, little 
is known about the mechanism by which they rearrange. Mitotic minisatellite rearrangements 
were thoroughly studied in yeast, in which gene conversion, usually without crossover, was 
shown to be the main mechanism of rearrangement [35]. 
Similar to D4Z4, the polymorphic human RS447 megasatellite repeat, which is 
comprised of 4.7 kb units displays both mitotic and meiotic instability. For RS447, a high 
frequency of repeat contraction and expansion has been shown [29]. The tandemly repeated 
human U2 snRNA genes (RNU2 locus) have been studied more extensively and provided 
insight into the mechanism of concerted evolution. These 6.1 kb U2 repeats display repeat 
homogenisation by rare interchromosomal gene conversion followed by rapid 
intrachromosomal homogenisation [18]. 
The mechanism by which D4Z4 rearranges was further examined in the presented study, 
through use of the 4qA/4qB polymorphism as distal flanking marker in combination with a 
newly identified RFLP within D4Z4 proper, serving as a proximal flanking marker. Studying 
these proximal and distal markers provided insight into the mechanism and timing of D4Z4 
rearrangements and may stand as a model for macrosatellite repeat mutation in general. 
 
 
3.3 Subjects and methods 
 
3.3.1 Patients and control individuals 
All families were ascertained via one of the Dutch Neuromuscular Centers. In all but one family, 
the mosaic child received a clinical diagnosis of FSHD, and the parents did not display any 
FSHD features. In family 55611, the FSHD allele of the affected mother was further somatically 
contracted in the affected child. Blood from these families was collected after informed consent 
was obtained. The PvuII polymorphism was determined in a previously described population of 
anonymised Dutch blood donors with a standard allele configuration of homogeneous 4-type 




patients with FSHD studied carried a homogeneous translocated 4-type repeat on chromosome 
10. 
 
3.3.2 Somatic cell hybrids and DNA clones 
The following chromosome 4qA sources were used: YAC Y25C-2E [41]; the monochromosomal 
rodent somatic cell hybrids HHW1494, SU10 (a gift from S Winokur, Irvine, CA), and 
GM11448 (Coriell Institute for Medical Research); and lambda clones λ42, λ68, and λ260201 
Figure 3.1 
(A) Polymorphic PvuII site at position 6044 of GenBank accession number AF117653 was used to study 
recombination between 4qA and 4qB alleles. A double digestion with PvuII/BlnI normally gives rise to fragments 
of 4559 bp (chromosome 4 alleles) and 2464 bp (chromosome 10 alleles). However, the presence of an extra PvuII 
site within the proximal D4Z4 unit yields a fragment of 2849 bp. 
(B) Example of the modified PvuII/BlnI dosage test after hybridisation with probe p13E-11. Samples in lanes 1-3 
carry two 4qA alleles and two 10q alleles, all of which are PvuII-resistant (PvuII-). Samples in lanes 4-6 carry two 
4qB alleles and two 10q alleles; in lane 4 and lane 6, a PvuII-sensitive (PvuII+) fragment is visible. “Y” indicates the 
cross-hybridising Y chromosome. The table on the right shows dosage experiment results on the PvuII RFLP in 
the proximal D4Z4 unit of 78 different 4qA and 62 different 4qB alleles. Twenty-nine percent of the 4qB alleles 
are PvuII+, whereas 4qA alleles are almost exclusively PvuII- (P < 10-5). 
(C) Distribution of the PvuII RFLP on 4qA and 4qB alleles. The PvuII- proximal D4Z4 unit on 4qA alleles is 










[4]. All sources, except for Y25C-2E and GM11448, represent patient alleles. Somatic cell 
hybrid GM11448 contains a human chromosome 4qA with a D4Z4 repeat of 125 kb (data not 
shown). 
As chromosome 4qB sources, we used the monochromosomal rodent somatic cell 
hybrids GM11687 (Coriell Institute for Medical Research), 4L-10 (a gift from E Stanbridge, 
Irvine, CA), HHW416 (a gift from M Altherr, Los Alamos, NM) and 361-9 (a gift from S 
Winokur, Irvine, CA), with D4Z4 repeats of 140 kb, 85 kb, 96 kb, and 290 kb, respectively. 
 
3.3.3 DNA isolation 
DNA was isolated from PBLs essentially as described by Miller et al. [26]. If possible, PBLs were 
embedded in agarose plugs (InCert agarose, [FMC]) at a concentration of 7.5× 105 cells per 
plug. 
 
3.3.4 D4Z4 analysis 
For allele sizing, DNA samples were double digested with EcoRI/HindIII and with EcoRI/BlnI. 
For analysis of the allelic variation at 4qter (probes 4qA and 4qB, [16]), DNA was digested with 
HindIII only. All digestions were performed according to the manufacturer’s instructions. EcoRI 
and HindIII were purchased from MBI Fermentas, PvuII and BlnI were purchased from 
Amersham-Pharmacia. DNA was separated in 22 hours on a 0.8% agarose gel (MP agarose 
[Boehringer]) by pulsed-field gel electrophoresis (PFGE) at 8.5 V/cm at 21°C in 0.5× tris-borate 
EDTA (TBE) supplemented with 150 pg/ml ethidium bromide. PFGE was performed in four 
identical cycles, with a switch time increasing linearly from 1 s at the start to 16 s at the end of 
each cycle. Subsequently, DNA was transferred to a Hybond XL membrane (Amersham-
Pharmacia) by Southern blotting and was hybridised in a buffer containing 0.125 M Na2HPO4 
(pH 7.2), 10% PEG6000, 0.25 M NaCl, 1 mM EDTA, and 7% SDS, for 16-24 h at 65°C. 
Hybridisations with probe p13E-11 (D4F104S1, [40]) were washed in 2× SSC/0.1% SDS, and 
those with probes 4qA or 4qB were washed more stringently in 1× SSC/0.1% SDS. The blots 
were exposed for 16-24 hours to phosphorimager screens and were analysed with the 
ImageQuant software program (Molecular Dynamics). 
The PvuII polymorphism in the first proximal unit of the D4Z4 repeat (position 6044 of 
GenBank accession number AF117653) was analysed by applying a modified BglII/BlnI dosage 
test [21] on genomic DNA samples by double digestion with PvuII and BlnI (Figure 3.1). After 
Southern blot and hybridisation with probe p13E-11, blots were washed in 0.3× SSC/0.1% SDS. 
Chromosome 4-derived fragments are 2849 bp or 4559 bp in size, depending on the presence or 
absence of the PvuII restriction site, whereas chromosome 10-derived fragments are 2464 bp in 




were quantified with the ImageQuant software program. Restriction analysis of this 
polymorphism in internal D4Z4 units was performed on chromosome 4-only sources. A set of 
seven 4qA- and four 4qB-derived repeats were hybridised with the D4Z4 repeat probe 9B6A [41] 
after digestion with PvuII, separation on a 0.8% TBE agarose gel, and transfer to Hybond XL 
membranes. The 3.3 kb fragment is derived from PvuII   units, whereas the 1.6 kb fragment 
represents PvuII+ units. The most distal D4Z4 unit of the repeat array was analysed by specific 




Haplotype analysis for family 36 was performed using 24 polymorphic markers, including 
D4S163, D4S139, D10S555, and D10S595 (P de Knijff, personal communication). 
 
3.3.6 Statistical analysis 
The presence of the PvuII site in the proximal unit of the D4Z4 repeat of 4qA and 4qB alleles 
was compared using the Pearson χ2 test. Allele size distributions in 88 control individuals (84 
4qA and 92 4qB alleles) were analysed according to one-way ANOVA and a non-parametric 





3.4.1 Chromosomal partner for D4Z4 rearrangements 
Repeat rearrangements usually occur between sister chromatids or homologous chromosomes. 
To reveal the common partner for D4Z4 rearrangements, the allele size distributions of 4qA- 
and 4qB-derived D4Z4 repeats were compared. A different D4Z4 repeat length distribution of 
4qA- and 4qB-type alleles would indicate that these chromosomes do not often interact. The 
sizing was performed by PFGE on homogeneous 4-type D4Z4 repeats obtained from high-
quality agarose-embedded DNA plugs. In total, 84 4qA- and 92 4qB-type alleles were analysed. 
Statistical analyses revealed that D4Z4 repeats derived from 4qA alleles (mean ± 95% CI: 136 ± 
7 kb) were significantly longer than those derived from 4qB alleles (mean ± 95% CI: 93 ± 4 kb) 
and that they had a different size distribution (P < 0.001). This indicates that, in general, D4Z4 







































































































































To further elucidate the mechanism underlying D4Z4 rearrangements, we studied a 
polymorphic PvuII site (position 6044 in GenBank accession number AF117653 [6]) in the 
proximal D4Z4 unit of the repeat through use of a modified BglII-BlnI dosage test (Figure 3.1) 
[21]. A PvuII/BlnI double digestion was performed to separate chromosome 4 PvuII-sensitive 
(2849 bp) from PvuII-resistant (4559 bp) alleles. In addition, BlnI was used to avoid 
interference of chromosome 10-type alleles (2464 bp). Analysis of this PvuII-RFLP in 78 
independent 4qA alleles and 62 independent 4qB alleles (Figures 3.1.A and 3.1.B) showed that 
the PvuII site is present in 29% of 4qB alleles and only in 1% of 4qA alleles (P < 10-5), 
suggesting a marked linkage disequilibrium (LD) between the proximal and distal ends of the 
D4Z4 repeat. Next, internal D4Z4 units were analysed for the PvuII-RFLP on DNA sources 
containing only a single chromosome 4-derived D4Z4 repeat. A set of seven 4qA- and four 
4qB-derived D4Z4 repeats revealed that the repeat units following the first unit were 
polymorphic for the PvuII polymorphism on both alleles (data summarised in Figure 3.1.C). 
Figure 3.2 
Example of p13E-11 hybridisation after PFGE and Southern blot analysis: analysis of mosaic family 26 with FSHD 
(GC-CO = gene conversion without crossover). DNA was double digested with EcoRI/HindIII (“E”) and 
EcoRI/BlnI (“B”), separated by PFGE and hybridised with p13E-11. The patient inherited the paternal (p) 60 kb 
chromosome 10 allele and 90 kb 4qB allele and, from his mother (m) the 100 kb chromosome 10 allele and the 
140 kb 4qA allele (unblackened arrowhead), which is present in only 50% of his PBLs. The 14 kb 4qA allele 
(blackened arrowhead) causing FSHD is derived from the 140 kb maternal allele and is detected in 50% of his 
PBLs. Estimation of the proportion of mosaic alleles is based on the signal intensities of the D4Z4 fragments, with 





3.4.2 D4Z4 repeat analysis of mosaic FSHD kindreds 
Eleven kindreds with FSHD, consisting of father, mother and mosaic child with FSHD, were 
analysed for their D4Z4 repeat size and distal 4qA/4qB origin (Table 3.1). From most of these 
families, D4Z4 allele sizes have been described elsewhere [22]. In all mosaic individuals, we 
identified three non-mosaic alleles: two alleles derived from chromosome 10 and one derived 
from the unaffected chromosome 4 homologue. In all cases, the de novo mosaic alleles had the 
same distal flanking marker (4qA) as their ancestral alleles, despite heterozygosity for this distal 
flanking marker in seven of them [16] (Table 3.1). This suggests that D4Z4 rearrangements 
generally do not occur between both chromosomes 4. In 8 of these 11 mosaic individuals, we 
observed a mosaic mixture of a de novo FSHD allele and an unchanged parental allele, 
suggestive of a mitotic D4Z4 rearrangement by gene conversion without crossover. An example 
is shown in Figure 3.2 The remaining three mosaic patients displayed a more complex mosaic 
Figure 3.3 (part 1) 
Example of p13E-11 hybridisation after PFGE and Southern blot. Analyses, as in Figure 3.2, of mitotic 
interchromatid gene conversion with crossover (GC+CO) in families 36 and 1 with FSHD. Estimation of the 
proportion of mosaic alleles is based on the signal intensities of the D4Z4 fragments, with a CI of 5%. Allele types 
are not shown. 
 
EcoRI/HindIII (E) and EcoRI/BlnI (B) digestion of DNA from family 36 with de novo FSHD. The affected male 
inherited 10q alleles of 50 kb and 130 kb and a 140 kb 4qA allele. He also has mosaic alleles of 384 kb (40%; 4Aexp) 
and 16 kb (60%; 4AFSHD), which are expanded and contracted alleles, respectively, most probably produced by an 
interchromatid gene conversion with crossover in the maternal 100 kb or 240 kb allele. Maternally and paternally 
inherited alleles are indicated by “m” and “p”, respectively. Co-migrating chromosome 4 and 10 alleles of 130 kb 





pattern, since they carry two somatically rearranged D4Z4 alleles, suggestive of rearrangements 
with crossover. 
In family 36, we observed a mosaic patient with a mosaic mixture of a 384 kb-sized 
expanded and a 16 kb-sized contracted allele in almost equal proportions of PBLs (Figure 3.3 
part 1). Haplotyping of the patient and his parents excluded non-parenthood (data not shown). 
In family 1, the presence of three mosaic alleles was initially overlooked due to the co-migration 
of one of these mosaic alleles with the non-rearranged chromosome 4qB homologue (Figure 3.3. 
part 2). However, sequence comparison of the region distal to D4Z4 on 4qA (GenBank 
accession numbers. U74496 and U74497) and 4qB (GenBank accession number AF017466, 
[8]) revealed an RFLP for EcoRV. This EcoRV restriction site is directly adjacent to D4Z4 on 
Figure 3.3 (part 2) 
Example of p13E-11 hybridisation after PFGE and Southern blot. Analyses, as in Figure 3.2, of mitotic 
interchromatid gene conversion with crossover (GC+CO) in families 36 and 1 with FSHD. Estimation of the 
proportion of mosaic alleles is based on the signal intensities of the D4Z4 fragments, with a CI of 5%. Allele types 
are not shown. 
 
The left panel shows EcoRI/HindIII (“E”) and EcoRI/BlnI (“B”) digestion of DNA from family 1 with de novo 
FSHD. The patient from this family has three mosaic alleles, of 14 kb, 70 kb and 96 kb, that originated from the 
paternal 70 kb 4qA allele. The 96 kb 4qA mosaic allele is co-migrating with a maternal 96 kb 4qB allele. 
Furthermore, he inherits a paternal 60 kb 10q allele and a maternal 135 kb 4qB allele (marked with an asterisk), 
which originated from chromosome 10 (translocated 4-type repeat (t10;4)) [3]. Quantification of all alleles 
revealed 100% intensity for the 135 kb (t10;4) 4qB allele, 137% for the co-migrating 96 kb 4qA and 4qB alleles, 
37% for the 70 kb 4qA allele, 100% for the 60 kb 10q allele, and 26% for the 14 kb 4qA allele. An EcoRV (“EV”) 
digestion allows separation of the co-migrating 4qA and 4qB alleles at 96 kb (137%). On the basis of EcoRV 
digestion (right panel) the patient clearly has six alleles; of these, the contracted 14 kb 4qA allele (26%; FSHD 
allele, 4AFSHD) and the expanded 96 kb 4qA allele (37%; 4Aexp) originate from the mitotic rearranged parental 70 
kb allele (37%; 4A0). Two arrows indicate D4Z4 expansion and contraction. Allele quantifications after EcoRV 
digestion are indicated in the right example panel. Marker sizes (M; in kb) are indicated at the right. In the box, 





4qA, whereas its location on 4qB is 10 kb distal to the D4Z4 repeat (data not shown), allowing 
separation of these co-migrating 4qA and 4qB alleles and visualisation of the previously 
undetected mosaic allele. The patient now clearly displayed three mosaic alleles: one FSHD-
sized allele of 14 kb, one expanded allele of 96 kb, and the parental unchanged allele of 70 kb, 
each of them equally frequent in the PBLs (Figure 3.3 part 2). The third complex mosaic 
patient, in family Rf120 (data not shown), displays a mixture of three mosaic alleles: two de 
novo contracted alleles of 20 kb and 55 kb in 70 and 10% of PBLs, respectively, and the 





To elucidate the mechanism by which D4Z4 rearranges, we analysed the exact repeat size, 
composition (PvuII-RFLP), and origin (4qA/4qB) of all D4Z4 repeats in individuals in whom 
we had established that a D4Z4 rearrangement had occurred de novo through the presence of 
mitotically rearranged D4Z4 repeats. We observed that the mechanism by which D4Z4 
rearranges shares features common to that of other tandemly repeated DNA sequences. 
 
3.5.1 General features of D4Z4 rearrangements 
To reveal the common partner in D4Z4 rearrangements, D4Z4 repeat length distributions on 
4qA and 4qB alleles were compared. Statistical analyses show a significant difference in the 
distribution between 4qA- and 4qB-type alleles, excluding a frequent recombination between 
D4Z4 repeats on 4qA and 4qB chromosomes. Most probably, D4Z4 rearrangements 
preferentially occur between sister chromatids, the most common partners for rearrangements 
in mammalian cells [13]. In addition, the repetitive nature of D4Z4 enables an intrachromatid 
rearrangement by the formation of an intra-alellic DNA loop. 
In all mosaic cases studied we observed no change of distal flanking marker 4qA/4qB 
between de novo and ancestral alleles, despite the fact that the majority of mosaic individuals 
were heterozygous for this distal marker (Table 3.1). The different D4Z4 repeat length 
distributions of 4qA and 4qB alleles and the observed LD between the proximal PvuII RFLP 
and the 4qB allele is suggestive of a strong suppression of recombination between 4qA and 4qB 
alleles. This suppression of recombination between 4qA and 4qB appears not to be sustained 
throughout the entire repeat, on the basis of the observation that internal D4Z4 units are 
equally polymorphic for the PvuII restriction site on 4qA and 4qB chromosomes. This latter 
may be explained by ongoing or incomplete concerted evolution, as has been described for the 




to 4qA and subsequently spread over this repeat by interallelic rearrangements. It is possible that 
the proximal D4Z4 unit has escaped this homogenisation until now (Figure 3.1.C), which is 
suggestive of a 3' polarity of D4Z4 rearrangements, as described for meiotic minisatellite 
rearrangements [11]. 
 
3.5.2 D4Z4 rearrangements by gene conversion without interchromatid crossover 
The results of the present study strongly suggest that most mitotic D4Z4 rearrangements occur 
via an interchromatid gene conversion mechanism without crossover in which the donor allele 
remains unchanged, since the majority of mosaic patients with FSHD carry two distinct cell 
populations: one that encompasses the parental-sized D4Z4 alleles prior to rearrangement and 
one that encompasses the de novo disease-causing D4Z4 allele (for an example, see Figure 3.2). 
Gene conversions not associated with crossover can be explained by synthesis-dependent 
strand annealing (SDSA) models, as proposed for recombination in yeast [28]. In these models, 
a 3' end of a resected double-strand break (DSB) invades the donor template and primes DNA 
synthesis. Next, the newly synthesized DNA strands are unwound from the template and 
returned to the broken molecule, allowing them to anneal to each other. Out-of-frame 
annealing of the newly synthesized strand can lead to repeat contractions or expansion, while 
the donor template remains unchanged. Alternatively, intrachromatid looping-related or single-
strand annealing rearrangements could also explain our observations. However, these 
mechanisms can give rise only to D4Z4 contractions, which cannot explain the rapid expansion 
of D4Z4 repeats in the hominoid lineage [9] or our observation of D4Z4 expansions in the 
population (RJLF Lemmers, unpublished data). 
 
3.5.3 D4Z4 rearrangements by gene conversion with interchromatid crossover 
The presence of two rearranged D4Z4 repeats in 3 of 11 mosaic families with FSHD is 
indicative of the relatively frequent occurrence of gene conversion with interchromatid 
crossover (as shown in Figure 3.3). Gene conversion with crossover is commonly observed in 
only a small proportion of rearrangements [36]. It is possible that the telomeric localization of 
D4Z4 repeats is underlying the increased crossover rate. In family 36, a mitotic D4Z4 
rearrangement of the maternal 100 kb or 240 kb allele resulted in alleles of 384 kb and 16 kb, 
which are observed in almost equal proportions in the patient’s PBLs. The patient with de novo 
FSHD from family 1 has three PBL cell populations, one of which carries the original allele 
(37%), whereas the other two contain contracted and expanded alleles of the same 
chromosome in 26% and 37% of cells, respectively. Regardless of the exact mechanism, to our 
knowledge this is the first observation of a de novo expansion of the D4Z4 repeat. In family 




Gene conversions that allow for crossovers are often explained by a DSB repair model 
[37] but can also be explained by a SDSA model that includes the possibility of crossover [36]. 
In both models, DSB formation is followed by 5'-to-3' resection, leaving two recombinogenic 
3' ends that can invade the donor template. In both models, the resolution is postulated to 
occur through cutting and resolving of two Holliday junctions, which may result in either 
crossover or no crossover [10]. The DSB repair model was initially proposed to explain gene 
conversions in yeast that were accompanied by crossover in half of the cases [30]. When 
subsequent studies showed much lower crossover rates, other models were proposed that did not 
require Holliday junctions. However, the suppression of crossover during the resolution of these 
junctions can also explain the overrepresentation of gene conversion without crossover [42]. 
On the basis of our findings, we propose that mitotic D4Z4 rearrangements occur preferentially 
via a SDSA model that allows for crossovers. 
 
3.5.4 Timing of D4Z4 rearrangements 
The coexistence of mosaicism for D4Z4 in PBLs, germline and fibroblast cells of patients with 
FSHD already indicated that mitotic D4Z4 rearrangements occur early during embryogenesis. 
More specifically, the absence of the mosaic parental-sized repeat in family 36 might suggest 
that the rearrangement had occurred at the one-cell stage, before the first embryonic cell 
division. Also, all other somatic rearrangements most probably occurred during the first few 
zygotic divisions after fertilization, resulting in a proportion of affected cells that depended on 
the timing of the rearrangement and on stochastic events related to which cells contribute to 
the embryo proper. Mitotic D4Z4 rearrangements that occur at a later stage of development will 
generally result in de novo mosaic alleles in <25% of the cells, as detected in asymptomatic 
carriers of the FSHD allele [22]. 
Different mechanisms could underlie this early occurrence of D4Z4 rearrangements. 
During the first replication steps after fertilisation, paternal and maternal genomes still display 
some characteristics of their progeny cells [24, 25]. It is tempting to speculate that chromatin 
conformational changes during the first rounds of cell division may result in DNA strand breaks 
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Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) is caused by a deletion 
of most copies of the 3.3 kb subtelomeric D4Z4 repeat array on chromosome 4q. The molecular 
mechanisms behind the deletion and the high proportion of new mutations have remained 
elusive. We surveyed 35 de novo FSHD families and found somatic mosaicism in 40% of cases, 
in either the patient or an asymptomatic parent. Mosaic males were typically affected; mosaic 
females were more often the unaffected parent of a non-mosaic de novo patient. A genotypic-
severity score, composed of the residual repeat size and the degree of mosaicism, yields a 
consistent relationship with severity and age at onset of disease. Mosaic females had a higher 
proportion of somatic mosaicism than did mosaic females. The repeat deletion is significantly 
enhanced by supernumerary homologous repeat arrays. In 10% of normal chromosomes, 4-type 
repeat arrays are present on chromosome 10. In mosaic individuals, 4-type repeats on 
chromosome 10 are almost five times more frequent. The reverse configuration, also 10% in 
normal chromosomes, was not found, indicating that mutations may arise from 
transchromosomal interaction, to which the increase in 4-type repeat clusters is a predisposing 
factor. The somatic mosaicism suggests a mainly mitotic origin; mitotic interchromosomal gene 
conversion or translocation between fully homologous 4-type repeat arrays may be a major 





Facioscapulohumeral muscular dystrophy (FSHD [MIM 158900]) is a neuromuscular disorder 
with an autosomal dominant pattern of inheritance. Clinically, the disease is characterised 
mainly by a progressive wasting of the facial, shoulder, and upper arm muscles, and it displays 
substantial inter- and intrafamilial variation. FSHD has an incidence of 1 in 20000 in the 
European population, and there is a relatively high proportion of new mutations (10-30%) [20, 
23, 24, 27, 30]. 
 All patients with a confirmed diagnosis and for who detailed molecular studies have 
been performed carry a chromosomal rearrangement within the subtelomere of chromosome 4q 
(4q35). This subtelomere is composed mainly of a polymorphic repeat structure consisting of 
3.3 kb repeated elements (D4Z4). The number of repeat units varies from 10 to >100 in the 
population, and, in FSHD patients, an allele of 1-10 residual units is observed because of the 




 A highly homologous polymorphic repeat array is located near the telomere of 
chromosome 10q [4, 7], and a specific BlnI site within each chromosome 10-derived repeat unit 
allows discrimination between the arrays [8]. This BlnI side-dependent discrimination 
demonstrated the presence of 10-type repeats on chromosome 4 and, vice versa, 4-type repeats 
on chromosome 10, suggesting a dynamic exchange between these chromosomes. Of 50 healthy 
control males studied, 5 out of 100 chromosomes carried a 4-type repeat on chromosome 10, 
and 5 out of 100 chromosomes carried a 10-type repeat on chromosome 4 (Figure 4.1) [9]. 
Hybrid repeat arrays consisting of clusters of both 4-type and 10-type repeat units are also found. 
Only short repeat arrays on chromosome 4 cause FSHD, irrespective of the type of repeat units. 
Small repeat arrays on chromosome 10 are non-pathogenic [6, 17]. 
 To understand the molecular basis of FSHD, the repeat array and adjacent regions have 
been scrutinised for expressed sequences [12, 16]. Also, the severity and age at onset of the 
disease have been correlated with the size of the residual repeat array on chromosome 4 [22, 27]. 
However, this has not yet clarified the genetic mechanism underlying the deletion event, nor 
have the relatively high mutation frequency and the inter- and intrafamilial variation in the 
Figure 4.1 
Subtelomeric repeat array constitutions on chromosomes 4 and 10 in the Dutch control and FSHD population. 
Chromosomes 4 are white, whereas chromosomes 10 are blackened. 
Top: In the control population, 80% of the individuals carry a standard configuration, with 4-type repeats on 
chromosome 4 and 10-type repeats on chromosome 10. In 10%, a 4-type repeat is also present on one of the 
chromosomes 10 (4 on 10), and 10% carry a 10-type repeat on chromosome 4 (10 on 4). 
Bottom: The repeat array constitutions of mosaic individuals from de novo FSHD families. The deletion is 
indicated by a gray bar. These individuals carry two cell populations indicated within a box. In the original 
population, no FSHD-associated rearrangement is present, whereas, in the other population, a deletion has 
occurred on chromosome 4. In mosaic individuals, 54% carry a standard allele configuration, and 46% carry a “4 





clinical expression of the disease been explained. To elucidate the deletion process and the 
clinical variability of the disease, we have focussed our attention on the repeat constitutions of 
de novo patients and their parents. The high degree of somatic mosaicism described here implies 
that the deletion is mainly mitotic. Furthermore, we find a distinct and yet unexplained 
relationship between sex and affection status in mosaic carriers. Finally, we find that the 
numerical excess of 4-type repeats on chromosome 10 is a significant if not the major 
predisposing factor for the occurrence of the FSHD-type deletion. 
 
 
4.3 Subjects and methods 
 
4.3.1 Patients and controls 
After informed consent, DNA isolated from peripheral blood lymphocytes (PBLs) of 35 
sporadic FSHD patients and their parents was obtained via one of the Dutch Neuromuscular 
Centers. All patients had clinical diagnosis of FSHD. In all cases, diagnosis was confirmed by 
the presence of a short (<35 kb) D4Z4 repeat array. The repeat array constitutions of 50 healthy 
control males have been described elsewhere [9]. 
 
4.3.2 Clinical manifestations 
The age at onset of the various stages of FSHD was established in 12 mosaic individuals. Clinical 
severity scores were based on the age at onset of the initial clinical symptoms: 0 (no signs, no 
symptoms), 1 (facial weakness, no symptoms), 2 (onset of symptoms at age ≥20 years), 3 (onset 
of symptoms at age 15-19 years), 4 (onset of symptoms at age 10-14 years), and 5 (onset of 
symptoms at age <10 years). 
 
4.3.3 PFGE 
Five micrograms of DNA was double digested with EcoRI/HindIII (E/H) or double digested with 
EcoRI/BlnI (E/B) according to the manufacturer’s instructions. DNA was separated by PFGE. In 
brief, DNA was loaded on a 0.8% agarose gel (Boehringer MP agarose) in 0.5× TBE and 
separated by PFGE for 20 h at 8.5 V/cm [9]. After blotting to a Nytran+ membrane (Schleicer & 
Schuell), the DNA was hybridised sequentially with p13E-11 (D4F104S1) and 9B6A (D4Z4) 
[28] as described elsewhere [17]. After exposure to phosphorimager screens, repeat arrays were 
assigned to their chromosomal location on the basis of their BlnI sensitivity. Somatic mosaicism 
was defined as a fifth fragment hybridising with p13E-11 in one individual. The proportion of 




with the expected intensity. Signal intensities of the various hybridising fragments were 
obtained with the ImageQuant program (Molecular Dynamics). 
 
4.3.4 Statistical evaluation 
The allele constitutions on mosaic and control individuals were evaluated according to Fisher’s 
exact test. D4Z4 repeat array lengths in mosaic and control individuals were compared by 
means of the Mann-Whitney U test (one sided). 
 A relationship between age at onset and the proportion of cells carrying the deleted 
allele was calculated by linear regression analysis. For this purpose, we constructed a composite 
genotypic-severity scale: (5 – remaining number of repeat units) × the fraction of cells showing 
A plus sign (+) indicates presence, and a question mark (?) indicates unknown. a: This individual carries a hybrid 
allele on chromosome 10, consisting of both 4-type and 10-type repeat units. b: This individual carries only 4-
type repeat arrays (Figure 4.3.B). c: In this patient, the partial deletion of the D4Z4 repeat array includes the 
p13E-11 region. d: These individuals are mosaic for two short repeat arrays.  
 










4.4.1 Allele identification by PFGE 
The repeat array constitutions of 35 Dutch sporadic FSHD patients (19 males and 16 females) 
and their parents were analysed by PFGE (Table 4.1). For all but two patients, DNA from 
parents was studied. In 23 families we could determine the chromosomal origin and the size of 
each of the four repeat arrays (on chromosomes 4 and 10) in both patients and parents. In the 
10 remaining families with incomplete information, the DNA quality of one of the individuals 
was not sufficient to assign all alleles. 
 All patients showed one BlnI-insensitive repeat array <35 kb (9 units), consistent with 
FSHD diagnosis [3, 20] (Table 4.1). The lengths of these arrays varied from 8 kb (1 unit and 
flanking sequences) to 25 kb (6 units). One patient inherited a 6 unit repeat array from his 
clinically unaffected father. 
 
4.4.2 Mosaicism 
We observed 14 cases of somatic mosaicism (defined by a fifth band on PFGE; Tables 4.1 and 
4.2 and Figure 4.1). In 3 of 23 fully informative families, we observed mosaicism for the disease 
allele in unaffected parents (2 mothers and 1 father), and in 5 more families the patients were 
 a: Thirteen individuals with complete information of both alleles. 




mosaic (4 males and 1 female; Tables 4.2 and 4.3). In the remaining 12 families, for which we 
did not have full information on all repeat lengths, we observed mosaicism in one father, one 
mother, and four patients (three males and one female; Tables 4.2 and 4.3). 
The ImageQuant program was used to estimate the percentage of the cell population 
carrying the deleted allele in mosaic individuals; this varied from 15 to 95% (Table 4.3). Where 
possible, the parental origin of the mosaic allele was determined, as well as the original repeat 
array size and the size of the deletion (Table 4.3). In 8 of 11 mosaic individuals, the smallest 
D4Z4 allele was reduced to an FSHD-sized repeat array. A genotypic-severity score composed of 
the size of the residual repeat array and the proportion of cells carrying this array could be 
established in 11 mosaic individuals (Table 4.3). 
 The age at onset of the clinical manifestations was used for a clinical severity score for 
the mosaic individuals (Table 4.3). A relationship could be established between the age at onset 
of the disease, on the one hand, and the fraction of cells carrying the deleted allele and the 
residual repeat array lengths (Figure 4.2), on the other hand. Individuals with a large proportion 
of cells carrying the disease allele have an earlier age at onset of the disease (P ≈ 0.02). 
 
4.4.3 Repeat array inheritance 
To determine whether the presence of either 4-type repeat arrays on chromosome 10 or 10-type 
repeat arrays on chromosome 4 might play a role in the deletion mechanism, we analysed the 
repeat array constitutions in those mosaic individuals in which we could score all alleles (13 of 
14). Of these 13, 6 carried one or more 4-type repeat arrays on chromosomes 10 (Figure 4.1 and 
Table 4.3). Typically, in these cases, PFGE analysis revealed the presence of five p13E-11 
hybridising fragments: three BlnI-insensitive (4-type) repeat arrays >35 kb; one BlnI-sensitive 
(10-type) repeat array; and the mosaic, truncated, disease- associated repeat array <35 kb 
(Figures 4.1 and 4.3.A and Table 4.2). In one of these six individuals, the “non-standard” repeat 
array consisted of both 4-type and 10-type repeat units (data not shown). One mosaic 
individual even carried only 4-type repeat arrays (Figure 4.3.B). According to the Fisher’s exact 
test, the frequency of 4-type repeats on chromosomes 10 in the mosaic individuals (5 of 13 
[40%]) differs significantly from the Dutch control population (P = 0.0125), previously 
determined at 10% [9]. In contrast, 0 of 13 mosaic individuals showed the reverse configuration 




























































































































































Although the deletion of an integral proportion of D4Z4 repeat arrays has been well established 
as the causal mutation of FSHD, little is known about the mechanism by which the deletion 
arises. We recently found that highly homologous repeat units on chromosomes 4 and 10 may 
interact, resulting in exchanged repeat units on both chromosomes in 20% of the population [9, 
17]. Recently, we could confirm this finding in a larger sample of both males and females (SM 
van der Maarel, unpublished data). To obtain more insight into the deletion mechanism and 
the putative role of interchromosomal repeat interference, we studied the repeat array 
constitution of chromosomes 4 and 10 in 35 de novo FSHD families ascertained via the Dutch 
neuromuscular centers. The results highlight several aspects of FSHD, not previously reported, 
that are relevant to the basic and clinical insight in FSHD aetiology. 
 
4.5.1 Mitosis or meiosis 
We identified somatic mosaicism in 40% of our de novo families. Mosaicism has previously 
been reported for several human X-linked and autosomal dominant diseases, including 
Duchenne muscular dystrophy and haemophilia A [2, 5, 25]. Also, for several tumor-prone 
syndromes, such as neurofibromatosis type 2 and retinoblastoma, mosaicism has been reported 
[11, 26]. However, the high proportion of mosaicism identified in FSHD, as reported here, is 
unprecedented. Considering that we had full allele information on only 23 of 35 de novo 
families and that PFGE reveals only a significant degree of mosaicism, we estimate that ≥40%, 
Figure 4.2 
Relationship between clinical and genotypic severity in mosaic individuals. The clinical severity is on the y-axis, 
whereas the genotypic severity, calculated by [(5 - number of remaining repeat units) × fraction of cells with that 




and possibly much more, of de novo families carry somatic mosaicism for the disease allele. 
Therefore, we propose that the FSHD rearrangement is predominantly mitotic. 
 
4.5.2 Interchromosomal repeat interference 
In 6 (45%) of 13 of the mosaic individuals in whom we could score all alleles, we observed one 
or more 4-type repeat arrays on chromosome 10. In the Dutch population, this type of repeat 
array configuration is present in only 10% of the individuals [9]. The reverse configuration, 
equally present in 10% of controls, was never found in association with mosaicism. This 
provides strong support for the causal involvement of the extra 4-type repeat in the partial 
Figure 4.3 
(A) Somatic mosaicism in a de novo FSHD patient (FSHD1). DNA, digested by EcoRI/HindIII (“H”) or 
EcoRI/BlnI (“B”) and separated by PFGE, was visualised with probe p13E-11. The patient inherited a 65 kb 4-type 
repeat array from his father, which is reduced by 50% of his PBLs to the FSHD range of 10 kb (both alleles have a 
reduced intensity [arrows]). Note that this patient inherited from his mother two 4-type repeat arrays and, 
therefore, has a “4 on 10” repeat array configuration. “Y” alleles are marked with an asterisk (*). The son of this 
patient inherited both grandmaternal alleles and is therefore not affected. 
(B) Somatic mosaicism in a female carrier of de novo FSHD kindred (FSHD9). DNA, digested by EcoRI/HindIII 
(“H”) or EcoRI/BlnI (“B”) and separated by PFGE, was visualised with probe p13E-11. The patient carries a short 
BlnI-insensitive repeat array of 10 kb (arrow), indicating FSHD. This allele (arrow) is also weakly present in the 
mother, who carries on chromosomes 4 and 10 four-type repeat arrays, identified on the basis of their BlnI 






deletion of one of them and, in the case of chromosome 4, leading to FSHD. Studies of 
minisatellite repeat structures and a similar megasatellite repeat (RNU2) in the human genome 
indicate that intrachromosomal recombination, such as unequal sister-chromatid exchange 
(USCE) or intrachromatid gene conversion, dominates over interchromosomal recombination 
processes [13, 19]. A high rate of intrachromosomal recombination effects homogenisation and 
hence concerted evolution of repetitive multigene families, which is thought to maintain the 
integrity of each repeat gene [18]. In FSHD, a similar process might well play a role in the 
partial deletion of the D4Z4 repeat array rearrangements. Since USCE should result in a 
reciprocal allele in the mosaics, which we have never observed, these deletions may arise by gene 
conversion. 
 On the other hand, the numerical excess of 4-type repeats on chromosome 10 in mosaic 
individuals indicates that supernumerary 4-type repeats may physically facilitate the partial 
deletion on either chromosome 4 or 10 (which would go undetected). In this model, the 
deletion arises independent of its inter- or intrachromosomal nature. Since recombination 
depends highly on homology between both alleles [15], normal 10-type repeat units may have 
diverged sufficiently to suppress their contribution to D4Z4 repeat deletions. For rDNA repeat 
arrays, recombination between non-homologous chromosomes has been reported and was 
attributed to the close proximity of these repeat alleles in the nucleolus [1]. 
 
4.5.3 Allele sizes 
In most of the mosaic individuals, the original allele from which the disease allele has arisen 
could be identified by the lower hybridisation intensity. Strikingly, in most of the cases (8 of 11), 
it was the shortest D4Z4 repeat allele that was reduced to an FSHD-sized repeat array. This 
finding may be due to ascertainment bias wherein mosaicism of relatively large alleles remains 
unnoticed, since they will not be reduced to arrays smaller than 35 kb. Indeed, the size 
distribution of the original alleles was significantly smaller than the size distribution of 78 
standard chromosome 4 alleles in the control population (P < 0.05). This may indicate that 
deletions from relatively large alleles may in general have no pathological consequences. 
 As already observed by Zatz et al. [29], the FSHD allele in asymptomatic individuals is 
relatively short. The average repeat length in mosaic individuals in this study is 3.1 units, whereas 
non-mosaic patients carry, on average, 3.9 units. This may be explained in part by the 
association between the residual repeat size and severity and age at onset of the disease. In 
general, small alleles result in a more severe phenotype [22, 27], and it may well be that, in 
mosaic individuals, the tolerance for short alleles is smaller than that for larger FSHD alleles. In 
this scenario, high proportions of cells carrying larger FSHD alleles may be required, to elicit a 




 Alternatively, in addition to the mosaic rearrangement described here, which exhibits 
relatively short arrays, and undefined mutational mechanism may exist that results in relatively 
larger FSHD arrays. If such an alternative exists, the high proportion of severely affected patients 
among de novo cases may be explained by a mechanistic difference rather than by a clinical 
ascertainment bias. 
 
4.5.4 Sex and affection status 
Somatic mosaicism has been observed in 15-20% of the unaffected parents of de novo FSHD 
patients. In these studies, a female predominance of mosaic carriers (15 females : 6 males) was 
reported and was then attributed to a higher mutation rate in females than in males [14, 20, 29]. 
In agreement, we found parental mosaicism in 14% of our de novo families (3 females and 2 
males). 
 In addition to mosaicism in parents, we found a high frequency (26%) of somatic 
mosaicism in de novo FSHD patients who belong to different families as the mosaic carrier 
parents. In these mosaic patients we find, in contrast, an excess of mosaic males over mosaic 
females (7 of 2). The proportion of cells carrying the deletion allele varied from 15 to 19% on 
the basis of the signal intensities of the different alleles. Typically, in mosaic female patients, the 
proportion of the deleted allele was higher than in mosaic male patients (Table 4.3). Combining 
the female excess among unaffected mosaic carrier parents with the male mosaic excess among 
the patients themselves, we propose that the female predominance of mosaic asymptomatic 
carriers is not due to a higher mutation rate in females, but rather to a higher clinical tolerance 
for mosaic disease alleles in females compared with males. Consistent with this proposal, males 
are more severely affected than females [21, 23, 24, 29]. 
 Although the extent of somatic mosaicism depends on the timing of the deletion event 
and on tissue-specific selection, we established a relationship between the residual repeat size 
and the proportion of cells carrying this disease allele, on one hand, and the severity and age at 
onset on the other (P ≈ 0.02). This suggests that the mutation may already occur early in 
embryogenesis, before divergence of muscle and lymphocyte lineages. Nevertheless, it will be 
important to analyse the mosaicism in muscles of mosaic patients and parents. 
 
4.5.5 Implications for FSHD diagnosis 
For autosomal dominant diseases, recurrence risks in parents of de novo patients are considered 
very low, whereas disease carriers have 50% probability of having affected offspring. Since we 
have detected somatic mosaicism in ≥40% of the de novo families, this is not necessarily true for 
de novo FSHD families. According to Table 4.3, since asymptomatic mosaic carriers may have as 




offspring will be affected. In contrast, the mosaic FSHD patient in family 5 may have as little as 
10% risk of having affected offspring. Detailed analysis of somatic and germline mosaicism in 
de novo FSHD families will be required, to obtain more accurate figures for genetic counselling. 
 In conclusion, we have shown (1) that the D4Z4 repeat reduction associated with FSHD 
arises in ~40% of the de novo cases, mitotically, in either parent or patient; (2) that the basic 
mechanism of the repeat reduction likely involves inter- or, possibly, intrachromosomal gene 
conversion; (3) that this is facilitated by the presence of D4Z4 repeat arrays on chromosome 10, 
which thus predisposes for the deletion; (4) that somatic mosaicism occurs in both males and 
females, but that males are more often affected than females; therefore, the proposed sex 
difference in the occurrence of somatic mosaicism may in fact be a sex-dependent clinical 
threshold for the mosaic disease allele; and (5) that a relationship exists between, on one hand, a 
combination of the residual repeat size and proportion of cells carrying the disease allele and, on 
the other hand, the age at onset and the severity of the disease. This chromosomal copy number-
dependent repeat interference may well turn out to be a basic mechanism for genome 
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The autosomal dominant myopathy facioscapulohumeral muscular dystrophy (FSHD1, OMIM 
158900) is caused by contraction of the D4Z4 repeat array on 4qter. We show that this 
contraction causes marked hypomethylation of the contracted D4Z4 allele in individuals with 
FSHD1. Individuals with phenotypic FSHD1, who are clinically identical to FSHD1, but have 
an unaltered D4Z4, also have hypomethylation of D4Z4. These results strongly suggest that 





Epigenetic changes of DNA have been investigated as causes of monogenic disorders, 
tumorigenesis and aging and are suspected to be important for common multifactorial diseases 
also. Monogenic diseases associated with epigenetic phenomena are caused either by mutations 
in chromatin remodelling factors [1] or by position effect variegation mechanisms mostly 
involving regulatory elements [19]. An epigenetic role is also prominent in imprinting disorders 
[16]. 
FSHD1, which progressively and variably affects muscles of the face, shoulder and upper 
arm [15], has such a suspected epigenetic aetiology. We previously mapped FSHD1 to 4qter and 
showed that it is caused by contraction of the polymorphic D4Z4 repeat array [4, 20] 
(Supplementary Figure 5.1). In healthy individuals, D4Z4 consists of 11-150 units on both 
chromosomes, whereas individuals with FSHD1 carry one 4q array of 1-10 units. About 5% of 
individuals with FSHD1 do not have a contraction of D4Z4 and are considered to have 
phenotypic FSHD [10]. 
Several observations suggest an epigenetic aetiology in FSHD1. First, the subtelomere of 
chromosome 10q contains a nearly identical polymorphic D4Z4 repeat, but size reductions of 
this repeat are not pathogenic. Second, exchanges between the homologous repeat arrays on 4q 
and 10q are frequently observed, but these exchanged repeats are only pathogenic when the 
contracted form resides on chromosome four [3]. Finally, D4Z4 contractions on 4qter are 
necessary but not sufficient to cause FSHD1, because the actual pathogenicity is only associated 
with one of two alleles (4qA) of the 15-20 kb 4qter moiety located immediately distal to D4Z4 
[8]. 
The presentation of FSHD1 requires that there is a contracted D4Z4 repeat located on 




unlikely that contraction of the D4Z4 repeat array itself directly results in loss of all or part of a 
putative gene mutated in FSHD1. Thus, FSHD1 may be due to an epigenetic phenomenon that 
causes the transcriptional deregulation of genes close to D4Z4. 
To explain the epigenetic basis for FSHD1, we examined the DNA methylation, the 
most common modification of mammalian DNA, known to be involved in development, X-
chromosome inactivation, imprinting and gene silencing [18]. We examined two CpG 
methylation-sensitive restriction sites (BsaAI and FseI) in the first (proximal) unit of the D4Z4 
repeat array on chromosome 4q35 (see Supplementary subjects and methods and 
Supplementary Figure 5.1). First, we determined methylation of the proximal D4Z4 unit for 
the 4q-type repeat exclusively (see examples in Figure 5.1). We then showed by pulsed-field gel 
electrophoresis that these results were representative for the entire array (Supplementary Figure 
5.2). 
Using this test, we found significant hypomethylation of D4Z4 in individuals with FSHD1 
on both sites (Figure 5.2). Considering the presence of one wild type and one mutated allele in 
disomic individuals with FSHD1, hypomethylation was highly significant on both sites (P < 0.001). 
Figure 5.1 Methylation-sensitive digestions after Southern blotting and hybridisation with probe p13E-11. In the 
left panel, the pedigree of family I with two family members with classical FSHD is shown. Individual 1 is an 
unaffected monosomic (explained in Supplementary Figure 5.1) person with a D4Z4 repeat array of 73 kb. 
Individuals 2 and 3 are both monosomic and inherited the same pathogenic D4Z4 4qA repeat array of 22 kb from 
one of their parents. Individual 2 is a minimally affected gene carrier, and individual 3 has FSHD. In the middle 
panel, the pedigree of family II with phenotypic FSHD is shown. The father (individual 4) is a healthy disomic 
person. His wife (individual 5) and his daughter (individual 6) are both disomic and have clinical characteristics 
of FSHD but do not carry a contracted D4Z4 array on chromosome 4. Note the marked reduction of signal 
intensity of the undigested chromosome 4-derived fragments in individuals with FSHD. In the right panel (III), 
two unrelated individuals with ICF show pronounced hypomethylation of D4Z4 (individuals 7 and 8). 
Methylation-sensitive digestions (“B”, BsaAI; “F”, FseI) for each individual are shown in different lanes beneath 
the pedigrees, and arrows at the sides of the figures indicate the methylated and unmethylated fragments 
according to the colour codes used in Supplementary Figure 5.1. “Y” indicates cross-hybridisation with the 





Non-penetrant gene carriers, clinically unaffected individuals carrying the mutated allele, were 
similarly hypomethylated at their shortened D4Z4 allele (P < 0.001; Figure 5.2). We found no 
tissue-specific methylation differences between muscle and blood lymphocytes of three individuals 
with FSHD1 and three control individuals. Two biopsy samples from clinically affected and 
unaffected muscle from the same individuals with FSHD1 also show no differences in methylation 
(data not shown). We also found no effect of age or ageing in lymphocyte DNA from unaffected 
individuals and controls samples twice with a time interval of several years (data not shown). Thus, 
D4Z4 methylation seems to be established early and transmitted stably. 
In about 5% of affected individuals, FSHD1 shows neither linkage to 4qter nor 
contraction of D4Z4 and is thought to be caused by defects in other unidentified loci, one of 
which maps to chromosome 15 [17]. These individuals with phenotypic FSHD1 are clinically 
indistinguishable from those with 4q-linked FSHD1. Analysis of five individuals with 
phenotypic FSHD1 showed pronounced hypomethylation for both sites on both chromosomes 
four (P < 0.001), strongly supporting a central role for D4Z4 hypomethylation in the aetiology 
of FSHD1 (Figures 5.1 and 5.2 and Supplementary Figure 5.3). 
To further determine whether D4Z4 hypomethylation is specific to FSHD1, we analysed 
DNA of 14 unrelated individuals with muscular dystrophy and of individuals with autosomal 
recessive immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome. ICF 
syndrome (OMIM 242860) presents with immunodeficiency, facial anomalies, mental retardation 
Figure 5.2 
Bar diagram of the methylation of D4Z4. The methylation at the BsaAI and FseI methylation-sensitive restriction 
sites in the proximal D4Z4 repeat unit is shown for control individuals (n = 79), individuals with FSHD (n = 40), 
obligate gene carriers (n = 10), individuals with phenotypic FSHD (without contraction of D4Z4; n = 5), 
unrelated individuals with non-FSHD muscular dystrophy (MD; n = 14) and individuals with ICF (n = 2). See 
Supplementary subjects and methods for detailed information on all groups. Data are presented as mean ± S.E.M. 
* P < 0.05 versus control individuals; † P < 0.05 versus individuals with FSHD; # P < 0.05 versus individuals with 




and developmental delay and is caused by mutations in the gene DNA methyltransferase 3B 
(DNMT3B) [21]. Individuals with ICF have hypomethylation at D4Z4 [7]. 
Unrelated individuals with muscular dystrophy had methylation comparable to control 
individuals, but individuals with ICF had even lower methylation than individuals with FSHD1 (P 
< 0.05 for both sites; Figures 5.1 and 5.2). In contrast to FSHD1, in which hypomethylation is 
restricted to the disease chromosome, hypomethylation was detected on chromosomes 4q and 10q 
in ICF (FseI, P < 0.01; BsaAI, P = 0.07 (a trend)). 
Recent findings suggest that reduction of a specific repressor complex, associated with 
D4Z4 contraction, causes improper activation of 4q35 genes in a distance-dependent manner 
[5]. In contrast, a recent study based on histone H4 acetylation levels suggests that 4qter has 
properties of unexpressed euchromatin and that a differential long-distance looping mechanism 
seems to be the probable mechanism [6]. But neither model, spreading or looping, explains the 
etiological link between 4q allele-specificity of D4Z4 contraction and transcriptional 
upregulation. Our results showing chromosome-specific hypomethylation may provide this 
missing link between DNA changes and transcriptional derepression in FSHD1. Whatever the 
exact nature of this mechanism, our results showing D4Z4 hypomethylation in individuals with 
4q-linked and phenotypic FSHD1 strongly supports a central role of D4Z4 demethylation in 
the pathogenic pathway of FSHD1. 
 
 
5.3 Supplementary subjects and methods 
 
5.3.1 Individuals 
All individuals included were previously analysed after informed consent for their D4Z4 allele sizes 
and constitution of repeat arrays ([11, 12, 14] and unpublished results). 
Genomic DNA was isolated from PBLs of 79 control individuals, both family members 
and unrelated individuals (19 monosomic and 60 disomic), 40 FSHD patients (5 monosomic 
and 35 disomic), 5 disomic phenotypic FSHD patients, 10 non-penetrant obligate gene carriers (2 
monosomic and 8 disomic), 14 individuals with an unrelated muscle disease (BMD (n = 3), 
CAPN3 (n = 2), DMD (n = 3), DM1 (n = 1), OPMD (n = 3) and γ-SARC (n = 2); 2 monosomic 
and 12 disomic) and 2 disomic ICF patients. DNA was extracted essentially as described by Miller 
et al. [13]. 
 
Phenotypic FSHD patients were collected from three different families. Kindred 1 consists of 
two healthy parents and two children affected with FSHD, both disomic with a 4qA D4Z4 




Kindred 2 is composed of two healthy parents, two healthy daughters, and one affected disomic 
son who inherited from his mother a 48 kb large 4qA fragment and a 120 kb large 4qB 
fragment from his father. Finally, family 3 consists of a healthy father and an affected mother 
and daughter. The mother has a 50 kb large 4qA fragment that is inherited by her affected 
daughter and a 90 kb large 4qB fragment. The daughter inherited, besides the 50 kb D4Z4 
Supplementary Figure 5.1 
The D4Z4 methylation assay. 
Upper panel (I): Schematic diagram of chromosome 4q35 encompassing the FSHD candidate region. FSHD is 
caused by contraction of the polymorphic D4Z4 repeat (black arrow heads) to 1-10 units. Also shown are the 
locations of the ANT1, FRG1, FRG2 and DUX4 genes. The approximate distances to D4Z4 are depicted at the top 
of the figure. There is also one repeat unit present proximally to the D4Z4 repeat orientated in opposite direction. 
Lower panel (II): Schematic representation of the modified BglII/BlnI dosage test. By adding different 
methylation-sensitive enzymes subsequent to incubation with BglII, BlnI and EcoRI, methylation statuses of these 
sites can be determined. EcoRI does not cleave D4Z4, but is used to fragment the DNA and therefore to increase 
accessibility of the DNA for these methylation-sensitive enzymes. It cuts outside the BglII restriction sites and is 
therefore not shown in the overview. Underneath the overview, bars represent the different chromosome 4-
derived fragments, which are released after digestion with BsaAI or FseI. FseI will generate a fragment of 3387 bp 
(b) while BsaAI releases a fragment of 3031 bp (c). All fragments will only be generated when specific CpGs in 
these restriction sites are not methylated. Besides the chromosome 4-derived fragment of 4061 bp (a), which is 
not restricted by one of the methylation-sensitive enzymes, the chromosome 10-derived fragment of 1774 bp (d) 
is shown. Since the restriction sites of both methylation-sensitive enzymes are all located distal to BlnI, any 
putative methylation of the chromosome 10 is not detected and thus does not interfere in our assay. 
Exchange of repeat arrays between chromosomes 4 and 10 occurs in about 20% of the population [3, 
14]. Individuals who have a single 4-type array on one of their chromosomes 4, and a 10-type array on the other, 
and two 10-type arrays on both their chromosomes 10, are called ‘monosomic’ (for the 4-type array). This occurs 
in 10% of patients and healthy individuals. Individuals who have the regular constitution of two 4-type arrays on 
both chromosomes 4 and two 10-type arrays on both chromosomes 10 are called ‘disomic’. In monosomic 
individuals our methylation assay thus monitors specifically and exclusively one single 4q-type array (the 
pathogenic one in patients), while in disomic individuals both 4q-type alleles are monitored. Thus, applying this 
assay to DNA from monosomic individuals (M) will give a methylation status of one allele in and an average of 





repeat array from her mother, a 132 kb large 4qB fragment from her father. Neither of the 
maternal grandparents is affected. 
 
5.3.2 Methylation analysis of proximal chromosome 4 repeat unit 
Four µg of PBL-DNA was co-digested with restriction enzymes EcoRI, BglII (MBI Fermentas), and 
BlnI (Amersham Pharmacia Biotech). Subsequently, 12 units of CpG methylation-sensitive 
enzyme BsaAI (New England Biolabs Inc.) were added. For CpG methylation-sensitive enzyme 
FseI, after digestion with EcoRI/BglII/BlnI, five µg of PBL-DNA was precipitated with 1/10 3M 
NaAc pH 5.3, 2.5× 100% EtOH and the pellet was dissolved in 30 µl Tris/EDTA pH 7.5. 
Thereafter, an FseI digestion (12 units, New England Biolabs Inc.) was performed. All digestions 
were incubated overnight according to the manufacturer's instructions. 
DNA was separated on a linear 0.8% agarose gel (UltraPURE agarose, GibcoBRL 
Lifetechnologies Ltd). Electrophoresis was performed in 1× TAE supplemented with ethidium 
bromide. After electrophoresis, DNA was transferred to a Hybond-XL membrane (Amersham 
Pharmacia Biotech). The probe p13E-11 (D4F104S1) [20], and an empty vector control probe 
were labelled by random priming with 32P-dCTP using the megaprime DNA labelling system 
(Amersham Pharmacia Biotech). Hybridisations were performed as described previously [11]. 
Next, phosphorimager patterns were analysed using ImageQuant software (Molecular 
Dynamics). After correction for background, methylation of chromosome 4 alleles was 
calculated by comparing undigested and digested fragments. 
Several control experiments were performed to confirm complete digestion by 
methylation-sensitive enzymes. Since methylation-insensitive isoschizomers are not available 
for either of these enzymes, equimolar amounts of a plasmid containing one restriction site for 
each methylation-sensitive enzyme were added. This allows endogenous verification of complete 
digestion by hybridisation with an empty vector probe. Although this does not monitor the 
presence of impurities bound to the genomic DNA, identical results were achieved in the 
methylation PFGE assays. Moreover, the methylation assay was applied five times independently 
to DNA of one FSHD patient and two controls without significant differences (P = 0.74; with 
an average deviation of <3%). 
Finally, six FSHD patients and two controls were tested, sampled twice with an interval 
of at least five years without observing an effect of aging (BsaAI, P = 0.21 and FseI, P = 0.74), 
and with an average variation in methylation within each individual <2%. 
 
5.3.3 Methylation analysis of whole chromosome 4 repeat array 
Five µg of PBL-DNA embedded in agarose (InCert agarose, Cambrex) was equilibrated overnight 




or with EcoRI/BlnI. Subsequently, plugs digested with EcoRI/BlnI were washed in Tris/EDTA pH 
7.5 and equilibrated in FseI restriction buffer. Next, 20 units of FseI were added. All digestions 
were incubated overnight and performed according to the manufacturer's instructions. 
Supplementary Figure 5.2 
Example of methylation analysis by PFGE of one classical FSHD kindred.  
To assess whether the methylation status of the proximal unit reflects that of the entire array, DNA from 15 
individuals from 6 FSHD families was digested with EcoRI, BlnI and FseI and separated by pulsed-field gel 
electrophoresis (PFGE). After hybridisation, extended, regular ladders of digested D4Z4 arrays were detected in 
the FseI lanes, characteristic for equal partial methylation of all chromosome 4-type repeat units within one array. 
Moreover, a clear inter-individual and inter-allelic variation of methylation at the FseI site was observed. 
Demonstrating the hypomethylation of FSHD alleles, the FSHD-specific ladders were far shorter than the control 
ladders, while also the completely undigested disease fragments typically showed less residual signal intensity in 
FSHD samples than in normal samples. The four monosomic individuals tested by both pulsed-field and 
proximal repeat unit tests, showed an average deviation of <5% between both methylation assays. 
 
In this figure, the left panel gives a PFGE example of three individuals: two parents with a de novo FSHD kindred 
digested with EcoRI/HindIII (“H”), EcoRI/BlnI (“B”) and with EcoRI/BlnI/FseI (“F”), respectively. The father 
carries three 4-type arrays of 48 kb, 75 kb and 105 kb and one 10-type array of 200 kb (trisomic). The mother 
carries 4-type arrays of 90 kb and 96 kb and 10-type arrays of 60 kb and 70 kb (disomic). The affected son inherits 
from the father the 105 kb 4-type and 200 kb 10-type array and from the mother the 60 kb 10-type array and an 
apparently maternal rearranged FSHD allele of 23 kb (disomic). In the FseI lane, variable ladders of D4Z4 repeat 
arrays (indicated in white) are hybridising due to the equal partial methylation of each consecutive D4Z4 unit. 
The marker lane (in kb) is indicated with (M). 
In the right panel a schematic representation of the generation of ladders of D4Z4 fragments by partial 
methylation of the FseI restriction site (+/-) is drawn. Triangles represent D4Z4 units and the probe region p13E-
11 is indicated proximal to the array. Partial methylation of each consecutive unit will lead to a gradual fading of 
the signal intensity with increased array size (gray scales). Due to the hypomethylation of FSHD arrays, these FseI 





After digestion, DNA was separated by PFGE on a 0.8% agarose gel (MP agarose, 
Boehringer Mannheim) as described previously [3, 9, 11] with the exception that DNA was 
transferred to Hybond-XL membranes. Thus, 4q-type alleles were separated from 10q-type alleles 
by the BlnI sensitivity of the latter [2]. Phosphorimager patterns were again analysed using 
ImageQuant software. 
 
5.3.4 Statistical analyses 
Main effects of age (at time of blood sampling: in years) and gender were assessed with ANOVA. 
Methylation statuses were compared between healthy family members and healthy unrelated 
controls by independent sample T-tests. To determine whether methylation status was due to allele 
constitution, we compared the two most divergent allele constitutions (monosomic patients versus 
disomic controls) in a non-parametric two independent samples test (Mann-Whitney U test, 
asymmetric). To determine whether methylation status on either chromosome 4 or 4 and 10 is due 
to pathology or repeat array constitution, we used independent sample T-tests. 
Statistical analyses of all individuals showed no differences in methylation due to age or 
gender, nor between healthy family members and unrelated controls. In subsequent analyses, all 
data were pooled across these variables. 
The fractions of healthy and disease chromosomes 4 in patients and control individuals 
were used in a linear regression analysis to determine the contribution of these alleles on 
percentage of methylation at each restriction site. Monosomic FSHD patients have a fraction of 
zero (no healthy alleles), disomic patients have a fraction of 1/2 (one FSHD and one healthy allele). 
Monosomic control individuals have a fraction of 1 (one healthy allele out of one) and disomic 
Supplementary Figure 5.3 
Pedigrees of the three phenotypic FSHD kindreds. The affected patients are indicated in black. None of the 
affected individuals shows a contraction of the D4Z4 repeat on chromosome 4. Normal segregation of the D4Z4 
repeats is observed in all individuals. The sizes of the D4Z4 repeat (in kb) and the allelic origin of the repeat, 4qA 




control individuals have a fraction of 2 (two healthy alleles out of two). The data from monosomic 
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6 Residual D4Z4 repeat size and D4Z4 methylationlevels separate FSHD into two severity classes
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Facioscapulohumeral muscular dystrophy (FSHD) progressively affects the facial, shoulder and 
upper arm muscles, and is associated with contractions of the polymorphic D4Z4 repeat array in 
4q35. Recently, we demonstrated that FSHD alleles are hypomethylated at D4Z4. To study 
potential relationships between D4Z4 hypomethylation and residual repeat size and clinical 
severity, we compared the clinical severity score with D4Z4 methylation in unrelated FSHD 
patients. We show that correcting the clinical severity score for age at examination improves the 
parameter to define clinical severity and provide further support for a significant 
hypomethylation of FSHD alleles. However, a linear relationship between repeat size and 
severity of the disease cannot be established by this method. Interestingly, our data indicate that 
FSHD can be separated into two clinical severity classes: patients with residual D4Z4 repeat sizes 
of 10-20 kb are always severely affected and show pronounced D4Z4 hypomethylation. In 
contrast, patients with D4Z4 repeat sizes of 20-38 kb show a large interindividual variation in 
clinical severity and D4Z4 hypomethylation. As the vast majority of familial FSHD cases are 
represented in this interval and considering the overt variation in clinical severity in these 
familial cases, it is thus imperative to develop comprehensive allele-specific assays monitoring 
total D4Z4 methylation to investigate whether interindividual variation in D4Z4 methylation 





Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD1A, MIM 158900) 
progressively affects the facial, shoulder and upper arm muscles. This myopathy displays a high 
inter- and intrafamilial variability in age at onset and progression of the disease [21]. The major 
locus for FSHD has been mapped to the subtelomere of chromosome 4q (4q35) [26, 28] where 
it is associated with contractions of a polymorphic repeat array consisting of 3.3 kb repeated 
elements, designated D4Z4 [7, 27]. In healthy individuals the D4Z4 array consists of 11-100 
units, while patients with FSHD carry a repeat array of 1-10 units [27]. The subtelomere of 
chromosome 10 also harbours a polymorphic repeat array, which is 98% homologous to D4Z4 
[1, 5]. Despite the presence of translocated 10-derived repeat units on chromosome 4, and vice 






The D4Z4 repeat is very GC-rich, which is characteristic for CpG islands. Each unit encodes a 
putative open reading frame (ORF) containing two homeobox domains (DUX4). A promoter 
region precedes this ORF, which contains a TACAA box 150 bp upstream of the ATG start 
codon [8]. Sequence analysis of D4Z4 further revealed a 316 bp region with homology to the 
sequence of LSau, a GC-rich DNA repeat, and also a region with high similarity to the 
sequence of a low-copy repeat hhspm3. Both these repetitive elements are associated with 
heterochromatin [9]. FISH analysis showed an extensive dispersion of D4Z4 to 
heterochromatic regions of the genome [2, 9, 13, 29]. This heterochromatic association, and 
the high GC content of the repeat, may indicate that normally DUX4 is transcriptionally 
inactive. Indeed, no transcripts of DUX4 have been identified so far in vivo. 
The heterochromatic properties of D4Z4 and the lack of evidence for active 
transcription emanating from D4Z4 have led to the hypothesis that FSHD is caused by an 
epigenetic disease mechanism [3]. In this model contraction of the D4Z4 repeat results in a 
local change in chromatin structure and consequently the transcriptional deregulation of one 
or more FSHD genes. These genes were originally proposed to be located in, or close to the 
D4Z4 repeat array, but recent evidence suggests that they may also be located at considerable 
distance through a long distance looping model [10] or even at different chromosomes 
through a nuclear disorganisation model as 4qter occupies a distinct peripheral nuclear 
territory [16]. 
 
Recently, we presented evidence for an epigenetic factor involved in FSHD by demonstrating 
that FSHD alleles are hypomethylated at D4Z4 [20]. We applied a methylation assay on DNA 
isolated from peripheral blood lymphocytes (PBLs) and muscle of monosomic and disomic 
individuals. Individuals carrying a standard allele constitution of 4-derived repeat units on 
chromosome 4 and 10-derived repeat units on chromosome 10 are referred to as 'disomic' for 
D4Z4, while individuals carrying one array of 10-derived repeat units at one of their 
chromosomes 4 are referred to as 'monosomic' for D4Z4. The methylation assay quantifies the 
methylation of two CpG dinucleotides within the most proximal unit of the D4Z4 array on 
chromosome 4 by use of two different methylation sensitive restriction enzymes. Due to the 
extensive spreading of D4Z4 through the genome, methylation analysis of D4Z4 is very 
complex. Currently, this is the only assay with sufficient specificity to demonstrate significant 
hypomethylation of D4Z4 in FSHD alleles despite the fact that only 2 of the 290 CpG 
dinucleotides in the D4Z4 unit are tested. As we can discriminate between chromosomes 4 and 
10 in our methylation assay, only monosomic individuals, who are observed in only 7% of the 
population [6, 17, 19, 23, 25], allow the analysis of the methylation of D4Z4 in a single 




population), can only be analysed for methylation at both chromosomes 4 simultaneously 
which prohibits precise methylation measurements of the disease allele. 
DNA analysis of monosomic individuals thus provides the unique possibility to examine 
the methylation of single healthy or disease alleles, without interference or masking of any other 
homologous locus in the genome. To obtain more information on the degree of 
hypomethylation at the FSHD allele and to investigate a possible relationship of methylation 
with repeat array size and severity, and the clinical implications, we analysed D4Z4 methylation 
in 40 independent chromosome 4 alleles. 
 
 
6.3 Subjects and methods 
 
6.3.1 Patients and control individuals 
All 40 individuals (21 patients and 19 control individuals) included in this survey were analysed 
previously for their allele sizes and constitution of repeat arrays on chromosomes 4 and 10 ([14, 15, 
19] and unpublished results). Five of these patients were already included in a previous study [20]. 
Only monosomic individuals with a 4-type array on chromosome 4, a translocated 10-type array 
on chromosome 4 and two 10-type arrays on chromosome 10 were included in this study to 
compare the methylation status of the proximal D4Z4 repeat unit with repeat array size and with 
two different parameters that define severity of the disease. 
All 21 patients, 12 probands and 9 non-proband affected family members, were clinically 
evaluated and the expression of their phenotype was scored according to the clinical severity score 
list (CSS) formulated by Ricci et al. [22]. Since FSHD is a slowly progressive myopathy, it is very 
difficult to determine the precise onset in a patient [21]. Age at onset is usually determined in 
retrospect and often depends on the recollection and perception of the patient and on a 
possible family bias. We therefore corrected the CSS for age at examination, given that the 
duration of this progressive disease determines the CSS at the time of examination: 
age-corrected CSS = ((CSS × 2) / age at examination) × 1000 
The severity score was multiplied by two to generate whole numbers and we then multiplied the 
outcome of this calculation with 1000 to improve interpretation of the results and visualisation in 
graphs. 
 
6.3.2 DNA analysis 
Genomic DNA was isolated from peripheral blood lymphocytes (PBLs) from all monosomic FSHD 
patients and control individuals, both family members and unrelated individuals. DNA was 




For analysis of D4Z4 by the methylation-sensitive restriction enzymes BsaAI and FseI 
(New England Biolabs), we applied a method illustrated in Figure 6.1 and as described previously 
[20]. To monitor complete digestion, we added equimolar plasmid DNA to the genomic DNA 
prior to digestion with the methylation-sensitive enzyme of interest and after a BglII/BlnI digestion, 
all according to the manufacturer’s instructions. DNA was then separated by linear gel 
electrophoresis and after Southern blotting the membranes were hybridised with radioactive 
labelled probe p13E-11 (D4F104S1) [27] and subsequently with an empty plasmid vector to 
confirm complete digestion of the exogenous DNA control. Next, membranes were exposed to 
phosphor-imager screens and signal intensities were analysed with ImageQuant software 
(Molecular dynamics). 
 
6.3.3 Statistical analyses 
Methylation was analysed by ANOVA with disease status (control individuals and FSHD patients) 
as a fixed factor. Possible relationships between (1) repeat array size versus FSHD severity, (2) 
repeat array size versus methylation and (3) methylation versus FSHD severity were estimated using 
linear regression analyses and were tested by Pearson correlation. The mean of a set of data is given 
as mean ± S.E.M. Analyses were performed on all available data. 
Figure 6.1 
Schematic overview of the modified BglII/BlnI dosage test developed for analysis of the proximal D4Z4 repeat 
unit. Bars represent the different fragment sizes, which are released when PBL-DNA from monosomic individuals 
is digested with BsaAI or FseI subsequent to BglII and BlnI. FseI will generate a fragment of 3387 bp (“B”) and 
BsaAI of 3031 bp (“C”). Besides the chromosome 4 fragment of 4061 bp (“A”), generated by BglII, when both 
BsaAI and FseI do not cut, also the chromosome 10 fragment of 1774 bp (“D”) is shown that is released by the use 
of BglII and BlnI. Both methylation-sensitive restriction sites are located distal to BlnI, so any putative 
methylation of the chromosome 10 will not be detected with this assay. Monosomic individuals have a single 4-
type array on one of their chromosomes 4, and a 10-type array on the other, and two 10-type arrays on both their 







6.4.1 Repeat array size in relation to FSHD severity 
As expected, all monosomic FSHD patients displayed smaller chromosome 4 repeat arrays 
compared to the control group (FSHD: 24.14 kb ± 1.09 kb versus control individuals: 91.81 kb 
± 5.94 kb). 
We first tested whether we could confirm previous findings that showed a correlation 
between the severity of the phenotype and D4Z4 fragment size in FSHD patients [12, 24]. We 
evaluated this in our monosomic patients with two different definitions for clinical severity; 
comparing repeat array size with the clinical severity scale (CSS) according to Ricci et al [22] and 
with an age-corrected CSS in which we corrected for the age at examination as FSHD is a 
progressive disease. This first comparison revealed a significant relationship (r = -0.45; P = 0.05) 
and confirmed that severity of the disease increases with decreasing residual repeat size. 
Moreover, when the CSS was corrected for age at examination, age-corrected CSS, the inverse 
relationship between repeat array size and severity became even stronger (r = -0.52; P < 0.05). 
 At close examination, we observed considerable variation in the clinical severity within the 
20-38 kb interval, while in the 10-20 kb interval all patients were severely affected based on age-
corrected CSS. 
 
6.4.2 Comparison of FSHD patients with control individuals 
Next, we compared the methylation of the proximal D4Z4 unit on chromosome 4 in 21 
independent FSHD alleles and 19 independent control alleles. Corroborating and extending on 
our previous study [20], we observed a significant hypomethylation in FSHD alleles (P < 0.001) on 
Figure 6.2 
Bar diagram of methylation percentages in monosomic individuals. Methylation at BsaAI and FseI methylation-
sensitive restriction sites within the proximal D4Z4 repeat unit is shown for 19 control individuals and 21 FSHD 






both restriction sites (FSHD: BsaAI 29.05% ± 2.43% and FseI 19.47% ± 2.77% versus control 
individuals: BsaAI 48.88% ± 2.23% and FseI 55.68% ± 4.21%). All results are presented in Figure 
6.2. 
When the patient group was analysed in more detail, we did not observe any differences 
between probands and non-proband affected family members for both methylation-sensitive 
enzymes, repeat array size, age at examination, CSS or age-corrected CSS. 
 
6.4.3 Repeat array size, methylation and severity 
Since we were interested in a possible relationship of methylation on D4Z4 and both severity 
and residual repeat array size, we performed a linear regression analysis. The results for both 
enzymes are plotted in Figure 6.3. Although initially, statistical analysis displayed a very 
significant relationship (P < 0.001), this is solely due to the clustering into two groups that were 
formed by the patients on the one hand and the control individuals on the other hand. When 
these two groups were analysed separately, the relationship was abolished (FSHD patients: BsaAI 
P = 0.24 and FseI P = 0.45; control individuals: BsaAI P = 0.54 and FseI P = 0.18), indicating 
that there is no apparent relation between methylation and residual repeat array size by this 
method. Accordingly, we did not observe a linear relation between methylation of the D4Z4 
repeat array and phenotypic severity of the disease, whether for CSS of for age-corrected CSS. 
 However, separating the patient group in a 10-20 kb and 20-38 kb interval, we again 
observed a marked difference in methylation status of D4Z4, although the groups are too small 
to test statistically. Patients in the 10-20 kb interval were on average 18% methylated at BsaAI 
and 11% methylated at FseI, with an average age-corrected CSS of 186. In contrast, in the 20-
38 kb interval average intermediate methylation levels were detected of 31% for BsaAI and 21% 
for FseI, with an average age-corrected CSS of 108. Moreover, in analogy with the considerable 
variation in clinical severity in the 20-38 kb interval, methylation values in this interval were 





Recently, we demonstrated that an epigenetic mechanism likely plays a role in FSHD by 
demonstrating hypomethylation of D4Z4 in 4q-linked and non 4q-linked FSHD [20]. However, 
only 5 monosomic Dutch FSHD patients were then compared with all other analysed groups 
(including 79 control individuals), due to the rarity of the monosomic allele constitution in the 
FSHD population. These five patients displayed a significant hypomethylation for restriction sites 




disomic patients displayed intermediate methylation levels between monosomic patients and 
control individuals, we concluded that in these patients the reduced methylation of the disease 
allele was masked by the high methylation of the healthy allele [20]. The observed average 
methylation in disomic patients can therefore not adequately be related to repeat array size or 
disease severity. 
In contrast, when applying our restriction enzyme-based assay on DNA from monosomic 
individuals only, it enabled us to examine the characteristics of a single chromosome 4q35 locus 
without interference of any other homologous locus. We therefore collected 16 additional 
monosomic FSHD patients to study potential relationships between methylation and residual 
repeat size and clinical severity. This survey of 21 monosomic patients corroborates and extends 
our previous study by revealing a significant reduction in methylation of D4Z4 in FSHD alleles at 
the sites tested (P < 0.001), as depicted in Figure 6.2. This figure also shows that the CpG 
dinucleotides at both restriction sites were similarly reduced for their methylation status in FSHD 
Figure 6.3 
Scatter plots of methylation-sensitive enzymes BsaAI (A) and FseI (B) versus repeat size. Methylation status per 
enzyme (%) is plotted against the residual fragment size (kb). FSHD patients are depicted as black circles and 






alleles, indicating that these sites are representative for the changes in methylation at the whole 
repeat array. 
Various research groups have established a correlation between the severity of the FSHD 
phenotype and residual repeat fragment size [12, 24]. Some studies have used age at onset as 
clinical parameter in this comparison. We used the Clinical Severity Scale (CSS) by Ricci et al. 
[22], since determination of disease onset depending on the patient’s recollection is not a 
reliable parameter. In our sample set we could confirm the previously observed relationship 
between residual repeat array size and severity of the disease as defined by CSS. Furthermore, 
when we corrected the CSS for the age at examination, this relationship became stronger. It 
therefore seems that this age-corrected CSS is a more accurate method to define severity in FSHD. 
Although a significant relation between the residual repeat size and either CSS or age-corrected 
CSS was observed, the R2 indicates a weak predictive validity (R2 = 0.2, R2 = 0.3, respectively). 
Evaluating the individual data allows a division of FSHD patients into two severity classes: within 
the 20-38 kb interval there is large variation in the clinical severity, while, in contrast, patients with 
a residual repeat size of 10-20 kb are all severely affected based on age-corrected CSS. A similar 
pattern with a similar predictive validity of the correlation between fragment size and clinical 
severity was previously observed by Ricci et al. [22]. Both studies thus indicate that patients with a 
small residual fragment size (and concomitantly a high age-corrected CSS) are solely responsible 
for the observed linear relation. Although it is generally accepted that small residual repeat arrays 
coincide with a high CSS, our data indicate that there is no linear relationship between both 
parameters for the FSHD patient population as a whole. 
We next determined if a relationship existed between D4Z4 methylation and repeat array 
size or between clinical severity and methylation. Although we do observe a significant 
hypomethylation on the 4q35 locus in individuals with repeat array sizes of 10-38 kb, we could not 
establish a linear relationship between methylation and repeat sizes, nor between methylation and 
disease severity, scored by CSS or age-corrected CSS. However, when separating the patients again 
according to the two severity classes, patients in the 10-20 kb interval show much more 
pronounced hypomethylation of D4Z4 than patients in the 20-38 kb interval, where the 
hypomethylation is also much more variable. 
Although both groups are too small to perform statistical tests, our results indicate that 
D4Z4 methylation may in part determine the FSHD severity. Therefore, a comprehensive 
methylation test assaying the average methylation of all CpG dinucleotides within the entire 
array rather than the analysis of two single CpG dinucleotides within the most proximal D4Z4 
unit may prove more suitable for establishing phenotype-(epi)genotype relationships. However, 
due to the extensive spreading of D4Z4 copies throughout the genome, such test is currently not 




differential D4Z4 methylation between affected individuals within a single family may explain 
the overt intrafamilial variation in clinical severity. It is therefore imperative to develop 
comprehensive allele-specific D4Z4 methylation assays to address this issue and to investigate 
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Facioscapulohumeral muscular dystrophy (FSHD) is a unique dominant disorder involving 
shortening of an array of tandem 3.3 kb repeats. This copy number polymorphic repeat, D4Z4, 
is present in arrays at both 4q35 and 10q26, but only 4q35 arrays with one to 10 copies of the 
repeat are linked to FSHD. The most popular model for how the 4q35 array-shortening causes 
FSHD is that it results in a loss of postulated D4Z4 heterochromatinisation, which spreads 
proximally, leading to overexpression of FSHD genes in cis. This would be similar to a loss of 
position-effect variegation (PEV) in Drosophila. To test for the putative heterochromatinisation, 
we quantitated chromatin immunoprecipitation with an antibody for acetylated histone H4 
that discriminates between constitutive heterochromatin and unexpressed euchromatin. 
Contrary to the above model, H4 acetylation levels of a non-repeated region adjacent to the 
4q35 and 10q26 D4Z4 arrays in normal and FSHD lymphoid cells were like those in 
unexpressed euchromatin and not constitutive heterochromatin. Also, these control and FSHD 
cells displayed similar H4 hyperacetylation (like that of expressed genes) at the 5' regions of 
4q35 candidate genes FRG1 and ANT1. Contrary to the loss-of-PEV model and a recent report, 
there was no position-dependent increase in transcript levels from these genes in FSHD skeletal 
muscle samples compared with controls. Our results favour a new model for the molecular 
genetic aetiology of FSHD, such as differential long-distance cis looping that depends upon the 





Facioscapulohumeral muscular dystrophy (FSHD) has a very unusual molecular genetic aetiology. 
It involves a 3.3 kb DNA repeat, D4Z4, in a tandem array. In FSHD patients, the array is 
shortened below a threshold copy number on only one homologue at the disease-associated 
4q35. While the dominantly inherited genetic defect in FSHD has been identified, the way in 
which it causes the characteristic type of muscular dysfunction is mysterious [35]. In almost all 
FSHD patients there are only 1-10 tandem copies of the D4Z4 repeat in a subtelomeric region 
of one chromosome 4 (Chr 4) homologue [30]. Unaffected individuals have 11-100 copies on 
both Chr 4 homologues. Below this threshold copy number (11 copies) for D4Z4 repeats at one 
4q35 allelic region, there is about 95% penetrance of the disease by age 20. The disease is 
generally much worse (earlier onset and greater clinical severity) when the short 4q D4Z4 array 




 Copy number polymorphic arrays of D4Z4 are also found in the subtelomeric region of 
10q (10q26) [3, 11]. The homology between the canonical D4Z4 repeats at 4q35 (GenBank 
AF117653) and those at 10q26 (GenBank AY028079) is 99% and includes an open reading 
frame (ORF), DUX4, within the D4Z4 repeat [4, 24] and an upstream sequence (Figure 7.1) 
that functions as a promoter in a reporter gene assay [18]. The ORF could encode a protein 
containing two homeobox-type sequences. However, no polyadenylation signal is present 
downstream of this ORF, and while there is evidence for transcription of partially homologous 
sequences from the acrocentric chromosomes, in vivo transcripts exactly homologous to DUX4 
in 4q or 10q D4Z4 repeats have not been detected [4, 13, 24]. Homology between 4q35 and 
10q26 is also seen 42 kb proximally to D4Z4 repeat arrays (>95% homology) and distally for 
approximately 15-25 kb in the region preceding the telomeric (TTAGGG)n [19]. A short D4Z4 
array at 4q35 appears to be only indirectly causing FSHD by cis interactions because the almost 
identical D4Z4 repeats in equally short arrays on 10q26 do not result in a disease phenotype [3], 
despite the extensive homology within, proximal, and distal to the D4Z4 arrays on 4q35 and 
10q26. Furthermore, in FSHD patients, who have one short 4q35 array, the phenotype is 
unaffected by the exact copy number of D4Z4 at the two 10q26 allelic regions or one normal 
4q35 allelic region, even though each of these regions can vary by over an order of magnitude in 
their D4Z4 copy numbers.  
Figure 7.1 
Schematic for the distal end of 4q35. 
(A) Map of 4q35 region (not drawn to scale). Genes or putative genes (ANT1, FRG1, DUX4C, FRG2) and the 
non-gene region 13E11 (formally named p13E-11) are indicated, and the distance between these regions and the 
beginning of the first D4Z4 repeat is noted above each. 
 (B) Map of the D4Z4 monomer (GenBank AF117653). The unique KpnI site is shown as half sites at the end of 
the monomer. Several of the subregions mentioned in the text and their positions relative to the KpnI cleavage 







It has been hypothesised that the vicinity of the D4Z4 array in 4q35 in unaffected 
individuals is heterochromatic, because it normally has many large tandem repeats containing 
two subsequences, LSau and DUX4, with highly homologous copies in known heterochromatic 
regions (the short arms of the acrocentric chromosome and 1qh) [24, 38]. Furthermore, the 
4q35 region harbouring the array appears as a dark band on Giemsa staining, and is very close to 
telomeres [62]. However, whether human telomeric regions themselves are heterochromatic is 
unclear [64]. We found that unaffected individuals have one property indirectly associated with 
condensation of this DNA repeat, a high level of 5-methylcytosine [53]. However, DNA regions 
can be highly methylated without residing in constitutive heterochromatin [37]. 
 The most frequently invoked model for how short arrays of D4Z4 at one allelic 4q35 
region lead to the FSHD syndrome is derived from the putative heterochromatic structure of 
normal D4Z4 arrays and is based upon position-effect variegation (PEV) in Drosophila [58] and 
telomere silencing in yeast [23]. In PEV and yeast telomere silencing, there is a decrease in the 
percentage of cells expressing a euchromatic gene because that gene has been placed in the 
vicinity of heterochromatin by a rearrangement [43]. PEV can also result from multimerisation 
of a DNA sequence, e.g. three to seven copies of a 10 kb Drosophila transposon, with the 
severity of the silencing correlated with transgene copy number and proximity to constitutive 
heterochromatin [14, 50]. This cis-acting repression in PEV in Drosophila had been assumed to 
display a gradient of heterochromatin spreading and consequent decreased expression inversely 
proportional to the proximity of the gene to the endogenous heterochromatin region [56]. 
Telomeric silencing at broken chromosome ends in Saccharomyces cerevisiae has been 
demonstrated to involve linear spreading of repressive chromatin structures originating from the 
telomeric C1-3A repeats by means of extended binding of heterochromatic proteins from the 
distal end proximally for about 2-4 kb inward from the C1-3A repeats [44, 47]. 
 The adaptation of the Drosophila PEV and yeast telomere silencing models to FSHD 
involves the assumption that the long D4Z4 arrays are normally heterochromatic and this 
heterochromatinisation in unaffected individuals spreads from the array to genes important to 
FSHD on 4q35 [17, 24, 29, 62]. According to this model, the putative normal 
heterochromatinisation at 4q35 is lost when there is only a short D4Z4 array on one Chr 4 
homologue, as in FSHD patients. The consequence of the loss of this heterochromatin-
spreading is predicted to be an inappropriate increase in expression of some critical gene(s) in 
cis in affected skeletal muscle of patients. We will refer to this type of cis-spreading of repressive 
structures as the loss-of-PEV hypothesis, which is predicated upon the loss of a genetically 
programmed repression rather than the gain of rearrangement-associated repression, as is usually 
the case for PEV. In considering this hypothesis, it should be noted that three essential starting 




individuals is highly condensed, whether this condensation spreads, and whether FSHD patients 
have too little of this condensation. 
 Histone H3 methylation in the N-terminal tail at lysine 9 (K9) has been linked to 
heterochromatinisation in PEV and in normal gene control [9, 33, 45]. In contrast, 
hyperacetylation of a number of positions in the N-terminal tails of core histones and 
hypermethylation of H3 at K4 are characteristic of expressed gene or promoter regions or those 
poised for expression [21, 25, 41]. In S. cerevisiae there is a gradient of histone H4 K16 
acetylation ranging from hypoacetylation within 1 kb of the telomere to hyperacetylation about 
5-30 kb from the telomere [27]. Furthermore, in human cells, constitutive heterochromatin can 
be distinguished from unexpressed euchromatin by its stronger hypoacetylation of core histones 
[26, 42]. By chromatin immunoprecipitation (ChIP) assays on uncultured blood samples and 
cultured cells from unaffected individuals, as well as on somatic cell hybrids (SCHs), we looked 
for the type of histone hypoacetylation seen in constitutive heterochromatin in the following 
chromatin regions: normal long D4Z4 arrays; a non-repeated region present very close to the 
proximal end of the D4Z4 array on 4q and 10q; two gene or gene-like regions on both 4q35 
and 10q26 (FRG2 and DUX4C); and two candidate FSHD genes (FRG1 and ANT1) found only 
on 4q35 (Figure 7.1). Several of these regions were also examined in analogous samples from 
FSHD patients to test for the predicted increase in histone acetylation that should accompany a 
decrease in heterochromatinisation according to the loss-of-PEV model. Also, we have re-
examined the relative expression of FRG1 and ANT1 in control and FSHD skeletal muscle 
biopsy samples using quantitative real-time PCR (Q-PCR) because their expression was reported 
to be very much higher in FSHD samples [17]. Furthermore, in that study, genes closer to the 
D4Z4 array on 4q35 were reported to be more overexpressed than more distant genes in FSHD 
muscle, which is also in accordance with the loss-of-PEV hypothesis. In contrast, our results 
from both Q-PCR and ChIP contradict this hypothesis for FSHD and indicate that some other 
molecular genetic mechanism links FSHD symptoms to the presence of a 4q35 D4Z4 array 
having less than a threshold number of copies of the 3.3 kb repeat. 
 
 
7.3 Subjects and methods 
 
7.3.1 Cell lines and tissues 
Normal human LCLs [15] and skin fibroblast cell strains derived from newborn foreskin were 
grown under standard conditions. Somatic cell hybrids GM11687 (mouse-human), GM14193 
(Chinese hamster-human), and GM11448 (Chinese hamster-human) contained the following 




and Chr 8, respectively. To obtain PBMC samples, EDTA-treated human peripheral blood 
samples from healthy individuals or FSHD patients (about half of each from females) were used 
to generate a mononuclear cell fraction by density gradient centrifugation (Lymphocyte 
Separation Medium, Cappel). Unless otherwise noted, FSHD muscle samples were biopsy or 
orthopaedic scapular fixation tissue from moderately affected deltoid or biceps skeletal muscle 
and were from patients 13-79 years of age, with the exception of FM917, which was from 
unaffected muscle. Analogous disease-control muscle biopsy samples were from patients with 
unrelated neuromuscular diseases involving myopathic changes or denervation atrophy. Control 
and FSHD muscle samples showed normal standard histochemical reactions and histological 
examination revealed at most a very small percentage of fibres with evidence of active 
regeneration or necrosis. D4Z4 repeat copy numbers were determined from 5   µg of DNA from 
LCLs or PBMC samples embedded in agarose (InCert agarose, Cambrex) and digested with 20 
U of EcoRI and HindIII, or EcoRI and BlnI and subject to PFGE and blot hybridisation with a 
13E11 probe as described previously [30]. The 4q-type alleles were resolved from the 10q-type 
alleles by the BlnI sensitivity of the latter [11]. All human samples were obtained from 
individuals who signed consent forms for this study that were approved by the Institutional 
Review Board of Tulane Medical Center and the University of Mississippi Medical Center in 
Jackson. 
 
7.3.2 Chromatin immunoprecipitation assays 
About 0.5× 106 cells were treated with 1% formaldehyde, sonicated in 1 ml of protease 
inhibitor-containing buffer, and then chromatin was immunoprecipitated essentially according 
to the manufacturer’s specifications (Upstate Biotechnology) with a 1:100 dilution of an H4 
acetylation-specific antibody prepared to H4 N-terminal peptide acetylated at lysine 5, 8, 12, 
and 16. The input DNA for comparison to the immunoprecipitates was an aliquot of the 
supernatant from each centrifuged sonicate (DNA size range, about 200-600 bp). The pre-
clearing before addition of antibody and the collection of the immunoprecipitates was done for 
3 hours at 4°C with constant agitation using 60   µl of salmon sperm DNA/protein A-agarose 
beads added to the 1 ml samples. The purified immunoprecipitated DNA was dissolved in 50   µl 
of 10 mM Tris-HCl (pH 8.0) / 0.1 mM EDTA. PCR primers were from 4q35 (Table 7.1) or 
standards and gave products in the size range of about 130-300 bp. The primers (5' to 3') for the 
standards and the annealing temperatures were as follows: satellite 2 (Sat2) from Chr 1, 
CATCGAATGGAAATGAAAGGAGTC and ACCATTGGATGATTGCAGTCAA, 58°C; satellite 
(Sat  ) from Chr 1, TCATTCCCACAAACTGCGTTG and TCCAACGAAGGCCACAAGA, 
54°C; Chr 4 Sat  , CTGCACTACCTGAAGAGGAC and GA-TGGTTCAACACTCTTACA, 52°C; 




CAGCAG, 58°C; G-  globin exon 2, TCTACCCATGGACCCAGAGGT and CCACATGCA-
GCTTGTCACAGT, 58°C; AFP exon 1, GTTTCTCGTTGCTTACACAAAG and AGGCCAA-
TAGTTTGTCCTCACT, 59°C; albumin exon 4, GTTGCAACTCTTCGTGAAAC and TCACA-
TCAACCTCTGGTCTC, 58°C; ADH5, intron 1, GCATAATTGAGCCTACGCC and GCAGA-
GGTGTTTGTTACGTG, 59°C; and GAPD primers, 62°C [16]. 
 
7.3.3 Real-time quantitative PCR and determining the specificity of PCR primers 
Q-PCR (Bio-Rad iCycler) was performed using SYBR green dye fluorescence and Taq 
polymerase (SYBR Green PCR Master Mix, Applied Biosystems; iCycler Optical analysis 
software, version 3, BioRad). Each 20   µl reaction contained 350 nM primers and 2   µl of 
undiluted immunoprecipitated DNA or a 1:100 dilution of input DNA. The specificity of the 
product was demonstrated by the presence of one peak in a melting curve and spot-checking by 
gel electrophoresis. To quantitate the amount of product DNA from the threshold cycle number, 
a standard curve for each primer-pair was generated for each PCR set from serial 2-fold dilutions 
of a reference mixture of sonicated human DNA. This curve was used to determine, in arbitrary 
a: Other primers are given in Subjects and methods. The FRG1 [12] and ANT1 primers [17] were previously 
described. TSP: transcription start point according to GenBank annotation except for DUX4C, whose putative 
TSP was inferred from that of DUX4 and FRG2, which is annotated only in the homologous 10q FRG2 sequence 
(AY028079). b: the positions of the PCR product with these primers is given relative to the KpnI site of a D4Z4 
monomer. These entire subregions are shown in Figure 7.1.B. c: Where indicated, a 13E11 sequence that is 175 bp 
proximal to the start of the D4Z4 array was examined with the following primers and annealing temperature: 
CACGGACAAGGCCAGAGTT and TGCCTGTGAGTTCGAATGC, 60°C. 
 




units, the relative amounts of input DNA and IP DNA. The slope of the standard curve for each 
test reaction was -3.3 ± 0.4 and the correlation coefficient was ≥ 0.99. 
To determine the specificity of primers for subregions of 4q35, a panel of human-rodent 
SCHs (Mini Mapping Panel 2, Version 3; Coriell Institute) was amplified using 50 ng of DNA 
and 25 pmol primers in a standard 25   µl mixture with Taq DNA polymerase (Qiagen, 1 U per 
25   µl reaction) for 35 cycles. 
 
7.3.4 RNA isolation and RT-PCR 
For isolation of total RNA from muscle biopsy samples, about 5 mg of tissue that had been 
snap-frozen and stored at –80°C, was converted to a powder in liquid N2. RNA was isolated 
from approximately 5 mg tissue samples or 3× 106 LCL cells, fibroblasts, or PBMC by standard 
techniques [8]. RNA (3   µg) was digested with 4 U of RNase-free DNaseI (Invitrogen) in a 40 
  µl reaction mixture for 15 minutes at room temperature and then for 30 minutes at 37°C. 
After addition of EDTA and incubation at 65°C for 10 minutes, 25   µl was used for reverse 
transcription (RT) in a standard 50   µl reaction mixture with M-MLV reverse transcriptase (300 
U, Invitrogen) and random hexamer primers at 37°C for 60 minutes followed by heating to 
95°C for 5 minutes. All RNA samples were confirmed to give no PCR product without the prior 
RT reaction. Q-PCR on 2   µl of the cDNA samples was done as described except that the RT-
PCR primers and annealing temperatures were as follows: ANT1 exons 2 and 3, AGCGTGA-
TTTCCATGGTC and GCATCATCATTCTACTACG, 56°C; HPRT, 52°C and   β-actin, 60°C 
[31], and the GAPD primers referenced above. The 18S rRNA primers were used together with a 
competing oligonucleotide (3:7 molar ratio) to dampen the signal so that it was more like that 
from mRNAs (QuantumRNA 18S internal standards; Ambion). The same primers from the 5' 
exon of FRG1 were used for RT-PCR and for ChIP assays (Table 7.1). For RT-PCR reactions the 
mean of triplicate amplifications, which usually differed by less than 20%, are shown. The 
standard curve for each primer pair was generated for each PCR set as described above except 





7.4.1 The chromosomal distribution of 4q35 sequences related to FSHD 
To use histone hypoacetylation of different subregions of 4q35.2 as a marker for 
heterochromatin [26, 42], we first had to define the specificity of the primers for real-time 




specificity is particularly important because the 4q35 region of interest has much homology with 
the acrocentric p arms and pericentric regions [2, 24, 36] not adequately represented in DNA 
databases, as well as with 10q26. By amplification of template DNA from a panel of rodent-
human SCHs, each containing a different single human chromosome, primer pairs from the 
following D4Z4 array-proximal sequences (Table 7.1 and Figure 7.1.A) were evaluated: 13E11 
(D4F104S1), a 0.8 kb non-genic sequence [24] previously called p13E-11 [63], which is 111 bp 
from the 4q and 10q D4Z4 array; the FRG2 promoter; and the presumed promoter of the 
putative DUX4C gene (GenBank AF146191, AF117653, and AY028079). DUX4C is highly 
homologous to a putative gene, DUX4 [18, 24, 29], present within each D4Z4 repeat, but the 
upstream regions for these putative genes are not homologous, and DUX4C is located as an 
isolated sequence 42 kb proximal to the D4Z4 array and in the opposite orientation [19, 36]. 
The Chr 10 hybrid gave the same size PCR products as did the Chr 4 hybrid with 13E11, FRG2 
and DUX4 primers (data not shown), in accordance with the extensive homology between the 
42 kb region proximal to the D4Z4 array on chromosomes 4 and 10 that contains these 
sequences (Figure 7.1.A) [5, 10, 19, 62]. All the other chromosomes had sequences amplified by 
the DUX4C primers. Chromosomes 18, 21, 22, X and Y, as well as 4 and 10, were amplified by 
the FRG2 primers. The 13E11 primers amplified only Chr 4 and Chr 10 in accordance with its 
use as a hybridisation probe for molecular diagnosis of FSHD by pulsed-field gel electrophoresis 
(PFGE) of EcoRI/HindIII and EcoRI/BlnI digests [11, 54, 60]. Other than the D4Z4 arrays, only 
one fragment of 9.5 kb from an invariant Y chromosome sequence cross-hybridises with 13E11, 
and this fragment is apparently not amplified with our 13E11 primers. We also searched for a 
~125-300 bp sequence in the D4Z4 repeat that might amplify only Chr 4 and 10. The six tested 
subregions of D4Z4 were as follows: DUX4, the above-mentioned sequence with the potential 
to encode a double homeobox gene, although it lacks a poly A site [4, 18, 24]; the putative 
DUX4 promoter (hhspm3, homologous to sequences displaying sperm-specific DNA 
hypomethylation) [18, 24, 68]; the LSau subrepeat homology region, which is also present in the 
short arms of the acrocentric chromosomes and some pericentromeric regions [38]; region A, 
which is upstream of hhspm3; and two sequences in the vicinity of the KpnI site in D4Z4 
(Figure 7.1.B). None of these subsequences proved specific in PCR, which is consistent with the 
cross-hybridisation of D4Z4 probes to the acrocentric chromosomes [2, 24]. However, primers 
for region A and hhspm3 amplified only acrocentric chromosomes and Chr 11 or Chr Y in 






7.4.2 The D4Z4 array-adjacent 13E11 region at 4q35 and 10q26 showed levels of histone H4 
acetylation typical of unexpressed euchromatin rather than of constitutive heterochromatin 
The existence of homologous sequences to D4Z4 in many chromosomes precludes testing 
human cells for histone hypoacetylation, a marker for constitutive heterochromatin [26, 42], 
within the 4q and 10q D4Z4 arrays. However, we could analyse histone acetylation very close to 
the proximal end of the D4Z4 array using the above-mentioned 13E11 primers. Preliminary 
ChIP assays were done with eight commercially available antibodies to acetylated or methylated 
histones and the immunoprecipitates were analysed by Q-PCR for the relative amounts of 
precipitation of euchromatic and heterochromatic standards. We found that an antibody 
specific for acetylation of histone H4 (H4 Ac Ab) was the most informative for distinguishing 
unexpressed euchromatin standards (genes inactive in the cell types being analysed) and 
constitutive heterochromatin (satellite DNA-rich heterochromatin). For example, an antibody 
to histone H3 dimethylated at K9 gave no significant difference between unexpressed 
Figure 7.2 
Comparison of histone H4 acetylation in different 4q35 regions in Chr 4-containing SCHs by ChIP with H4 Ac 
Ab. Gray, black and white bars represent the percentage immunoprecipitation of the given sequence in SCH 
GM11687, GM14193 and GM11448, containing the following human chromosomes: Chr 4; Chr 4 and 5; and Chr 
4, 5, and 8, respectively. Q-PCR for the different immunoprecipitates were done on the same day with the same 
standard DNA mixture for quantitation and so are comparable. The copy numbers of the D4Z4 repeats in the 
4q35 region of these SCHs are 40, 35 and 39, respectively. The results for DUX4 and DUX4C subsequences are 
given only for GM11687, which does not have non-Chr 4 sequences that can be amplified by the corresponding 
primer pairs. In parentheses are shown the approximate distances of 4q35 proximal sequences from the D4Z4 
array; 13E11a and 13E11b, two different 13E11 subsequences situated the indicated distances from the beginning 
of the D4Z4 array. The immunoprecipitation of chromatin from these SCHs was done in a second experiment 





euchromatin and constitutive heterochromatin in five ChIP assays using PCR primers for 
seven DNA sequences. This antibody did give an average of 5-fold less immunoprecipitation of 
expressed gene standards than unexpressed gene standards (data not shown). In contrast, in 
more than 20 ChIP assays with H4 Ac Ab on lymphoblastoid cell lines (LCLs), peripheral 
blood mononuclear cells (PBMC), and diploid fibroblasts, an average of about 2.5-fold less 
constitutive heterochromatin immunoprecipitated compared with unexpressed euchromatin, 
and the differences between these two types of chromatin were statistically significant (P < 
0.001; Table 7.2 and data not shown). 
 In H4 Ac Ab immunoprecipitates obtained from control PBMC, LCLs, and diploid 
fibroblast cell strains, the relative amounts of 13E11 DNA and DNA from heterochromatic and 
Figure 7.3 
Relative ANT1 and FRG1 expression in FSHD and disease-control muscle samples determined by Q RT-PCR.  
(A) ANT1 RNA levels normalised with respect to 18S rRNA. 
(B) FRG1 RNA levels normalised with respect to 18S rRNA.  
The D4Z4 copy number on the FSHD-causing 4q35 allele is indicated underneath each bar for the FSHD samples. 
The 4q35 D4Z4 copy number should be >10 for each Chr 4 homologue in the control samples. ND: not 
determined. The D4Z4 copy numbers were 4, 9, 10 and 36 for the 4q and 10q arrays of cells from this patient, but 
for technical reasons the position assignment could not be made. The units for RNA levels are arbitrary but all 









euchromatic standards were evaluated by Q-PCR. The assays shown in Table 7.2 involved the 
13E11 primers that amplify the above-described DNA sequence 651 bp from the beginning of 
the D4Z4 array on both Chr 4 and Chr 10 (Table 7.1 and Figure 7.1.A). If the 13E11 chromatin 
had behaved like constitutive heterochromatin, the ratio of the percent immunoprecipitation of 
this 13E11sequence to that of constitutive heterochromatin regions should have been about 1 
and the ratio to that of unexpressed euchromatic gene regions should have been about 0.4 for 
these control samples. Instead, the average ratios comparing the three groups of control samples 
were 3.7 ± 0.2 and 1.4 ± 0.2, respectively (Table 7.2). Furthermore, FSHD PBMC and LCLs 
and samples with low copy numbers of D4Z4 at 10q arrays displayed no more H4 acetylation of 
the 13E11 region than did the controls (Table 7.2). We also designed another set of 13E11 
primers that amplified a sequence only175 bp (instead of 651 bp) away from the start of the 
array. From two control PBMC samples and three control LCLs, these primers gave the 
following average ratios of immunoprecipitated 13E11 to immunoprecipitated heterochromatin 
standards or unexpressed euchromatin standards: 2.2 ± 0.7 and 0.8 ± 0.3, respectively. 
Therefore, this region, which is very close to the D4Z4 array, is also more like unexpressed 
euchromatin than constitutive heterochromatin in its histone acetylation in these control 
human cells. 
 
7.4.3 Chromosome 4-containing somatic cell hybrids exhibited unexpressed euchromatin-like 
H4 acetylation levels at D4Z4 subsequences 
In rodent-human SCHs containing as the only human Chr 4 (GM11687), Chr 4 and 5 
(GM14193, or Chr 4, 5 and 8 (GM11448), we could analyse hhspm3, the D4Z4 subregion 
immediately upstream of the putative DUX4 gene [18, 24], and another D4Z4 subregion about 
0.7 kb proximal, which we call region A (Figure 7.1), without interference from homologous 
human sequences. Rodent genomes do not have D4Z4 homologous sequences [24] and they 
were not amplified with any of the tested D4Z4 subregion primers. In the Chr 4-only SCH, we 
could also study DUX4, the putative gene in D4Z4, as well as the presumed promoter of the 
putative DUX4C gene, a sequence 42 kb proximal to the D4Z4 array (Figure 7.1.B). In addition, 
we tested in all three SCHs the two aforementioned 13E11 subsequences and the promoter 
region of FRG2 (Figure 7.1.A). These SCHs contain long D4Z4 arrays (35-40 D4Z4 repeats) at 
4q35. The three D4Z4 subsequences in these SCHs displayed a low level of 
immunoprecipitation with H4 Ac Ab, but not as low as that of the Chr 4 Sat   centromeric 
region (Figure 7.2). In contrast, considerable amounts of the ANT1 promoter and FRG1 exon 1 
were in the H4 Ac Ab immunoprecipitate. Interestingly, the FRG2 promoter and the putative 
DUX4 and DUX4C promoters gave a low extent of immunoprecipitation suggesting that, 




transcription in these hybrids. In the region spanning the D4Z4 array to 42 kb proximal, there 
was not a gradient of H4 acetylation with the lowest levels in the D4Z4 array, as would be 
expected if there were spreading of heterochromatinisation seeded at long D4Z4 arrays. 
 
7.4.4 FSHD and control samples showed similar expressed gene-like histone H4 acetylation 
levels in FRG1 and ANT1 at 4q35  
We looked for evidence in control cells of histone-hypoacetylated repressive chromatin 
structures at the FSHD 4q35-specific candidate genes ANT1 and FRG1 using the same 
immunoprecipitates analysed for H4 acetylation in the 13E11 region. FRG1 exon 1 and the 
ANT1 promoter in control PBMC, LCLs, and fibroblasts resembled expressed genes in their 
high degree of immunoprecipitation with the H4 Ac Ab (Table 7.3). Similarly, 
hyperacetylation of the ANT1 promoter and FRG1 exon 1 was seen in Chr 4 SCHs but the ratio 
of percent immunoprecipitation of FRG1 exon 1 to that of the ANT1 promoter was higher for 
lymphoid cells than for the SCHs (Table 7.3 and Figure 7.2). In both control human cells and 
the SCHs, there was less H4 acetylation in the last ANT1 exon than at the ANT1 promoter, as 
has been found for some expressed genes [40]. When comparing H4 acetylation in any of these 
regions in FSHD and control PBMC or LCLs, no consistent differences were observed between 
FSHD and non-FSHD samples nor was there a discernible effect of the exact number of 
tandem D4Z4 copies on this H4 acetylation. We will extend our ChIP analyses to FSHD and 
control myoblasts (which have just become available) and to chromatin proteins other than 
histones and include well-characterized myoblast cultures induced to differentiate in vitro as a 
model for in vivo muscle fibres. 
 
7.4.5 FSHD skeletal muscle samples did not show higher levels of FRG1 or ANT1 transcripts 
than controls 
We found that muscle biopsy samples were not amenable to ChIP assays to test predictions 
about histone acetylation in 4q35 subregions. To examine another prediction of the loss-of-
PEV hypothesis, FRG1 and ANT1 transcript levels in seven FSHD skeletal muscle biopsies and 
seven disease-control biopsies were analysed by Q-PCR. First we demonstrated, as previously 
reported [17], that there were much higher average levels of ANT1 RNA in control muscle 
samples than in four control PBMC samples or three LCLs assayed the same day and 
normalised to 18S rRNA (19, 0.09, and 0.7, respectively, in arbitrary units). We observed more 
similar levels of FRG1 RNA from control muscle biopsies, LCLs, and PBMC samples (2.7, 2.7, 
and 0.4, respectively). In the lymphoid samples from FSHD patients compared with the 




FRG1 transcript levels (data not shown). That FRG1 and ANT1 RNAs were expressed in LCLs 
and PBMC is consistent with the H4 hyperacetylation in their 5’ gene regions (Table 7.3). 
 It was recently reported that there were, on average, about 10-fold higher ANT1 
transcript levels in FSHD versus control skeletal muscle biopsies by end-point RT-PCR with 
normalization to the glyceraldehyde phosphate dehydrogenase (GAPD) RNA levels [17]. 
However, by real-time RT-PCR, we found no consistent differences in steady-state ANT1 RNA 
levels normalised to those for 18S rRNA when FSHD and disease-control muscle were 
compared (Figure 7.3.A; averages of 6.7 ± 2.0 and 6.6 ± 4.9, arbitrary units ± SD, respectively). 
Ribosomal RNA has been considered the best internal standard RNA for quantitating transcript 
levels in several recent reports [22, 48], although there is still controversy about which 
constitutively expressed mammalian RNA quantitation standard is optimal. The FSHD sample 
with the lowest D4Z4 copy number (two copies, FM39) in the deletion-associated 4q35 region 
did not show higher levels of ANT1 RNA and FRG1 RNA compared with the FSHD samples 
having the highest deletion-associated 4q D4Z4 copy numbers (six copies, FM1112; 5 copies, 
FM912), as would have been predicted by the loss-of-PEV hypothesis and the above-mentioned 
study [17]. Because it has been suggested that averaging the results from several standards may 
be better than using just one [55], we employed three constitutively expressed mRNA standards 
in addition to 18S rRNA. The average values for ANT1 RNA normalized to GAPD RNA were 
10.4 ± 4.8 (FSHD) and 5.9 ± 4.9 (control); to HPRT RNA, 2.9 ± 1.4 (FSHD) and 3.1 ± 2.2 
(control); and to   α-actin, 6.6 ± 3.9 (FSHD) and 4.4 ± 1.9 (control). The mean ratios derived 
from averaging the levels normalised to each of the four RNA standards were 6.7 ± 3.0 and 5.0 
± 1.5 for FSHD and control skeletal muscle biopsies, respectively. There was no significant 
difference between the two groups of muscle samples (P > 0.8 for normalization to 18S rRNA 
or HPRT, P > 0.1 for normalisation to   α-actin and GAPD, respectively). 
 For FRG1 RNA, the FSHD skeletal muscle samples unexpectedly [17] displayed lower 
levels than did the control samples. The average FRG1 RNA levels (arbitrary units ± SD) 
normalized with respect to 18S rRNA were 1.2 ± 0.7 and 5.0 ± 3.3 for FSHD and control 
muscle samples, respectively (Figure 7.3.B). When the values for FRG1 RNA were normalised to 
GAPD RNA levels, they were 6.7 ± 2.3 and 14 ± 9, respectively, and for normalisation to HPRT 
RNA levels, they were 0.5 ± 0.4 and 2.1 ± 1.6, respectively. The differences in the average FRG1 
RNA level for FSHD muscle samples versus control samples were statistically significant whether 
the samples were normalised with respect to 18S rRNA, GAPD RNA, or HPRT RNA (P = 0.01, 
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Almost all cases of FSHD show linkage to short D4Z4 arrays in the subtelomeric region of 4q 
although there is no association with short D4Z4 arrays at subtelomeric 10q [54] despite their 
near sequence identity and similar copy-number polymorphism as well as their homology 
proximally and distally (Figure 7.1) [11, 20, 31]. Given the threshold effect of the D4Z4 copy 
number at 4q35 on the disease, the dominant nature of FSHD is most easily explained by 
inappropriate upregulation of one or more 4q35 disease-causing genes rather than by 
haploinsufficiency. No genes have been found in the ~15-25 kb region between the 4q35 D4Z4 
array and the telomeric hexanucleotide repeat, although the region is only partly sequenced [19]. 
Therefore, the FSHD gene (or genes) is likely to be proximal, rather than distal, to the 4q35 
D4Z4 array. The 161 kb region proximal to the D4Z4 array at 4q35 is very gene poor. The high 
homology between 4q and 10q for 42 kb proximal to the D4Z4 array and recent evidence from 
patients with deletions extending this far [32] make it unlikely that this region is involved in 
FSHD. Because the closest identified gene proximal to this region is FRG1, 125 kb from the 
D4Z4 array at 4q35, the FSHD 4q35 target gene is probably quite far from the D4Z4 array. The 
loss-of-PEV hypothesis, which involves differential heterochromatinisation, was proposed to 
explain how a shortened D4Z4 array exerts this cis effect at a distance. However, no subregion 
of 4q35 has been tested for a specific attribute of heterochromatin. We examined histone 
hypoacetylation as a marker for constitutive heterochromatin [26, 42] (Table 7.2), in the 
vicinity of D4Z4 arrays at sequences that could be studied in human cells (13E11, FRG1, and 
ANT1) or, because of homology elsewhere, only in somatic cell hybrids (D4Z4, FRG2, and 
DUX4C; Figure 7.1.A).  
 In PBMC, LCLs, and fibroblasts from unaffected individuals, 13E11 chromatin only 
651 or 175 bp proximal to the long D4Z4 arrays exhibited histone H4 acetylation levels typical 
of unexpressed euchromatin rather than of constitutive heterochromatin (Table 7.2). This 
makes it highly unlikely that D4Z4 arrays are sources of cis-spreading heterochromatinisation. 
Although, we were unable to immunoprecipitate constitutively expressed gene standards from 
muscle biopsies to study the tissue involved in FSHD, several factors suggest that the conclusions 
from the above cell populations are applicable to skeletal muscle. Firstly, constitutive 
heterochromatin, e.g. centromeric and juxtacentromeric heterochromatin, does not show 
tissue-specific differences in heterochromatinisation. PEV is associated with constitutive 
heterochromatin [65], which displays tight packing and distinct nucleosome spacing [1, 34, 49, 
57], rather than with the less highly condensed structure of transcriptionally inactive 
euchromatin. Secondly, we did not see tissue-specific differences between LCLs (rapidly dividing, 




extent of H4 acetylation at 13E11. Furthermore, there were similar steady-state concentrations 
of transcripts from FRG1, the closest FSHD candidate gene to the D4Z4 array, in control 
skeletal muscle samples and LCLs. That FRG1 RNA was present at considerable levels in control 
skeletal muscle indicates that there is not a region of repressive heterochromatin spreading far 
from the normal-sized D4Z4 arrays at 4q35 in skeletal muscle, the target tissue for FSHD. Also 
inconsistent with the loss-of-PEV model was our finding that in lymphoid cells and fibroblasts 
from unaffected individuals, the FRG1 exon 1 and ANT1 promoter regions were not 
hypoacetylated in H4, and no gradient of H4 acetylation proportional to the distance from 
D4Z4 was seen (Table 7.3). Moreover, there was no increase in H4 acetylation in PBMC or 
LCL samples from affected versus unaffected individuals in the FRG1 and ANT1 regions (Table 
7.3). 
 ChIP assays of H4 acetylation at the FRG2 promoter, the putative DUX4C promoter, 
13E11, and D4Z4 monomer subregions in human-rodent SCHs also did not provide support 
for the loss-of-PEV hypothesis for FSHD. Rodent-human SCHs have been shown to often 
maintain the chromosome structure of the respective regions in human cells [6, 67]. In hybrids 
containing a normal Chr 4 or Chr 4 plus one or two other non-interfering human 
chromosomes, the long D4Z4 array did not exhibit the lowest amount of H4 acetylation 
(Figure 7.2). Also, there was not a distance-dependent gradient of H4 hypoacetylation 
originating from the D4Z4 array and extending to proximal genes at 4q35. While our data on 
H4 acetylation at long D4Z4 arrays in SCHs argue against this region being heterochromatic, 
and therefore being capable of losing this heterochromatin structure upon contraction of the 
array in FSHD, it is quite possible that there are other changes in histone modification, not 
associated with a heterochromatin-to-euchromatin transition that take place upon shortening 
of the D4Z4 array from >10 to 1-10 copies of the repeat. 
 A linear gradient of heterochromatinisation initiating at constitutive heterochromatin 
or transgene repeats had been postulated as the basis for PEV in Drosophila (reviewed in [56]). 
However, this model of linear propagation of heterochromatinisation is currently out of favour 
because it is difficult to reconcile with the trans effects (transvection) seen in some cases of 
Drosophila PEV; with PEV operating over very large distances (up to several Mb) from 
constitutive heterochromatin; and with the complexity of some of the PEV-generating 
rearrangements [50, 56]. Nonetheless, heterochromatinisation is implicated in most cases of 
Drosophila PEV [50, 65]. That we did not find evidence for heterochromatin-like 
hypoacetylation about 1 kb from normal-length D4Z4 arrays or within these arrays argues 
against a loss-of-PEV mechanism for the effect of reduced D4Z4 copy number at 4q35. 
 Nonetheless, evidence consistent with the loss-of-PEV hypothesis for FSHD was 




FRG2 RNA from several 4q35 genes. Of these genes, ANT1 [12, 17, 61] is the best candidate 
because it encodes an adenine nucleotide translocator that has been implicated in a myopathy 
(progressive external ophthalmoplegia), has been reported to be predominantly expressed in 
heart and skeletal muscle [17], and is specific for 4q35. However, it is very distant from the 
D4Z4 array (Figure 7.1.A). In the study of Gabellini and co-workers, which did not involve 
real-time quantitative RT-PCR, ANT1, FRG1, and FRG2 transcript levels were an average of 
about 10-, 25-, and 65-fold higher, respectively, in FSHD versus control skeletal muscle 
biopsies. Also, Gabellini et al. [17] noted that the ratio of expression of the above genes in 
FSHD skeletal muscle relative to control muscle was higher for the genes closer to the 4q35 
D4Z4 array. That finding was considered in agreement with a gradient of spreading of 
repression from a normally long D4Z4 array. Lastly, they observed that the lower the copy 
number of the D4Z4 disease-associated repeat, the higher the FRG2 transcript level determined 
by RT-PCR after digestion of the PCR product with restriction endonucleases that allowed 
homoduplexes of 4q35 and 10q26 RT-PCR products to be distinguished. However, in skeletal 
muscle samples examined by Q-PCR, we did not find any significant FSHD-associated increase 
in the level of either FRG1 or ANT1 transcripts upon normalisation with four different internal 
RNA standards. For FRG1, we obtained the opposite result, a modest but significant decrease 
in transcript levels (Figure 7.3). By RNA-based single-strand conformation polymorphism 
analysis, van Deutekom et al. [12] also found no evidence for increased levels of FRG1 
transcripts from the disease-associated allele in skeletal muscle biopsies of FSHD patients. The 
report of Gabellini et al. [17] involved three FSHD muscle biopsies as compared with seven in 
the present study and only one normalisation standard, GAPD, instead of four in our study. 
Most importantly, they used end-point PCR without providing evidence from reactions with 
different dilutions of the cDNA or different numbers of cycles to show that they were in the 
linear response range with respect to template cDNA concentration for each test and reference 
gene. Real-time PCR, as in the present study, avoids the pitfalls of misleading comparisons of 
product yields due to the exponential nature of PCR and the possible plateauing of the reaction 
for the test sequence or normalisation standards. A caveat in any biochemically based 
expression analysis of FSHD versus control muscle is that we cannot discount the possibility 
that there is overexpression of a 4q35 gene in a small percentage of nuclei in the FSHD muscle 
fibres or satellite cell precursors, which starts a disease-inducing signal transduction cascade. 
Nonetheless, our data strongly argue against the previous model of an FSHD-linked loss of 
postulated heterochromatin spreading from a D4Z4 array to proximal 4q35 genes. 
 We propose that the intrachromosomal communication at an FSHD-causing D4Z4 
array and an FSHD target gene in cis occurs by looping rather than by a loss of progressive 




array [20, 31], this looping may be of a very long-distance nature involving a gene more than 
160 kb away. Such abnormal looping interactions with a short D4Z4 array at 4q35 might 
inappropriately upregulate transcription of the 4q35 target gene by direct chromatin-to-
chromatin delivery of a positive transcription factor, by locally altering the structure of 
chromatin at the target gene’s promoter, and/or by influencing the association of the target 
gene region with the nuclear scaffold or nuclear membrane. There is evidence for transcription 
regulatory looping interactions between enhancers and promoters [52], locus control regions 
and the rather distant genes that they positively control [7, 52], and polycomb response 
elements and associated promoters up to 100 kb away [39]. We further hypothesise that disease-
associated long-distance loops involving the D4Z4 repeat array form only when a specific 
interaction between D4Z4 repeats at least 33 kb apart, i.e. intra-array looping, does not 
sequester the array. The intra-array looping would sequester both moderate-length and very long 
D4Z4 arrays. While there is no exact precedent for the type of alternative loop formation that 
we are proposing, there may be some parallels in the way certain insulators affect promoter-
enhancer interactions via inferred chromatin loops [28, 59] as well as in LCR interactions with 
alternate promoters [7]. 
 There could be constraints on the higher-order organisation of chromatin in the D4Z4 
array that could account for the threshold effect of D4Z4 copy number at 4q35 in FSHD. The 
nature of the higher-order structure of chromatin is still poorly understood but the 
extraordinarily high GC content of the D4Z4 repeat (73%) compared with the overall GC 
content of human DNA (42%) might facilitate the hypothesised intra-array interactions 
between sufficiently distant tandem copies of the D4Z4 repeat. As a corollary of this model of 
alternative looping structures, it is predicted that D4Z4 arrays with >10 copies efficiently form 
the stable intra-array interactions, those with 5-10 copies of the D4Z4 repeat at 4q35 sometimes 
establish less stable intra-array interactions, and arrays with 1-4 copies almost never form these 
interactions. This would explain the above-mentioned increased severity of symptoms and 
decreased age at diagnosis associated with very short D4Z4 arrays at 4q35 [35, 46, 51]. Because 
all examined D4Z4 patients have at least one copy of the D4Z4 repeat, we propose that it is the 
D4Z4 sequence itself in a short array at 4q35 which activates inappropriate expression by long-
distance looping interactions. This D4Z4 interaction could involve the DUX4 putative 
promoter region, which may not be active itself in vivo (hhspm3; Figure 7.2) but apparently 
binds four nuclear proteins [17, 18]. These are the transcription factor Sp1, the transcription 
activator/repressor YY1, the DNA helicase-containing nucleolin, and the chromatin 
architectural protein HMGB2, all of which might enable D4Z4 to upregulate transcription of a 
cis promoter as a result of looping interactions. Moreover, analysis of stable transfectant clones 




expression of genes located elsewhere in the genome [66]. In summary, a model involving 
alternative looping (intra-array or between the D4Z4 array and a distant cis transcription 
control region) now appears to be a more attractive hypothesis for how the copy number of 
tandem 3.3 kb D4Z4 repeats at 4q35 controls the disease phenotype than does a PEV-like 
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The subtelomeric 4q35 locus associated with FSHD has a repetitive character that is in part due 
to a variable number of tandemly arranged D4Z4 repeat units. The number of repeat units 
varies between 11 and 100 copies in healthy individuals, while a contracted array with 1-10 
copies carrying the 4qA variant distal to D4Z4 is associated with the clinical expression of the 
disease [5, 26, 66]. As a consequence of its subtelomeric location, this region is more prone to 
rearrangements than other parts of chromosome 4q. Furthermore, as a result of the repeat array 
contraction the chromatin conformation of the 4q35 region may change. 
Even though the discovery of the D4Z4 repeat contraction in FSHD patients was 
published in 1992 [66], the exact mechanism that causes the FSHD phenotype is still not 
elucidated. Therefore, knowledge on both structure and behaviour of the 4q35 region will 
contribute to the disentangling of the defect that underlies FSHD. With regard to molecular 
behaviour, the objectives of this thesis were to focus on subtelomeric exchanges between the 
highly homologous repeat arrays on chromosomes 4 and 10 (Chapters 2 and 3) and on the 
occurrence of mosaicism for a contracted D4Z4 repeat with the consequences for FSHD 
(Chapters 3 and 4). To gain more knowledge about D4Z4 structure, we concentrated on DNA 
methylation and histone acetylation of the 4q35 region (Chapters 5, 6 and 7). In this chapter 
our major findings and data from other research groups will briefly be summarised to introduce 
a proper framework for discussion and future perspectives. 
 
 
8.1 Subtelomeric exchanges between 4q35 and 10q26 
 
In order to obtain more insight in the occurrence of translocated repeat arrays between 
chromosomes 4q and 10q and in repeat array size distributions we investigated these 
phenomena in a large Dutch control population and concomitantly elucidated some aspects of 
the dynamic behaviour of the subtelomeres of chromosome 4 and 10. 
 
8.1.1 Exchange frequencies 
8.1.1.1 Comparisons between different control and patient populations 
The presence of repeat exchanges between chromosomes 4 and 10 has previously been 
demonstrated in small groups of Dutch FSHD patients and control individuals [4, 27]. In a 
more extensive follow-up study in a population of blood donors (Chapter 2) we observed 21% 
translocated alleles, either being homogeneous or heterogeneous, which was in agreement with 
earlier observations [4]. Of these translocated alleles, 9% was present on chromosome 4 and 
12% on chromosome 10. Furthermore, chromosome 4-derived repeat arrays on chromosome 10 




After publication of our Dutch translocation data, the frequencies of subtelomeric 
translocations in several other healthy control populations were studied [39, 42, 57, 64, 67, 68]. 
All published data are summarised in Table 8.1. The observed exchange frequencies between 
these repeat arrays of chromosomes 4q and 10q in the Asian populations were roughly similar to 
that of the Dutch population. Preliminary data recently presented by Olckers and colleagues 
[42] might indicate a remarkable difference in these frequencies between Eurasian and black 
South African populations. Individuals from the Eurasian population probably carry an excess 
of chromosome 4-derived repeats on chromosome 10, while the black South African population 
harbours an excess of chromosome 10-derived repeats on chromosome 4 [42]. 
 
4 on 10: Presence of chromosome 4-derived repeat units on chromosome 10. 10 on 4: Presence of chromosome 
10-derived repeat units on chromosome 4. a: This population also contains individuals that carry hybrid repeat 
arrays. b: Published percentages could be based on control individuals only (n = 52) or on both controls and 
kindred with FSHD (n = 107). c: The population study described in this article had previously been published 
[68].  
 
Table 8.1 Subtelomeric exchanges between repeats on chromosomes 4q35 and 10q26 in control populations 
 
4 on 10: Presence of chromosome 4-derived repeat units on chromosome 10. 10 on 4: Presence of chromosome 
10-derived repeat units on chromosome 4. a: Published frequencies are calculated based on results from patients 
with both de novo and inherited mutations. b: All exchanges were observed in mosaic FSHD patients.  
 





When comparing data from FSHD patients from different ethnic origins [13, 38, 39, 57, 64, 
67] (Table 8.2), exchanges of chromosome 4 repeat units to chromosome 10 were observed 
more frequently than for chromosome 10 repeats to chromosome 4, 14 versus 4% respectively. 
Four research groups also differentiated within their patient population between de novo and 
familial cases [13, 38, 64, 67] (Chapter 4). This grouping (Table 8.3) revealed that translocations 




8.1.1.2 Discussion and perspectives for future research 
When all observed exchange frequencies of different populations were merged, translocations 
between the subtelomeres of chromosomes 4q and 10q were observed in 22% (Table 8.1). 
However, when each Asian study was compared separately to the Dutch population, a higher 
exchange frequency of chromosome 4 repeat units to chromosome 10 was seen in the studies 
Matsumura et al. performed on DNA samples from the Japanese, Korean and Chinese 
population [39]. With regard to the frequencies observed in the four Chinese studies, it is 
conceivable that within the large Chinese population specific ethnically differences occur and 
this may explain the discrepancy between the data from Matsumura et al. [39] and the other 
three studies. Preliminary data presented by Olckers et al. [42] from the Eurasian population 
also points towards an excess of chromosome 4-derived repeats on chromosome 10. Olckers 
and colleagues [42] furthermore reported preliminary data on the black South African 
population, where they observed an excess of chromosome 10-derived repeats on chromosome 4. 
Especially in combination with the observation that there are no de novo patients published 
with a translocated chromosome 10 repeat array on chromosome 4 [13, 38, 64, 67] (listed in 
Table 8.3), the fact that no FSHD patient has yet been reported in the black South African 
population [42] might suggest that a chromosome 4 repeat array exchanged to chromosome 10 
Table 8.3 Subtelomeric exchanges between repeats on chromosomes 4q35 and 10q26 in de novo and familial 
FSHD patients. 
 
4 on 10: Presence of chromosome 4-derived repeat units on chromosome 10. 10 on 4: Presence of chromosome 





could predispose to the development of FSHD or even that a chromosome 10 repeat array 
exchanged to chromosome 4 may protect against disease. 
Analysing translocation frequencies in various patient populations, including both 
sporadic and familial cases, is thus necessary to confirm if the observations made so far in 
patients with a de novo mutation is a consistent finding. It would also be important to separate 
datasets that actually contain subpopulations, since this provides new clues on the dynamics and 
evolution of the 4q35 and 10q26 repeat array configurations. For example, the different 
subpopulations from the Eurasian dataset should be separated and compared with published 
data to see if indeed Japanese, Korean and some regions in China carry an excess of 
chromosome 4-derived repeats on chromosome 10. 
 
Most population studies were done using the BglII/BlnI dosage test that cannot detect the 
presence of hybrid repeat arrays consisting of repeat units derived from both chromosomes [37]. 
For both Dutch studies ([4]; Chapter 2), we applied pulsed-field gel electrophoresis to identify 
all four fragments of chromosomes 4q and 10q, which also enabled the detection of hybrid 
fragments. When analysing these repeat arrays, we observed more homogeneous chromosome 4-
derived repeats on chromosome 10 than chromosome 10-derived repeats on chromosome 4, 
which may indicate a biological difference between both repeat copies that results in a 
preference for homogeneous chromosome 4-derived repeats on chromosome 10. Repetitive 
sequences generally undergo concerted evolution, a process that homogenises repetitive DNA 
sequences, which occurs at a much higher rate within than between arrays [30, 31]. However, we 
observed many heterogeneous repeat arrays next to homogeneous repeat arrays, regardless of 
their chromosomal origin. This appears to suggest that D4Z4 repeats of chromosomes 4 and 10 
in part escape concerted evolution and evolve via relatively unrestricted intrachromosomal and 
interchromosomal recombination, which might be initiated by the microsatellites and low copy 
repeat sequences within the D4Z4 repeat [1, 24, 25, 71]. 
Since concerted evolution normally ensures the integrity of repetitive sequences coding 
for genes, this may imply that the putative open reading frame, DUX4, present within each 
D4Z4 repeat unit, has lost its function during the expansion of the repeat array. Combining the 
observation of exchanged arrays with the findings that no expression of DUX4 has been 
observed in vivo, haploinsufficiency of the 4q35 region does not cause FSHD [62] and that 
FSHD is only associated with a contracted D4Z4 on the 4qA telomeric variant [26], makes the 
model that D4Z4 repeat units harbour part or the whole FSHD gene unlikely. However, other 
models putting forward a role for the repeat itself are still compatible with the presence of 
homogeneous and heterogeneous repeat arrays. Since the repeats of chromosomes 4q and 10q 




binding sites for the multiprotein D4Z4 recognition complex observed by Gabellini et al. [11]. 
In this manner, only the number of copies would likely be important to generate the suggested 
suppression of gene expression [11]. It should be noted though that this model does not explain 
the 4q35- and 4qA-specificity of the disease. Finally, the configuration of the array is also not 
important for the looping model, proposed by Jiang and colleagues [19]. 
 
8.1.2 Size distributions of both repeat arrays 
8.1.2.1 Analysis of 4q and 10q size distribution 
To establish a normal unbiased allele size distribution, we grouped alleles with the standard 
pattern (i.e. disomic for D4Z4) in intervals of 20 kb. Because we cannot discriminate between 
the standard disomic configuration and the presence of double exchanged alleles, this 
distribution includes a very low frequency of apparent disomics (1% [44]; see also Chapter 1; 
Figure 1.5.A). It was unexpected to observe six healthy individuals with an FSHD-sized 4q35 
repeat array in our control population. For the purpose of our study these repeat sizes, which 
varied between 25-35 kb, were excluded, because of their association with FSHD. In the 
resulting population we observed an unequal repeat size distribution on chromosomes 4q and 
10q, presented as a multimodal pattern with a similar mixture of three normal distributions 
with equidistant means at intervals of approximately 65 kb (Chapter 2; Figure 2.1). 
 
Recently, it was demonstrated that the homology between chromosomes 4q and 10q also 
extends towards the telomere and that a polymorphic segment distal to D4Z4 exists in two 
variants, designated 4qA and 4qB [12, 26]. With this new information it was possible to study 
the D4Z4 size distribution of 4q and 10q alleles in more detail. We compared D4Z4 allele sizes 
of the 4qA and 4qB repeat arrays in a set of control individuals partially overlapping with the 
dataset tested in Chapter 2 and observed that 4qA alleles were significantly longer than 4qB 
alleles and that the sizes of alleles carrying one of these variants were also different (Chapter 3). 
Here too, 4q alleles were significantly longer than 10q alleles, but this was solely caused by alleles 
that carried the 4qA variant. 4qB and 10q alleles were not different in size. 
 
8.1.2.2 Discussion and perspectives for future research 
Since we observed six individuals that carry FSHD-sized repeat arrays in our population of blood 
donors, we hybridised their DNA with distal probes 4qA and 4qB [12, 26] and observed an 
equal and striking distribution among these contracted alleles: the three shortest alleles were of 
the 4qB variant, while the upper FSHD-sized fragments were of the 4qA variant. Individuals 
with a contracted allele of the 4qB variant do not suffer from FSHD [28], but this still did not 




4qA fragments such as theirs, which are borderline for FSHD diagnosis, are usually more often 
observed in non-penetrant gene carriers (approximately 30% of all individuals in large families) 
[35, 47, 51]. These individuals with short chromosome 4qA fragments might thus simply be 
asymptomatic individuals, but they could also still be extremely mild cases of FSHD that will, as 
a result, never visit a neurologist. 
These findings also imply that probably more individuals in the Dutch population carry a 
borderline-sized repeat array on chromosome 4, putting individuals in these pedigrees at risk for 
FSHD. Since overlap between D4Z4 fragment size in control individuals and FSHD patients 
seems to exist, it is therefore necessary to determine the penetrance for these 4qA fragments 
nowadays classified as borderline for FSHD and, when possible, to redefine a proper molecular 
threshold value for these 4q35 alleles associated with FSHD. 
 
A similar multimodal allele distribution as that of 4q and 10q has also been observed for 
unstable minisatellite repeats [18, 52, 54]. In Caucasian populations, bimodal size distributions 
have been described for the insulin minisatellite and D2S44, whereas trimodal size distributions 
were seen at D19S20 and MS51 (i.e. D11S97) [54]. These low variability repeats often showed 
discontinuous allele size distributions probably as a result of genetic drift compounded by low 
mutation rates and coupled with mutation processes, like slippage or interallelic gene 
conversion, that display a bias towards specific allele lengths or even show a selection for certain 
sizes [31, 32, 54]. However, it seems questionable whether a similar mechanism operates at the 
4q or 10q subtelomere. 
Rather than the mechanism controlling the multimodal distribution of minisatellites we 
hypothesized that the distribution observed for chromosome 4 and 10 repeat arrays could be a 
reflection of the local chromatin structure. In a study to elucidate the folding of DNA in higher 
chromatin structures, Filipski et al. [9] discovered two periodicities in chromatin that were 
approximately 50 and 300 kb. The ~50 kb fragment probably reflects the loop organisation of 
the chromatin into hexameric rosettes, whereas the 300 kb fragment might reflect the total 
rosette arrangement of these smaller 50 kb loops into a higher-order chromatin structure. For 
our two regions on 4q and 10q, peaks with intervals of ~65 kb, could also reflect a loop 
organisation that might impose restrictions on the repeat size. Furthermore, because usually the 
shortest allele rearranged to a FSHD allele (Chapter 4), this suggested that the unequal 
distribution on chromosome 4 separated the repeat arrays into a premutation domain in the 
first peak and a normal domain in the larger peaks. As a result, alleles in the premutation 
domain might be more prone to contraction than longer alleles, thus predisposing to the 





After the detection of the 4qA and 4qB variant [12], it became possible to determine the size 
distributions of repeat arrays associated with 4qA or 4qB. The size distribution of the 4qB alleles 
was similar to that of 10q alleles, but both did differ significantly from that of the 4qA allele size 
distribution. The evolutionary process of both chromosomes 4 and 10 may explain these 
findings. Van Geel et al. [12] evaluated the homology of the two 4q variants and suggested that 
an ancestral duplication event involving 4p and 4q sequences first created the 4qA allele. Then 
additional events distributed this copy with proximal flanking sequences to other chromosomes 
[12]. Not just the distal part of chromosome 4q was copied onto 10q, but also the D4Z4 repeat 
and part of the proximal sequence. The 4qB allele was suggested to be the result of a second, 
more recent duplication of 4p sequences that probably arose through recombination of highly 
homologous subtelomeric regions [12]. This implied that the 4qA allele is older than both the 
4qB and 10q allele. The observed differences in size between 4qA and 4qB might thus suggest 
that 4qB alleles have not yet reached the same size distributions as the 4qA alleles. By the same 
token the shorter chromosome 10q alleles fit with the same evolutionary sequence of events. 
Alternatively, chromosome 10 repeats could be shorter than chromosome 4 repeats, 
because chromosome size might be of influence on subtelomere length. It has been suggested 
that a significant amount of non-telomeric sequences contribute to the size of telomeres by a 
proposed existence of a 2-4 kb subtelomeric DNA region, termed the X-region, which is 
resistant to enzymatic digestion [56]. The X-region presents a variable domain, whose size 
changes as a function of telomere length [56]. Suda and colleagues [58] showed that relative 
telomeric repeat content (RTC) values are significantly correlated to chromosome size: in the 
human genome chromosome 10 is smaller than chromosome 4 (125 Mb vs. 193 Mb, 
respectively) and the telomere size of chromosome 10 is approximately 3.7 kb with an RTC of 
12.85, while the chromosome 4 telomere has a size of 5 kb with an RTC of 22.36 [58]. The 
telomeric structure provides protection against recombination, imposes positional effects on 
adjacent gene expression and releases key proteins for double strand break repair. This may 
indicate that longer telomeres are important for genome organisation and function and 
suggests that there is a lower and upper limit for telomere length [58]. Therefore, it is possible 
that the DNA base modifications that form the X-region are involved in preventing telomere 
recombination. This prevention subsequently results in the unusual pattern of exchanges seen 
between telomeres, up to 50 kb into the subtelomeric region [40], supported by high levels of 
recombination in subtelomeres [53]. The size of the subtelomere might therefore play a role in 
the integrity of the telomeres and might be correlated with telomere length for proper 
functioning. This thus provides an alternative explanation for the difference in size between the 
chromosome 10 subtelomere and the one on chromosome 4. However, this hypothesis does not 





One may assume that the size differences of 4q and 10q in our first dataset (Chapter 2) are 
most probably also the result of the longer 4qA alleles. However, a partially different group of 
control subjects was tested in the second study (Chapter 3), so to obtain absolute certainty 
whether repeats in the first dataset will show the same size differences of 4qA and 4qB, DNA 
from these individuals should be (re)tested with the A and B probes. 
 
 
8.2 Mosaicism for the FSHD-associated region 
 
The consequences of a mutation that gives rise to two or more different cell populations are 
dependent on the nature and location of the mutation, the cell types, and/or tissues that are 
involved [15]. Also timing could be crucial in the effect the mutation will have on phenotypic 
expression, since mutations that occur early in embryonic development involve both the 
germline and somatic cells [14]. We investigated the percentage of mosaicism for the D4Z4 
repeat in FSHD patients and their parents to gain more insight into the mechanism by which 
mosaic alleles may arise (Chapters 3 and 4). 
 
8.2.1 Detection of mosaicism and the relevance for FSHD development 
After determining the exchange frequencies between the repeats on chromosomes 4q and 10q 
in a healthy population (Chapter 2), our laboratory focussed on repeat array configurations of 
de novo patients and their parents (Chapters 3 and 4). In 38 Dutch FSHD families we showed 
that somatic mosaicism for the FSHD-associated region was detectable in 17 individuals, either 
in the patient or an asymptomatic parent. This mosaicism for a contracted D4Z4 repeat, 
generating two genetically distinct cell populations, was more often seen in male than in female 
patients (9 versus 3) and comparing male and female FSHD patients revealed a higher 
proportion of cells with the contracted allele in female patients. Furthermore, since the repeat 
array configuration of most healthy individuals in the Dutch population displays a standard 
disomic pattern and only 20% of individuals carry translocated repeat arrays [4, 44], it was 
striking to observe an exchanged chromosome 4 repeat array on chromosome 10 in 6 mosaic 
cases, while not a single mosaic individual had the reverse configuration. Finally, we identified 
three FSHD patients with even more complex rearrangements resulting in three genetically 
distinct cell populations. In one patient, the original allele was shortened into two smaller 
alleles, one of which was FSHD-sized and caused disease. In the other two individuals, the 
original allele was mutated to a short FSHD-sized allele in some cells, but expanded to an allele 





8.2.2 Discussion and perspectives for future research 
The observation that the proportion of cells carrying the contracted allele was higher in female 
de novo patients when compared to male de novo patients might indicate that females have a 
higher clinical tolerance for mosaic disease alleles than males and may thus explain the 
differences amongst de novo mosaic cases observed in our studies (9 males versus 3 females [28, 
38] see Chapter 1; Table 1.1) and are consistent with the findings that males are usually more 
severely affected than females [34, 45, 46, 69] and that there is, on average, a female excess 
among unaffected parents with mosaicism for the FSHD-associated region (Chapter 1; Table 
1.1). This indicates that there might be more apparently healthy women mosaic for a contacted 
D4Z4 repeat, who will, if this mosaicism is present in the germline, have an increased risk of 
having a child that develops FSHD. 
 
We determined the repeat array configuration in the observed 13 mosaic individuals, both 
healthy parents and patients. Next to 7 individuals with a standard pattern (disomic for D4Z4), 
this also revealed the presence of translocated chromosome 4 repeats on chromosome 10 in 
46% of cases (n= 6). In the Dutch control population, this type of repeat array configuration is 
also present, but only in 10% of individuals [4, 44]. This high percentage is comparable with 
earlier observations made in non-mosaic de novo FSHD patients summarised in Table 8.3, 
where a translocated chromosome 10 repeat array on chromosome 4 was never identified. This 
emphasizes again that an extra chromosome 4-dervived repeat array may predispose to the 
development of FSHD. Since we have only analysed 13 individuals, the frequency of an extra 
chromosome 4 repeat array should in our view be investigated in a larger sample set, for example 
in all mosaic cases that have already been reported (summarised in Chapter 1; Table 1.1). 
 
The mechanism that generally leads to mosaicism for D4Z4 is termed gene conversion, a non-
reciprocal recombination process between similar sequences that results in an alteration of a 
particular sequence to a homologous sequence during meiosis or mitosis [2, 30]. When an allele 
is damaged due to a double strand break (for example in or near the repeats on chromosome 4q 
or 10q), the sequence of the sister chromatid or of another homologous chromosome may be 
used as a template to repair the damage. This copying of the chromosome sequence can start on 
any arbitrary, but homologous point, potentially resulting in expansion or contraction of the 
involved chromosome sequences without affecting the integrity of the donor sequence. Gene 
conversion can be explained by a double strand break repair model that results in crossover and 
non-crossover products and by a synthesis-dependent strand annealing model that also allows 




gene conversion without crossover will, in the case of D4Z4 repeat rearrangements, eventually 
lead to two cell populations with a single rearranged allele for chromosome 4 or 10 in the 
majority of FSHD cases. The three identified FSHD patients with even more complex 
rearrangements are indicative of gene conversion with an unequal crossover that results in 
contraction and expansion. 
 
The co-existence of mosaicism for the FSHD-associated region in lymphocytes, fibroblasts and 
germ cells indicates that these mitotic rearrangements can occur early in embryogenesis. The 
proportion of affected cells in any tissue depends on the timing of the rearrangement, on 
selection processes and on stochastic events related to cells that contribute to the development 
of the embryo. Since molecular FSHD analysis is usually restricted to the analysis of DNA from 
blood lymphocytes due to paucity of skin or muscle tissue, (a low level of) mosaicism may go 
unnoticed. As the degree of mosaicism may differ between tissues or may even be restricted to a 
specific tissue alone, the estimated frequency of mosaicism will then always be underestimated. 
Therefore, the examination of several tissues and cell types is necessary to improve the ability to 
detect mosaicism for the contracted D4Z4 repeat, to provide correct information in genetic 
counselling and to gain more insight into mosaicism and its consequences for the FSHD 
phenotype. 
 
As we have identified individuals mosaic for the FSHD-associated region it may now be possible 
to isolate genetically identical cell lines differing solely in D4Z4 repeat array size, provided that 
the two (or three) cell populations within a mosaic culture derived from one individual can be 
separated. Such cell lines will allow researchers to study gene expression patterns that depend 
specifically on differences in repeat array size and tissue type in more detail. When used for 
specific biochemical assays, like chromatin immunoprecipitation, such cell lines may eventually 
clarify the consequences of D4Z4 repeat size for the FSHD phenotype. 
 
 
8.3 Epigenetic modifications of the 4q35 region  
 
Due to its repetitive nature and location on the subtelomere involved in FSHD, D4Z4 is 
proposed to have a heterochromatic character and several models suggested that loss of this 
heterochromatic structure as a result of contraction of the D4Z4 repeat array would cause 
activation of genes on 4q35. However, until recently, no studies were performed to test these 




in FSHD patients. While we were setting up a method to detect DNA methylation patterns in 
D4Z4, a publication of Kondo et al. [23] provided a first clue on D4Z4 chromatin structure. 
 
8.3.1 D4Z4 and the link with the ICF syndrome 
Kondo and colleagues [23] studied the ICF syndrome (reviewed in [7]). Mutations in the 
DNMT3B gene encoding a de novo DNA methyltransferase cause this rare recessive disease 
characterised by a phenotype with variable immunodeficiency, facial anomalies, psychomotor 
retardation and, less frequently, mental retardation and digestive disorders. The genome of 
these patients shows instability of heterochromatic regions located in the vicinity of 
centromeres (i.e. juxtacentromeric heterochromatin), which results in stretching, breakage and 
rearrangements of this heterochromatin of chromosomes 1, 9 and 16 including high frequencies 
of occurrence of multibranched chromosomes. In addition, several specific DNA sequences 
were reported to be hypomethylated, probably as a consequence of the reduced or even absent 
DNMT3B activity. These sequences are satellite DNA from the juxtacentromeric 
heterochromatin of chromosomes 1, 9 and 16, Alu repeats, sequences on the X- and Y- 
chromosome, H19 and α-satellite DNA [7, 23, 65].  
Kondo et al. [23] analysed DNA methylation patterns of CpG islands in ICF patients 
and confirmed that aberrant DNA methylation patterns were restricted to a small percentage of 
the genome. They observed ICF-specific DNA hypomethylation of two unrelated repeats 
present on several locations in the genome: a 1.4 kb repeat named NBL2, located at 
juxtacentromeric regions of chromosome 9 as well as the acrocentric chromosomes 13, 14 and 
21 [59], and D4Z4 located on 4q35. 
 
8.3.2 DNA methylation patterns of D4Z4 
8.3.2.1 FSHD-associated hypomethylation of D4Z4 
After detecting DNA hypomethylation of the D4Z4 repeat in ICF patients, this group also 
investigated the DNA methylation status of D4Z4 in FSHD by methylation-sensitive restriction 
enzyme analysis [61]. They observed that in healthy individuals D4Z4 repeat arrays were highly 
methylated in tissues, like brain, lung, liver and spleen, but hypomethylated in sperm. 
Furthermore, FSHD samples of different tissue origin displayed no DNA methylation changes, 
indicating a lack of association between FSHD and the methylation status of D4Z4 repeats in 
the tissues tested [61]. 
DNA methylation assays, based on digestion of DNA with CpG methylation-sensitive 
enzymes and hybridisation with probes adjacent to the restriction site of interest, are very 
suitable for a first investigation of methylation patterns in a specific region. However, owing to 




methylation of this repeat by Southern blot-based approaches. We modified our dosage test [37], 
which enabled us to determine the DNA methylation pattern within the proximal D4Z4 repeat 
unit on chromosome 4 without the interference of chromosome 10 repeat units or any other 
region in the genome. Using this method we observed a significant DNA hypomethylation of 
D4Z4 in FSHD patients, but within this group a further internal difference was displayed, as 
FSHD patients disomic for D4Z4 displayed higher methylation values than monosomic patients 
(Chapter 5). Whereas in disomic individuals only simultaneous analysis of both chromosomes 4 
is possible, yielding an average methylation of both alleles, in monosomic individuals the 
methylation of a single chromosome 4 can be determined. When corrected for the presence of a 
healthy and a disease allele in disomic patients, the observed hypomethylation could be 
attributed to the FSHD-sized allele. We subsequently confirmed that the observed DNA 
methylation within the proximal repeat unit is representative for the whole repeat array. 
Furthermore, the D4Z4 methylation pattern is FSHD-specific (thus not general for muscular 
dystrophies), is established early in development and transmitted stably through life (Chapter 5). 
Surprisingly, phenotypic FSHD patients, who are clinically indistinguishable from FSHD 
patients, but lack a contracted allele, also showed a pronounced DNA hypomethylation of the 
D4Z4 repeat (Chapter 5). In contrast to FSHD patients with a 4q35 contraction where 
hypomethylation is restricted to the disease allele, in these patients both chromosome 4 alleles 
are hypomethylated. Non-penetrant gene carriers, i.e. clinically unaffected individuals with a 
contracted D4Z4 repeat array, showed similarly hypomethylated repeats as FSHD patients with a 
4q35 contraction (Chapter 5). 
Because DNA from monosomic individuals provides a unique opportunity to examine 
DNA methylation of a single healthy or disease chromosome 4 repeat array, we took advantage 
of this phenomenon to gather more information on a possible relationship of DNA 
hypomethylation observed in FSHD patients with repeat array size and severity of disease 
(Chapter 6). Indeed, the methylation status changed in relation to the shortening of the repeat 
array, but this method did not reveal a linear relationship of DNA methylation with residual 
repeat length or disease severity. However, our data suggested a marked difference in 
methylation status of the D4Z4 repeat when we separated the patients into two groups: a 10-20 
kb and a 20-38 kb interval. 
 
8.3.2.2 Discussion and perspectives for future research 
Our data implied that there are significant changes in DNA methylation associated with 
contraction of the repeat array on chromosome 4. Therefore, this does not provide evidence for 
the model that suggests spreading of telomeric heterochromatin in a proximal direction upon 




Tsien et al. [61]. There are several explanations for this discrepancy. First, there is a difference in 
the number of samples tested. Tsien and colleagues [61] tested a limited set of FSHD and 
control samples of different tissue origin. From these samples no repeat array configurations 
were known. In contrast, we studied as many as 40 blood samples of FSHD patients and 79 
blood samples of healthy control individuals, all monosomic or disomic for D4Z4, to be certain 
that even subtle differences would be detected. Second, an interdependency between two or 
more identical restriction sites within the same fragment analysed cannot be excluded. 
Therefore, we used two different methylation-sensitive restriction enzymes that cut once in 
each D4Z4 repeat unit, in combination with probe p13E-11 that recognises a region proximal 
to D4Z4 specific for chromosome 4 alleles when combined with the restriction enzyme BlnI. In 
comparison, Tsien et al. [61] used four different methylation-sensitive enzymes that all have 
multiple restriction sites in the D4Z4 sequence in combination with a 700 bp subfragment of 
D4Z4 as a probe. Therefore, chromosome 4-specific methylation differences may be masked by 
cross-hybridisation of this probe to the many sequences in the genome homologous to D4Z4. 
Finally, the assay applied differed between both studies, which resulted in a major discrepancy 
concerning the number of D4Z4 copies analysed. Where we focussed on the proximal repeat 
unit of D4Z4 on chromosome 4, Tsien et al. [61] analysed the methylation pattern of the entire 
array on chromosomes 4 and 10, or in some cases only on chromosome 4. In our survey, we 
noticed that simultaneous quantification of the proximal units of chromosomes 4 and 10, by 
deliberately omitting BlnI from the methylation assay, could lead to an imprecision of the 
methylation values by at least 10% in either direction (PGM van Overveld, unpublished results). 
Therefore, DNA hypomethylation of FSHD alleles may have gone unnoticed by Tsien et al. due 
to the relatively small contribution of affected D4Z4 units to the total number of units assayed 
from chromosomes 4 and 10, and possibly other homologous units in the genome. 
 
That the observed methylation changes truly have an effect on FSHD pathology is most clearly 
demonstrated by the analysed alleles of phenotypic FSHD patients. These normal-sized 
chromosome 4 alleles also showed a pronounced DNA hypomethylation of D4Z4, and with 
levels even below those observed for FSHD patients with a short 4q35 repeat array. Methylation 
levels of the D4Z4 repeat in these phenotypic FSHD patients are comparable to the very low 
levels observed in ICF patients [23, 61]. While low DNA methylation values in FSHD patients 
linked to 4q35 were restricted to the contracted chromosome 4 allele, in phenotypic FSHD 
patients D4Z4 repeat arrays are hypomethylated on both chromosomes 4. 
In our assay all non-penetrant gene carriers (one person with 22 kb, two unrelated 
individuals with a 23 kb repeat size, two sisters with 27 kb fragments, one family with 3 




generations with an array of 33 kb) showed on average similar hypomethylation values as 
disomic FSHD patients. Even though we did not have any monosomic gene carriers to compare 
them to, the hypomethylation of the FSHD-sized allele in these individuals may also have been 
masked by the methylation of the long allele, similar to the effect observed in disomic FSHD 
patients. Non-penetrant gene carriers comprise one-third of all individuals over 20 years old in 
large pedigrees that do not have any complaints of muscle weakness [45, 47-49, 60], but carry a 
contracted 4q35 allele associated with D4Z4 hypomethylation. This suggests that 
hypomethylation of the D4Z4 repeat is necessary, but not sufficient for the expression of the 
FSHD phenotype. These individuals may thus carry a still unknown modifier gene(s) that 
prevents disease expression. 
 
To study potential relationships of D4Z4 hypomethylation with residual repeat size and clinical 
severity of FSHD, we compared the clinical severity score (CSS) of monosomic individuals with 
the methylation data of these independent FSHD alleles. Our finding that methylation values 
were significantly different from healthy alleles provided further support for hypomethylation of 
FSHD disease alleles. We also found additional evidence for involvement of chromatin 
organisation, as was already suggested by the multimodal size distribution of repeat arrays of 
chromosomes 4 and 10, because we did not observe monosomic individuals carrying a repeat 
array of 30-60 kb. Although the number of individuals tested here is small, this suggests that 
there is a borderline repeat size (>60 kb) necessary to remain a healthy chromosome 4 repeat 
array; i.e. a minimum of one chromatin loop. 
Furthermore, we observed a similar correlation between disease severity, using the CSS 
list formulated by Ricci et al. [51], and residual fragment size as was described previously [17, 22, 
36, 51, 60, 70]. However, this correlation had a weak predictive validity. In more detail, within 
the interval of 20-38 kb a large variability in clinical severity of the patient was observed, while 
patients with a residual fragment size of less than 20 kb all score high on the CSS list and are 
thus severely affected. Although it is generally accepted that short repeat arrays coincide with a 
high clinical severity, there was no linear relationship for the FSHD population as a whole. 
We did also not observe a linear relationship of D4Z4 methylation with repeat size or 
severity of the disease by this method, but our data suggested that D4Z4 methylation may in 
part determine FSHD severity. Although both groups were too small to test statistically, we 
observed that FSHD can be separated according to two clinical severity classes: patients with 
residual repeat arrays of 10-20 kb were always severely affected and showed pronounced 
hypomethylation of the D4Z4 repeat, while patients in the 20-38 kb interval showed both in 
clinical severity as in degree of hypomethylation a large interindividual variation not related to 




differential DNA methylation patterns within a single family may explain the observed 
intrafamilial variation in disease expression. The development of an assay to study the 
methylation status of all CpG dinucleotides in the D4Z4 sequence will thus be necessary to 
address this issue properly. 
A satisfactory, and already often applied method, is the treatment of genomic DNA 
with sodium bisulfite (reviewed in [10, 41]), a procedure that converts all unmethylated 
cytosines in the DNA to uracil by deamination, but leaving the methylated cytosines unchanged. 
The target sequence is then amplified by PCR using strand-specific primers, which replace the 
uracil residues with thymines and methylated cytosines with cytosines [29]. This can be done by 
methylation-specific PCR, in which primers are designed that exclusively anneal with either 
methylated or unmethylated converted DNA. Methylation patterns can then be derived from 
the presence or absence of a PCR product [16, 33]. Another option would be to amplify the 
converted DNA using primers that anneal at regions that lack CpGs in the original sequence. 
This results in different PCR products that each have the same size, but differ in sequence at 
potential CpG methylation sites. The relative occurrence of the different methylation statuses 
within this mixture can subsequently be analysed [6]. After performing a PCR the products can 
be analysed with any technique capable of detecting (quantitative) sequence differences. 
Although these methods could inform us on the percentage of methylated cytosines and their 
exact locations within the D4Z4 sequence, it will be a challenge to design primers specific for 
the D4Z4 sequence considering the high GC content of this repeat together with the repetitive 
nature and the genome-wide distribution of homologous sequences. In addition, one could 
apply pulsed-field gel electrophoresis on DNA digested with the appropriate restriction enzymes. 
This allows separation of a single healthy or disease chromosome 4 fragment and thus provides 
an accurate and complete overview on methylation status in the chromosomal area of interest 
in combination with specific primers. 
 
Although ICF syndrome patients also showed hypomethylation at D4Z4, this is in fact the only 
similarity between these two diseases. The observed generalised hypomethylation at all D4Z4 
sequences on chromosomes 4 and 10 in DNA from ICF patients is not surprising in view of the 
primary defect these patients have in DNMT3B, a gene that encodes a DNA methyltransferase 
involved in de novo methylation [23]. Therefore, we wondered if mutations in any of the 
DNMT genes would similarly cause the observed hypomethylation in phenotypic FSHD patients. 
We analysed the DNA sequences of DNMT3A and DNMT3B in patients with a contracted 
D4Z4 repeat and phenotypic FSHD patients, but did not yet find any mutation (PGM van 
Overveld, unpublished results). Once cell lines derived from various tissues of these phenotypic 




functional complementation to seek proteins that correct a defect in the recipient cell line. If 
adding the DNMT protein of interest to the cell culture would restore D4Z4 methylation 
patterns to those observed for the D4Z4 repeat in control individuals, this would suggest that 
the DNMT tested indeed may play a role in establishing the chromatin structure of D4Z4. 
 
The observed hypomethylation in FSHD patients with and without a D4Z4 repeat contraction 
indicates a prominent role for this epigenetic DNA modification in FSHD. Interestingly, the 
hypomethylation of FSHD alleles is most pronounced at the restriction site for FseI, located in 
the putative promoter region of DUX4, and to a lesser extent for BsaAI 350 bp proximal to FseI. 
It is conceivable that hypomethylation of the DUX4 promoter region may activate ectopic 
DUX4 expression. Homeobox proteins act as transcription factors in normal development. 
These homeobox-containing genes are often expressed during embryogenesis and their 
transcription can be influenced by DNA methylation [21]. As DUX4 encodes a putative 
homeobox-protein, we cannot exclude that, as a consequence of the DNA hypomethylation, 
expression of DUX4 in early development could be changed and might contribute to or even 
initiate FSHD pathology. Subsequent to the developmental stages, homeoboxes cannot be 
activated anymore and expression of DUX4 would then be terminated, thus explaining the 
absence of DUX4 expression in postnatal tissues. 
Recent findings suggest that a local reduction of a specific repressor complex bound to 
D4Z4 may cause inappropriate activation of 4q35 genes by contraction of the array [11], 
although this model does not explain the chromosome 4qA allele specificity of FSHD with 
aberrant transcription. This local reduction could be enhanced by D4Z4 hypomethylation. 
Besides this repression model of Gabellini et al. [11], DNA hypomethylation of the D4Z4 
repeats also fits the looping model proposed by Jiang et al. [8, 19] in which communication 
between a short D4Z4 repeat array and a target gene (or genes) occurs in cis by 
intrachromosomal looping. In this model, looping might be promoted by the more open 
chromatin structure of D4Z4 and/or activate inappropriate gene expression itself by allowing 
proteins to bind to hypomethylated sequences. In addition, the model suggesting that a 
heterochromatic chromatin conformation is a requirement for proper functioning of genes in 
the 4q35 region also still fits with our methylation data. Thus, with the observed DNA 
hypomethylation in FSHD patients we obtained support for an allele-specific chromatin change 
and this may provide an explanation unifying several disease models proposed for FSHD 
pathology. 
 
Our methylation assay may also have diagnostic value for two small groups of patients. In a pilot 




contained an unknown number of FSHD patients with a 4q35 contraction as well as an 
unknown number of phenotypic FSHD patients. Since we know that the level of methylation 
on both tested restriction sites in phenotypic FSHD patients should be below the average 
methylation of FSHD patients with a 4q35 contraction, it was possible to successfully 
distinguish which individuals were marked as phenotypic FSHD patients (PGM van Overveld, 
unpublished results). We also tested DNA from patients where the clinical findings do not 
point with certainty to FSHD. These individuals did not have a contracted 4q35 repeat array 
and showed methylation values comparable to control individuals (PGM van Overveld, 
unpublished results). However, the limitation of this technique is that it only provides 
information on the methylation status of two methylation-sensitive restriction sites. Once it 
becomes possible to determine the methylation status of every CpG in the D4Z4 sequence, this 
may provide a promising decisive molecular marker to confirm the status “phenotypic FSHD 
patient” in the absence of a D4Z4 contraction. The application of a method allowing complete 
detailed analysis of every methylated cytosine in the D4Z4 sequence, like bisulfite sequencing 
[10, 33, 41], can hopefully in the future be used for diagnostic and research purposes, especially 
to confirm the clinical diagnosis in phenotypic FSHD patients more accurately than be done 
with the modified dosage test that we have applied thus far. 
 
8.3.3 Histone modifications 
8.3.3.1 H4 acetylation of D4Z4 
Chromatin immunoprecipitation (ChIP) has become an important tool in studying chromatin 
and DNA-protein interactions in the living cell. The technique identifies DNA sequences that 
are directly bound to a nucleosome or protein complex [43, 55]. With a general antibody 
recognising histone 4 (H4) acetylation, which distinguished best and most consistently between 
constitutive heterochromatin and unexpressed euchromatin [20], we tested the presumed loss 
of heterochromatin of the 4q35 region (i.e. the loss-of-PEV model) with ChIP on cell fractions 
of cell lines, blood samples and muscle biopsies derived from a limited set of FSHD patients and 
healthy controls (Chapter 7). None of the regions studied showed any differences between cells 
from healthy individuals and FSHD patients. H4 acetylation levels of probe region p13E-11 
proximal to the D4Z4 repeat array were comparable to levels observed in unexpressed 
euchromatin both on chromosome 4 and 10. Furthermore, the different cell fractions displayed 
H4 hyperacetylation at the 5’ regions of candidate genes FRG1 and ANT1 located proximal to 
D4Z4. ChIP assays of the promoter region of DUX4 and the D4Z4 sequence itself did not 
provide evidence for low levels of H4 acetylation on 4q35. In addition, no evidence for H4 





8.3.3.2 Discussion and perspectives for future research  
This study was the first attempt to focus on histone modifications in the 4q35 region. When H4 
acetylation of chromatin from this chromosome 4 region was compared to that of the 
heterochromatic and euchromatic standards [20] in a limited set of samples, the 4q35 region 
appeared more similar to unexpressed euchromatin than to constitutive heterochromatin. This 
suggests that the D4Z4 repeat and the proximal sequences are unlikely to be heterochromatic in 
nature. Furthermore, there were no differences observed between samples from healthy 
individuals and FSHD patients and no relation between the number of D4Z4 copies and 
histone acetylation was observed. The H4 acetylation data thus do not support the model, which 
suggests that D4Z4 repeats are important for normal folding of the chromosome in a 
heterochromatic state and that a contraction may change the (local) chromatin conformation, 
resulting in a loss of heterochromatin and subsequent extinguishing or altering of gene activity 
on 4q35. These analyses do suggest that the FSHD-associated region is located in unexpressed 
euchromatin, but no difference between patients and control individuals was observed. It is 
possible that histone modifications other than acetylation take place upon contraction of the 
D4Z4 array and thus may influence the chromatin conformation. To elucidate if other 
chromatin modifications are involved in FSHD, ChIP analysis could be extended with 
antibodies detecting other histone modifications or proteins associated with chromatin 
components. The most interesting to test is the multiprotein complex capable of binding to 
D4Z4 [11], consisting of proteins that can activate or repress transcription or that are possibly 
involved in the organisation and maintenance of heterochromatic regions [3, 63]. 
Although muscle biopsies would be the first choice to test, they could unfortunately not 
be used for this ChIP procedure. Where possible, FSHD and control myoblasts, both 
proliferating and differentiating, should be analysed to obtain extra information on H4 
acetylation and other chromatin modifications, and to allow comparisons between the tested 
cell populations. In addition, obtaining information on chromatin structure and binding of 
protein complexes at potential candidate gene sequences would also broaden our knowledge on 
a possible effect of D4Z4 repeat array size on the 4q35 region. Therefore, more research needs 
to be done before the model that assumed the loss of heterochromatin in the 4q35 region as a 
cause of FSHD development can truly be discarded. With regard to the other proposed models, 
the repression model of Gabellini et al. [11], the looping model proposed by Jiang et al. [8, 19] 
and a role for DUX4 located within D4Z4 all still fit well with our data. In the future, a 
combination of ChIP with microarray technology (ChIP-on-chip) could be applied to detect 
protein binding to numerous loci [55]. This would facilitate the construction of whole-genome 
(disease-specific) maps of histone modifications, chromatin-modifying proteins and DNA-




provide a detailed picture of chromatin features in the 4q35 region and would hopefully result 
in a viable model, perhaps a combination of the several ones proposed today, that takes into 
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Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common hereditary muscle 
diseases with an estimated frequency of 1 in 20000. The disease has an autosomal dominant 
inheritance pattern and is characterised by a progressive and often asymmetric muscle weakness 
with an onset of disease in facial or shoulder girdle muscles.  
The major locus for FSHD is linked to 4q35, located in the subtelomere on the long arm 
of chromosome 4. This region harbours a highly polymorphic EcoRI fragment that contains a 
large polymorphic repeat structure, designated D4Z4, which consists of 3.3 kb tandemly 
arranged D4Z4 repeat units and is highly susceptible to rearrangement. In the majority of 
patients this repeat is contracted to an array of 1-10 repeat units. However, 5% of FSHD 
patients, termed phenotypic FSHD patients, do not manifest a contracted D4Z4 array on 
chromosome 4, but share all clinical characteristics. 
Complicating FSHD diagnosis, the subtelomere on the long arm of chromosome 10 
(10q26) is highly similar to 4q35 and also contains a nearly identical polymorphic repeat array. 
However, size reductions of the chromosome 10 repeat array are non-pathogenic. Furthermore, 
exchanges between arrays on chromosomes 4 and 10 are frequently observed in patients and 
control individuals, but will only cause disease when a contracted array resides on chromosome 
4. Finally, recent analysis of sequences distal to D4Z4 revealed two variants of the 4qter 
sequence, designated 4qA and 4qB. While both variants are almost equally present in the 
population, FSHD is uniquely associated with the 4qA variant. 
Although FSHD is associated with a repeat contraction on 4qA, the exact mechanism 
causing disease is still unknown. The work in this thesis focused on structure and behaviour of 
the 4q35 subtelomere, aiming at elucidating possible molecular mechanisms that may mediate 
or cause FSHD pathology. 
 
Subtelomeres are dynamic structures that are more often involved in recombination processes 
than other parts of the genome. Due to exchanges between subtelomeres of different 
chromosomes highly homologous DNA sequences can be dispersed throughout pericentromeric 
and subtelomeric domains in the genome. Since the repeat arrays located on the subtelomeres 
of the long arms of chromosomes 4 and 10 are highly homologous, we analysed these repeat 
array configurations in a healthy population, the results of which are presented in Chapters 2 
and 3. This revealed the existence of translocated repeat arrays in 20% of individuals. Besides 
the presence of homogeneous chromosome 4 repeat units on chromosome 10, and vice versa, 
we also detected hybrid arrays that contained repeat units derived from both chromosomes.  
With regard to repeat array size we observed that on average the arrays on chromosome 4 
were longer than those on chromosome 10. This size difference was solely caused by alleles that 




arrays of chromosomes 4 and 10 displayed a similar multimodal allele size distribution that 
possibly reflects a higher-order chromatin structure. This multimodal distribution on 
chromosome 4 furthermore indicated the presence of a premutation domain containing alleles 
shorter than approximately 100 kb. Alleles in this domain may be more prone to contraction to 
a disease allele than arrays located in the larger repeat size intervals and may thus be predisposing 
for FSHD development. 
 
In Chapters 3 and 4 we examined repeat array configurations in de novo FSHD families and 
observed somatic mosaicism in more than 40% of cases, in either an FSHD patient or an 
asymptomatic parent of a non-mosaic patient. This mosaicism for a contracted D4Z4 repeat 
was more often seen in male than in female patients. In addition, affected females showed a 
higher proportion of cells with the contracted 4q35 repeat array than males, indicating that 
females have a higher clinical tolerance for mosaic disease alleles. Consistent with this finding is 
that, on average, there are more females with mosaicism for the FSHD region among unaffected 
parents. 
Besides the observed mosaicism for a contracted FSHD allele generating two genetically 
distinct cell populations by gene conversion without crossover, we also identified FSHD patients 
with more complex rearrangements that resulted in three cell populations. This suggests that, 
alongside gene conversion without crossover, also gene conversion with crossover events that 
result in contraction and expansion of D4Z4 may contribute to the occurrence of mosaic D4Z4 
alleles. Furthermore, whereas we did observe D4Z4 repeat units derived from chromosome 4 on 
chromosome 10 in mosaic individuals, the reverse configuration was never detected. The 
presence of such an extra chromosome 4 repeat array may facilitate gene conversion and may 
thus be a predisposing factor for contraction of the D4Z4 repeat array. 
 
Eukaryotic cells have the capacity to epigenetically modify their genomes with a biochemical 
mark to alter the phenotype without changing the genotype. Two major epigenetic processes 
that mark chromatin are DNA methylation and the modifications of histones, such as 
acetylation. Due to the repetitive nature and the location on the subtelomere of 4q35, D4Z4 
has been proposed to have a heterochromatic character. Chapters 5, 6 and 7 present data on our 
studies on the chromatin structure of the D4Z4 repeat array, focussing on a possible change in 
structure of 4q35 in FSHD patients as a consequence of the chromosomal rearrangement. We 
demonstrated in Chapters 5 and 6 that the D4Z4 contraction is associated with a significant 
DNA hypomethylation of D4Z4 at the disease allele in FSHD patients. Furthermore, 
phenotypic FSHD patients that carry normal-sized 4q35 repeat arrays also showed a pronounced 




contracted D4Z4 repeat array. While low DNA methylation values in FSHD patients linked to 
4q35 are restricted to the disease allele, in phenotypic FSHD patients D4Z4 repeat arrays on 
both chromosomes 4 were found to be hypomethylated. These findings support an allele-
specific chromatin change in FSHD patients with a D4Z4 contraction and strongly suggest that 
hypomethylation is a key event in the cascade of events causing the FSHD phenotype. 
Analysis of histone 4 acetylation levels in the 4q35 region, as described in Chapter 7, 
indicated that the chromatin structure close to D4Z4 resembled that of unexpressed 
euchromatin rather than constitutive heterochromatin. This suggests that D4Z4 and proximal 
sequences are not heterochromatic. Contrary to our data presented on D4Z4 methylation, no 
histone 4 acetylation differences were observed between control individuals and FSHD patients. 
However, it remains possible that other histone modifications may influence the chromatin 
conformation upon contraction of the D4Z4 array. 
 
The data presented in this thesis challenge the model suggesting the spreading of telomeric 
heterochromatin in a proximal direction upon contraction of the D4Z4 array, but fit in with 
other models that have been put forward to explain FSHD pathology. In addition to the 
repression model, suggesting that upon contraction a local reduction of a specific repressor 
complex bound to D4Z4 will cause inappropriate activation of 4q35 genes, our data also fit with 
the looping model, in which communication between a short D4Z4 repeat array and a target 
gene (or genes) occurs in cis by intrachromosomal looping. The model proposing a 
heterochromatic chromatin conformation as requirement for proper functioning of D4Z4 
remains valid as well. Furthermore, as DUX4 located in D4Z4 encodes a putative homeobox-
protein, we cannot exclude whether expression of DUX4 in early development will be altered 
due to D4Z4 contraction and so contributes to or even initiates FSHD pathology. Probably the 
actual disease-causing process will be a combination of the proposed mechanisms in which also 
the unique perinuclear localisation of chromosome 4q also has to be taken into account. 
 
Besides providing new insights in the structure and complex behaviour of the chromosome 4q 
subtelomere associated with FSHD, this thesis also provides two observations relevant to the 
clinical practice. First, if mosaicism for D4Z4 is present in the germline, the percentage of these 
cells carrying the disease allele will determine the risk of having affected offspring, unlike in 
non-mosaic individuals carrying an FSHD-sized repeat array who have a 50% probability of 
transmitting the disease. More importantly, since mosaic females can carry a considerably 
higher percentage of cells with the disease fragment than male mosaics without manifesting 
FSHD, the disease may more easily go unnoticed in asymptomatic females than previously 




contracted FSHD allele who will have an increased risk of having a child that develops FSHD 
provided this mosaicism extends to the germline. It is therefore important to screen for 
mosaicism in de novo FSHD families to provide more accurate information on inheritance risks. 
Second, the methylation assay described in this thesis may have diagnostic and 
prognostic value, especially for phenotypic FSHD patients. Since we now know that the level of 
D4Z4 methylation in these individuals should be below the average methylation observed in 
FSHD patients with a 4q35 contraction, this can be used as a predictive molecular marker to 
confirm the status “phenotypic FSHD patient”. Hopefully, these two findings will become 






Facioscapulohumerale spierdystrofie (FSHD) is een van de meest voorkomende erfelijke 
spierziekten, met een incidentie van 1 op 20.000. FSHD wordt klinisch gekarakteriseerd door 
een progressieve en vaak asymmetrische verzwakking van de skeletspieren, waarbij in een vroeg 
stadium de aangezichtsspieren en schouderbladspieren worden aangetast. De ernst van de ziekte 
verschilt per patiënt. 
De erfelijke informatie (DNA) wordt in de cellen verpakt in 23 chromosoomparen, 
waardoor ieder chromosoom twee keer aanwezig is. FSHD is op DNA niveau geassocieerd met 
een genetische verandering dichtbij het uiteinde van de lange arm van chromosoom 4 (locatie 
4q35). In dit gebied ligt de zeer variabele repeat D4Z4, die bestaat uit een herhalend patroon 
D4Z4 eenheden met elk een lengte van 3.3 kilobasen. De D4Z4 repeat is verder erg gevoelig 
voor DNA uitwisselingen. In de meeste FSHD patiënten wordt een verkorting van de D4Z4 
repeat gevonden op één van de chromosomen 4, waardoor er nog maar 1-10 eenheden 
overblijven. In 5% van de FSHD patiënten wordt echter geen verkorte D4Z4 sequentie op 
chromosoom 4 gevonden, ondanks dat deze patiënten wel alle klinische kenmerken van de 
ziekte hebben. Deze patiënten worden daarom fenotypische FSHD patiënten genoemd. De 
ziekte heeft een autosomaal dominant overervingspatroon, waardoor een kind een kans van 
50% heeft om de verkorte D4Z4 repeat te erven van een aangedane ouder en ziek te worden. 
 Het stellen van de diagnose FSHD wordt op moleculair niveau bemoeilijkt door de 
aanwezigheid van een bijna identieke repeat dichtbij het uiteinde van de lange arm van 
chromosoom 10 (locatie 10q26). Verkorting van deze chromosoom 10 repeat leidt echter niet 
tot FSHD. Verder worden er uitwisselingen tussen de repeterende eenheden van chromosoom 4 
en chromosoom 10 repeats waargenomen. Desalniettemin leidt een repeatverkorting alleen tot 
ziekte wanneer deze op chromosoom 4 plaatsvindt en kan dus gebeuren onafhankelijk van de 
samenstelling van deze repeat, die darrdoor ook kan bestaan uit een mix van repeterende 
eenheden van chromosomen 4 en 10. Analyse van de sequentie tussen de D4Z4 repeat en het 
uiteinde van chromosoom 4 heeft bovendien twee varianten van deze sequentie aan het licht 
gebracht, die 4qA en 4qB worden genoemd. Beide varianten komen even vaak voor in de 
populatie, maar in FSHD patiënten is de repeatverkorting altijd gekoppeld aan de 4qA variant. 
 Ondanks dat FSHD geassocieerd is met een verkorting van de D4Z4 repeat met de 4qA 
variant, is het exacte mechanisme, dat de ziekte veroorzaakt, nog niet opgehelderd. Het werk 
beschreven in dit proefschrift heeft betrekking op de DNA structuur en het instabiele gedrag 
van de D4Z4 repeat op het uiteinde van de lange arm van chromosoom 4 met als doel de 
moleculaire mechanismen, die FSHD beïnvloeden of zelfs veroorzaken, te achterhalen. 
 
De gebieden in de nabijheid van het uiteinde van een chromosoom worden subtelomeren 




zijn bij uitwisselingen van overeenkomstige DNA sequenties. Door uitwisselingen tussen de 
subtelomere gebieden van verschillende chromosomen kunnen deze sequenties gemakkelijk 
verspreid worden over het genoom, met name naar andere subtelomere gebieden en de 
gebieden rondom de centromeren. Omdat de sequenties van repeterende eenheden op de 
locaties 4q35 en 10q26 erg homoloog zijn, hebben we in een populatie gezonde mensen de 
samenstelling van beide repeats geanalyseerd. De resultaten staan beschreven in Hoofdstuk 2 en 
3. Deze analyse leidde tot het waarnemen van uitwisselingen tussen de repeterende eenheden 
van de chromosoom 4 en 10 repeats in 20% van de individuen. We zagen op chromosoom 10 
repeats opgebouwd uit homogene repeterende eenheden afkomstig van chromosoom 4 en 
homogene repeterende eenheden afkomstig van chromosoom 10 op chromosoom 4. Ook 
troffen we gemengde repeats aan, die repeterende eenheden afkomstig van beide chromosomen 
bevatten. 
 Naast de verschillende mogelijkheden in de samenstelling van de repeats op beide 
chromosomen, bleek ook de repeat aanwezig op chromosoom 4 gemiddeld langer te zijn dan de 
repeat op chromosoom 10. Dit verschil in lengte werd voornamelijk bepaald door de repeats 
met de 4qA variant, want er werd geen significant lengteverschil gevonden tussen de 
chromosoom 10 repeats en de chromosoom 4 repeats met de 4qB variant. Verder kunnen alle 
waargenomen repeatlengten worden opgedeeld in domeinen. Dit geeft een voor chromosoom 4 
en 10 vergelijkbare multimodale verdeling, die een bepaalde voorkeursvouwing van de 
repeatsequentie suggereert. De multimodale verdeling geeft tevens een premutatie domein aan, 
dat repeatlengten kleiner dan 100 kilobasenparen bevat. Chromosoom 4 repeats die in dit 
domein vallen zijn mogelijk eerder geneigd te verkorten tot de lengte die geassocieerd is met 
FSHD dan langere repeats in de andere domeinen en kunnen daardoor mogelijk eerder leiden 
tot het ontstaan van FSHD. 
 
In Hoofdstuk 3 en 4 hebben we de samenstelling van de repeats bekeken in families waar de 
verkorting niet wordt doorgegeven van ouder op kind, maar waar FSHD ontstaan is door een 
nieuwe verkorting van de D4Z4 repeat. In deze de novo families bleek dat meer dan 40% van de 
onderzochte individuen mozaïek was voor de D4Z4 repeat, wat betekent dat een deel van de 
cellen in het lichaam de verkorte D4Z4 repeat heeft die geassocieerd is met FSHD, terwijl de 
andere cellen een lange, gezonde D4Z4 repeat bevatten. De aanwezigheid van twee 
celpopulaties met ieder een verschillende D4Z4 repeatlengte werd in zowel FSHD patiënten als 
niet-aangedane ouders waargenomen. In patiënten werd dit mosaïcisme vaker gezien in 
mannelijke dan in vrouwelijke patiënten. Bovendien bleek in vrouwelijke patiënten de verkorte 
D4Z4 repeat in een groter percentage cellen aanwezig te zijn dan in mannelijke patiënten, wat 




verdragen. In overeenstemming met deze tolerantie geldt, dat onder de niet-aangedane ouders, 
waarin we ook het mosaïcisme voor de D4Z4 repeat verkorting hebben waargenomen, er ook 
gemiddeld meer vrouwen zijn. 
 Mosaïcisme voor een verkorte D4Z4 repeat wordt meestal veroorzaakt door het 
mechanisme “genconversie zonder uitwisseling”, hetgeen resulteert in twee celpopulaties. We 
hebben echter ook FSHD patiënten geïdentificeerd, waarin een complexe herschikking van de 
repeterende eenheden van de D4Z4 repeat heeft geleid tot de aanwezigheid van drie 
celpopulaties, die elk een andere repeatlengte bevatten. Naast cellen met de oorspronkelijke 
D4Z4 repeatlengte vinden we hier ook een celpopulatie met een D4Z4 repeatverkorting en een 
celpopulatie met een verlenging van de D4Z4 repeatlengte. Dit geeft aan, dat ook het 
mechanisme “genconversie met uitwisseling” kan bijdragen aan het ontstaan van mosaïcisme 
voor de D4Z4 repeat. 
We hebben daarnaast ook de aanwezigheid van mogelijke uitwisselingen tussen de 
repeterende eenheden van chromosoom 4 en 10 repeats bestudeerd. In de mozaïeke individuen 
waren wel repeterende eenheden van de D4Z4 repeat aanwezig in de repeat op chromosoom 10, 
maar we hebben nooit repeterende eenheden van de chromosoom 10 repeat op chromosoom 4 
gevonden. De aanwezigheid van deze extra repeterende eenheden van chromosoom 4 op 
chromosoom 10 kunnen mogelijk het “genconversie” mechanisme vergemakkelijken en op die 
manier predisponeren voor het ontstaan van een D4Z4 repeatverkorting. 
 
DNA wordt samen met DNA-geassocieerde eiwitten, waaronder histonen, geordend tot 
chromatine. Dit ordenen leidt tot verschillen in vouwing van het DNA met grote gevolgen voor 
de expressie van genen. Chromatine wordt globaal ingedeeld in twee vormen: heterochromatine 
en euchromatine. In het algemeen hebben heterochromatische gebieden een compacte vouwing, 
waardoor genen niet geactiveerd kunnen worden, terwijl in euchromatische gebieden met een 
meer open structuur genen wel tot expressie kunnen worden gebracht. Eukaryotische cellen 
hebben de mogelijkheid om chromatine te modificeren met behulp van een biochemische 
markering, waardoor de expressie van een DNA sequentie kan veranderen zonder dat de 
genomische sequentie veranderd wordt. Dit worden epigenetische veranderingen genoemd. 
Twee belangrijke epigenetische processen die chromatine kunnen markeren zijn DNA 
methylatie en de verschillende modificaties van de histonen, waaronder acetylatie. In gebieden 
waar het DNA sterk gemethyleerd is en er weinig histonen geacetyleerd zijn staan genen meestal 
uit. Door het repeterende karakter van de D4Z4 repeat en de locatie in het subtelomeer van 
chromosoom 4 wordt er aangenomen, dat de D4Z4 sequentie in heterochromatine ligt. In 
Hoofdstukken 5-7 worden studies beschreven, waarin we ons gericht hebben op het bepalen van 




mogelijk een verandering in deze structuur optreedt als gevolg van de repeatverkorting. We laten 
in Hoofdstuk 5 en 6 zien, dat de verkorte D4Z4 repeat in FSHD patiënten geassocieerd is met 
een significante afname van DNA methylatie. In fenotypische FSHD patiënten, die geen 
verkorte D4Z4 repeat op chromosoom 4 hebben, nemen we zelfs een nog sterkere afname van 
DNA methylatie waar. Bovendien zijn in deze fenotypische FSHD patiënten de D4Z4 repeats 
op beide chromosomen 4 laag gemethyleerd, terwijl in FSHD patiënten met een verkorting van 
de D4Z4 repeats op één van de chromosomen 4 alleen de verkorte D4Z4 repeat laag 
gemethyleerd is. Deze waarnemingen ondersteunen het optreden van een 
chromatineverandering specifiek voor de verkorte D4Z4 repeat en suggereren sterk, dat een 
verminderde DNA methylatie een belangrijke factor is in de gebeurtenissen, die uiteindelijk 
leiden tot ziekte. 
De bestudering van de acetylatie van histon nummer 4 in de sequentie van 4q35 wordt 
beschreven in Hoofdstuk 7. Deze analyse geeft aan, dat de chromatinestructuur van het gebied 
naast de D4Z4 repeat meer op een open, maar inactieve chromatinestructuur lijkt dan op 
heterochromatine. Dit suggereert, dat de D4Z4 repeat en de sequenties voor de repeat geen echt 
heterochromatische structuur hebben, maar een intermediair tussen heterochromatine en 
euchromatine. In tegenstelling tot onze bevindingen voor DNA methylatie vonden we hier 
geen verschil tussen FSHD patiënten en controle individuen. Het is echter mogelijk, dat de 
andere histon modificaties door het verkorten van de D4Z4 repeat de chromatinestructuur wel 
beïnvloeden. 
 
Er zijn een aantal modellen voorgesteld om het ontstaansmechanisme van FSHD te verklaren. 
De in dit proefschrift gepresenteerde data leveren geen bewijs voor het model, dat de 
verspreiding van heterochromatine vanaf het uiteinde van chromosoom 4 bij een verkorting van 
de D4Z4 repeat voorspelt. Onze data ondersteunen wel het “repressor”-model, dat als gevolg 
van de repeatverkorting een lokale afname van een aan de D4Z4 repeat gebonden specifiek 
repressorcomplex oppert, wat vervolgens kan leiden tot een toename van genexpressie. Ook 
passen onze data in het “looping”-model, waarin communicatie tussen een verkorte D4Z4 
repeat en een specifiek gen (of meerdere genen) ontstaat door de vorming van een 
intrachromosomale lus. Het model, dat een heterochromatische structuur als eis stelt voor het 
goed functioneren van de D4Z4 repeat is ook nog steeds toepasbaar. Tenslotte is er in de D4Z4 
repeat een gensequentie aanwezig, die mogelijk codeert voor een eiwit, dat betrokken kan zijn 
bij de regulatie van genexpressie in de embryogenese. We kunnen niet uitsluiten, dat de 
expressie van dit gen verandert door de D4Z4 repeat verkorting en op die wijze kan bijdragen 




veroorzaakt een combinatie zijn van alle voorgestelde modellen, waarin ook de unieke plaats 
van chromosoom 4 in de kern meegenomen moet worden. 
 
Naast het verkrijgen van nieuwe inzichten in de structuur en het complexe gedrag van het 
chromosoom 4 subtelomeer heeft dit proefschrift ook twee observaties opgeleverd die van 
belang zijn voor klinisch onderzoek. Wanneer mosaïcisme voor de D4Z4 repeat ook aanwezig is 
in de geslachtscellen, is het van belang om het percentage geslachtscellen te bepalen dat 
daadwerkelijk de repeatverkorting bevat. Dit percentage bepaalt namelijk de kans om een kind 
met FSHD te krijgen en ligt anders dan bij niet-mozaïeke individuen, waar de kinderen 50% 
kans hebben om de verkorte D4Z4 repeat te erven en ziek te worden. En wat misschien nog wel 
belangrijker is, juist omdat vrouwen een hoger percentage cellen met een verkorte D4Z4 repeat 
kunnen hebben zonder ziek te worden, kan de aanwezigheid van een ziekte vaker onopgemerkt 
blijven dan eerder werd aangenomen. Dit geeft meteen aan, dat er waarschijnlijk meer vrouwen 
drager zijn van mosaïcisme voor een verkorte D4Z4 repeat dan mannen en dus een verhoogde 
kans hebben een kind te krijgen dat FSHD ontwikkelt, mits dit mosaïcisme inderdaad in de 
eicellen aanwezig is. Het is daarom van belang om op mosaïcisme te screenen in de novo 
families om accurate informatie te kunnen geven met betrekking tot de risico’s van ziekte-
overerving. 
Als tweede kan de in dit proefschrift beschreven analyse voor DNA methylatie mogelijk 
gebruikt worden als diagnostische test, met name voor fenotypische FSHD patiënten. Omdat 
we nu weten dat de DNA methylatie van de D4Z4 repeat in deze groep patiënten lager ligt dan 
de gemiddelde waarden gevonden in de FSHD patiënten met een verkorte D4Z4 repeat, kan dit 
gebruikt worden als marker om de status “fenotypische FSHD patiënt” te bevestigen. Hopelijk 
worden deze twee bevindingen geïmplementeerd in het moleculaire FSHD onderzoek en 
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Ab  antibody 
Ac  acetylation 
ADP  adenosine diphosphate 
ALP  actinin-associated LIM protein gene 
ANT  adenine nucleotide translocator gene 1 
ATP  adenosine triphosphate 
BMD  Becker muscular dystrophy 
bp  basepair 
cDNA  complementary DNA 
cen  centromere 
ChIP  chromatin immunoprecipitation 
Chr  chromosome 
cM  CentiMorgan 
CSS  clinical severity score 
del  deletion 
DM  myotonic dystrophy 
DMD  Duchenne muscular dystrophy 
DNA  deoxyribonucleic acid 
DNMT DNA methyltransferase 
DSB  double strand break 
DUX  double homeobox protein gene 
EST  expressed sequence tag 
FISH  fluorescence in situ hybridization 
FRG1  FSHD region gene 1 
FRG2  FSHD region gene 2 
FSHD  facioscapulohumeral muscular dystrophy 
GAPD  glyceraldehyde phosphate dehydrogenase 
GC+CO gene conversion with crossover 
GC-CO gene conversion without crossover 
H1  linker histone 1 
H2A  histone 2A 
H2B  histone 2B 
H3  histone 3 
H4  histone 4 
HAT  histone acetyltransferase 
HDAC  histone deacetylase 
ICF  immunodeficiency-centromeric instability-facial anomalies syndrome 
IP  immunopreciptiation 
K  lysine 
kb  kilobase 
LCL  lymphoblastoid cell line 
LD  linkage disequilibrium 
LINE  long interspersed nuclear element 
LTR  long terminal repeat transposon 
Mb  megabase 
mRNA  messenger RNA 
OPMD oculopharyngeal muscular dystrophy 
OR  olfactory receptor 
ORF  open reading frame 
p  as in 4p: the short arm of a chromosome 
PBL  peripheral blood lymphocyte 
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PBMC  peripheral blood mononuclear cell 
PCR  polymerase chain reaction 
PEV  position effect variegation 
PFGE  pulsed-field gel electrophoresis 
q  as in 4q: the long arm of a chromosome 
Q-PCR  quantitative real-time PCR 
RFLP  restriction fragment length polymorphism 
RNA  ribonucleic acid 
rDNA  ribosomal DNA 
rRNA  ribosomal RNA 
RT  reverse transcription 
RTC  relative telomeric repeat content 
Sat  satellite 
S.E.M.  standard error of the mean 
SCH  somatic cell hybrid 
SD  standard deviation 
SDSA  synthesis-dependent strand annealing 
SINE  short interspersed nuclear element 
SNP  single nucleotide polymorphism 
snRNA  small nuclear RNA 
SUMO  small ubiquitin-related modifier 
tel  telomere 
ter  as in 4qter: the terminal region of a chromosome 
TUBB4Q tubulin beta polypeptide 4Q gene 
USCE  unequal sister-chromatid exchange 







List of publications 
 
 253 
List of publications 
 
 
SM van der Maarel, G Deidda, RJLF Lemmers, PGM van Overveld, MJ van der Wielen, JE 
Hewitt, LA Sandkuijl, B Bakker, GJB van Ommen, GW Padberg and RR Frants. De novo 
facioscapulohumeral muscular dystrophy: frequent somatic mosaicism, sex-dependent 
phenotype, and the role of mitotic transchromosomal repeat interaction between chromosomes 
4 and 10. American Journal of Human Genetics (2000) 66: 326-366. 
 
PGM van Overveld, RJFL Lemmers, G Deidda, LA Sandkuijl, GW Padberg, RR Frants and SM 
van der Maarel. Frequent interchromosomal repeat array interactions between chromosomes 4 
and 10: a model for subtelomeric plasticity. American Journal of Human Genetics (2000) 67 
(Supplement): Abstract #171. 
 
PGM van Overveld, RJFL Lemmers, G Deidda, LA Sandkuijl, GW Padberg, RR Frants and SM 
van der Maarel. Interchromosomal repeat array interactions between chromosomes 4 and 10: a 
model for subtelomeric plasticity. Human Molecular Genetics (2000) 9 (19): 2879-2884. 
 
PGM van Overveld, LA Sandkuijl, L Enthoven, GW Padberg, RR Frants and SM van der 
Maarel. Hypomethylation of the D4Z4 repeat array in facioscapulohumeral muscular dystrophy 
alleles (a new assay to study methylation status of D4Z4 repeats in FSHD alleles). American 
Journal of Human Genetics (2002) 71 (Supplement): Abstract #1790. 
 
M Wohlgemuth, RJFL Lemmers, EL van der Kooi, MJ van der Wielen, PGM van Overveld, H 
Dauwerse, B Bakker, RR Frants, GW Padberg, and SM van der Maarel. Possible phenotypic 
dosage effect in patients compound heterozygous for FSHD-sized 4q35 alleles. Neurology 
(2003) 61: 909-914. 
 
SM van der Maarel, PGM van Overveld, RJFL Lemmers, LA Sandkuijl, L Enthoven, ST 
Winokur, GJB van Ommen, GW Padberg and RR Frants. D4Z4 hypomethylation in FSHD 
causes the transcriptional upregulation of 4qter genes. American Journal of Human Genetics 
(2003) 73 (Supplement): Abstract #154. 
 
M Ehrlich, G Jiang, F Yang, PGM van Overveld, V Vedanarayanan and SM van der Maarel. 
Histone acetylation assays for heterochromatin disprove the position effect variegation 
hypothesis for facioscapulohumeral muscular dystrophy caused by shortening of D4Z4 repeat 
arrays. American Journal of Human Genetics (2003) 73 (Supplement): Abstract #2438. 
 
PGM van Overveld, RJFL Lemmers, LA Sandkuijl, L Enthoven, ST Winokur, F Bakels, GW 
Padberg, GJB van Ommen, RR Frants and SM van der Maarel. D4Z4 hypomethylation in 4q-
linked FSHD and non 4q-linked FSHD. Nature Genetics (2003) 35 (4): 315-317. 
 
G Jiang, F Yang, PGM van Overveld, V Vedanarayanan, SM van der Maarel, and M Ehrlich. 
Testing the position-effect variegation hypothesis for facioscapulohumeral muscular dystrophy 
by analysis of histone modification and gene expression in subtelomeric 4q. Human Molecular 
Genetics (2003) 12 (22): 2909-2921. 
 
RJFL Lemmers, PGM van Overveld, LA Sandkuijl, H Vrieling, GW Padberg, RR Frants and SM 
van der Maarel. Mechanism and timing of mitotic rearrangements in the subtelomeric D4Z4 
repeat involved in facioscapulohumeral muscular dystrophy. American Journal of Human 
Genetics (2004) 75: 44-53. 
 
List of publications 
 
 254 
RJFL Lemmers, PGM van Overveld, LA Sandkuijl, H Vrieling, GW Padberg, RR Frants and SM 
van der Maarel. Mechanism and timing of mitotic rearrangements in the subtelomeric D4Z4 
repeat involved in FSHD. American Journal of Human Genetics (2004) 75 (Supplement): 
Abstract #2490. 
 
PGM van Overveld, RR Frants and SM van der Maarel. Mosaicism and FSHD. Chapter 12: 
169-183. In: Facioscapulohumeral muscular dystrophy: clinical medicine and molecular cell 
biology. ME Upadyaya and DN Cooper (Eds.) 2004 Garland Science/BIOS Scientific Publishers 
Limited. 
 
PGM van Overveld, L Enthoven, E Ricci, L Felicetti, M Jeanpierre, ST Winokur, RR Frants, 
GW Padberg, and SM van der Maarel. Residual D4Z4 repeat size and D4Z4 methylation levels 










Petra Grada Maria van Overveld werd geboren op 6 januari 1976 in de gemeente Roosendaal en 
Nispen. Ze behaalde haar gymnasium diploma in 1995 aan het St. Norbertus College te 
Roosendaal. In september 1995 begon zij haar studie biologie aan de Universiteit Leiden, waar 
ze in 1999 cum laude afstudeerde. Aansluitend was ze werkzaam als promovenda bij het 
Centrum voor Humane en Klinische Genetica, onderdeel van het Leids Universitair Medisch 
Centrum, onder begeleiding van Prof. Dr. Frants en Dr. Ir. van der Maarel. Het daar 
uitgevoerde onderzoek staat beschreven in dit proefschrift. Sinds 1 november 2004 werkt ze als 
postdoc bij de afdeling Urologie van het Leids Universitair Medisch Centrum, aan een project 
getiteld “Role of epithelial-mesenchymal transition and osteomimicry in bone metastasis from 
prostate carcinoma: new therapeutic opportunities”. Op 14 januari 2005 ontving ze de “Prinses 
Beatrix Fonds jaarprijs neuromusculaire ziekten” voor de beste publicatie van 2004 voor het 
artikel “Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral 




Petra Grada Maria van Overveld was born on January 6th, 1976 in Roosendaal en Nispen. In 
September 1995 she graduated from the gymnasium St. Norbertus College in Roosendaal. Later 
that year she started her biology degree at Leiden University, which she completed cum laude in 
1999. Subsequently she performed her PhD research at the Center of Human and Clinical 
Genetics from the Leiden University Medical Center, under supervision of Prof. Dr. Frants en 
Dr. Ir. van der Maarel. The work from this period is presented in this thesis. As of November 1st, 
2004 she works as a postdoctoral researcher on a project entitled “Role of epithelial-
mesenchymal transition and osteomimicry in bone metastasis from prostate carcinoma: new 
therapeutic opportunities” in the Department of Urology at the Leiden University Medical 
Center. On January 14th, 2005 she received the “Prinses Beatrix Fonds jaarprijs neuromusculaire 
ziekten” for the best publication of 2004 for her article “Hypomethylation of D4Z4 in 4q-








“Het leven is een oneindige weg die we bereizen en nergens naartoe leidt. 
Het enige dat telt is hoe je de weg bereist, niet waar je uitkomt” 




Na mijn studie begon ik aan een lange nieuwe reis met bestemming Academiegebouw! Er 
kwamen natuurlijk hindernissen op mijn pad en ik was (soms) eigenwijs, maar met 
enthousiasme en plezier ging ik verder. Totdat het moment kwam, dat ik een deel van mijn 
inspiratie verloor en ik onverwacht afscheid moest nemen van zowel oma van Overveld als 
Lodewijk. Ik had even het gevoel dat ik verdwaalde, maar mijn reddingsvest gevuld met 
geborgenheid, vertrouwen, humor en geluk hielp me –zoals altijd- weer op weg. Ik heb nu mijn 
eindpunt bereikt en ik weet, dat ik het zonder alle liefde en vriendschap niet had gered. Jan, 
Trudi, Sandra, Frank, Sijmen, oma Bijman, Pietje én Adriaan, Arja, Caroline, Cynthia, Guido, 
Inge, Jeanet, JoukeJan, Klazina, Marjolein, Maytal, Melissa, Mirka, Peter K., Peter S., Peter-
Bram, Sergiu, Silvana, Wouter, Yair en Yvonne: jullie zijn mijn reddingsvest, bedankt voor alles! 
Voor jou, Tinka, duizend maal dank! Zonder jou was mijn reis veel minder comfortabel 
geweest, want jij haalt me letterlijk altijd weer uit de knoop! Verder gaat mijn dank uit naar alle 
mensen bij het Centrum voor Humane en Klinische Genetica voor de gezellige reistijd en het 
altijd bieden van een helpende hand. Beste Frantsjes, dankzij jullie ga ik bij het horen van de 
woorden koffiepauze, cake, sinterklaas en kalkoen automatisch glimlachen! Iedereen bij 
Endocrinologie en Stofwisselingsziekten wil ik bedanken voor het warme onthaal en de steun 
bij het laatste stukje van mijn promotietraject. En voor jou, lieve Leo, zijn er eigenlijk geen 
woorden. Jij omringt me met warmte, vult mijn hart met liefde en geeft me altijd een veilige 
haven om naar terug te keren. Bedankt voor je optimisme, je eeuwige geduld en alle motivatie. 
We hebben het gehaald! 
 
Veel liefs, 
